text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
Which VR headset for iPhone is best?
Sifting through the options to find the best VR headset for iPhone can be tricky, especially with so many models available today. Fortunately, it’s hard to go wrong with most of the cheaper VR headset options, so long as they’re compatible with your particular iPhone.
While there are a number of affordable options available, many buyers go with the Pecosso 3D VR Headset for iPhone and Other Smartphones, since it’s fairly lightweight and offers a clear, immersive goggle display – on top of being affordable and super user-friendly.
What to know before you buy a VR headset for iPhone
VR headsets for iPhone vs. full VR systems
VR headsets for iPhone use the phone as a display, often through goggles or a headset of some sort. This is unlike full VR systems, which use a console or PC to run the games or VR experiences while featuring an actual high-resolution display built into the included goggles.
If you elect to go with a VR headset for iPhone, you’ll likely choose from the best VR headsets. It’s important to note that smartphone VR experiences have become commonplace and affordable. They are very easy to gain access to, which makes them a simple entry into the virtual reality world for newcomers and budget-friendly consumers.
Headset compatibility
One of the most important things to consider when purchasing a VR headset for iPhone is whether the VR headset is compatible with the size of your phone. Most smartphone VR headsets include a range of sizes of phones that the goggles fit, so be sure to check that the size fits your particular phone before making a purchase.
Preferred media types
The type of media you plan to consume could affect your choice of VR headsets for iPhone. If you want a quick VR experience, you may be able to find something cheaper with goggles that you need to hold. However, if you plan to watch movies, play games or use VR experiences that work with a controller, you’ll want something a little higher end with goggles that you can strap to your face.
What to look for in a quality VR headset for iPhone
Lightweight and adjustable fit
It’s important a VR headset is comfortable to wear for long periods of time – especially if you plan to play longer VR games or experiences or watch movies that require you to wear the headset for a couple of hours. A headset that’s lightweight, adjustable and comfortable is the best choice.
Clear, immersive goggle view
Since your phone screen is your display, there’s only so much your VR headset view can do. However, VR headsets that include goggles or lenses of some sort offer varying levels of view quality. So find one that offers crisp, clear views to your phone screen to make your VR experience as immersive as possible.
Controllers or other remote controls
Another feature many users find fun is getting a VR headset with a controller or other remote control options. This adds a layer of immersion to certain virtual reality games and apps that are compatible with a controller since it often lets the user directly control their environment.
How much you can expect to spend on a VR headset for iPhone
VR headsets for iPhone have a wide range of prices, but you can generally find cheap smartphone VR headsets for around $15, with more expensive models costing as much as $80.
VR headset for iPhone FAQ
Do VR headsets need a PC?
A. While many high-tier VR headsets use a PC to run their VR games and experiences, you can also find VR headsets for PlayStation consoles, or extremely affordable entry-level VR headsets that use iPhones or other smartphones as their display.
Do VR headsets for iPhone work with Android phones or other smartphones?
A. In general, you can make most iPhone VR headsets work with smartphones of a similar size, though you’ll want to double-check on the individual product listing to see what phones they’re compatible with.
What’s the best VR headset for iPhone to buy?
Top VR headset for iPhone
Pecosso 3D Virtual Reality Goggles VR Headset for iPhone
What you need to know: This iPhone VR headset is compatible with iPhone and other smartphones between 4.7 and 6.53 inches, offering a simple and affordable VR solution for those who can’t afford to get an actual virtual reality system.
What you’ll love: With its fairly low price, this smartphone VR headset works particularly well with iPhone, and the goggles give you a clear, immersive VR experience. It’s also lightweight despite being a goggle-style VR headset, making it more comfortable than most.
What you should consider: Some users have trouble getting this model to work with other devices and apps that don’t support VR, like drones that use smartphones as their display and certain media apps.
Where to buy: Sold by Amazon
Top VR headset for iPhone for the money
What you need to know: This super-affordable VR headset works with iPhone and offers a good, cheap first step into the world of virtual reality.
What you’ll love: This model is perfect for VR beginners and offers a simple, three-step setup. It includes a phone sucker, head strap, nose pad and forehead pad, giving you all the pieces you need for the full VR experience.
What you should consider: It is made of cardboard, so it may not be a long-lasting option.
Where to buy: Sold by Amazon
Worth checking out
Pansonite Virtual Reality Goggles VR Headset for iPhone
What you need to know: If you can afford to spend a few extra bucks, this powerful VR headset for iPhone and other smartphones also comes with a handy controller, which can make compatible VR games and apps even more versatile – at a fraction of the cost of a full-scale VR headset.
What you’ll love: Buyers of this model love using the controller, which is shaped like an old console controller. It has four buttons on the right, two at the top middle and two at the bottom middle and it has an analog stick on the left-hand side. This headset also features a robust and comfortable strap system, plus clear, crisp goggles for viewing the phone screen.
What you should consider: This model is more expensive than most iPhone VR headsets. Users report the controller doesn’t work with every app.
Where to buy: Sold by Amazon
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Zachary Visconti writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved. | https://www.wfla.com/reviews/br/toys-games-br/electronic-toys-br/best-vr-headset-for-iphone/ | 2022-04-11T07:17:27 | 1 | https://www.wfla.com/reviews/br/toys-games-br/electronic-toys-br/best-vr-headset-for-iphone/ |
Which Infinity Gauntlet toys are best?
The Marvel Cinematic Universe comprises over two dozen films with iconic characters and unforgettable moments. Fans young and old can embrace the story through a myriad of toys. While there are action figures and collectibles modeled after all the heroes and villains, one item represents the culmination of years of storytelling: the Infinity Gauntlet.
The powerful weapon is a focal point of two of the most successful movies ever made, making it a terrific toy for interactive play as well as showing off. The top pick, this LEGO Infinity Gauntlet, is a detailed build that produces a stunning creation. There are Infinity gauntlet toys for all ages and interests — but with great power comes great responsibility.
What to know before you buy an Infinity Gauntlet toy
What is the Infinity Gauntlet?
The Infinity gauntlet is a device that can safely hold and wield any or all of the six infinity stones; the story is part of Marvel Comics and was later adapted for the screen. These stones are powerful entities that control an aspect of life and made frequent appearances throughout the films before becoming a focal point in “Avengers: Infinity War.” It is wielded by the Mad Titan Thanos, though a later version is made by Iron Man, known as the Power gauntlet or Nano gauntlet.
Thanos and company are part of Marvel’s series of stories, which comprise the Avengers, the Guardians of the Galaxy, the X-Men and many other superheroes and villains.
Wearables
With a large fan base comprising a wide range of ages, toys inspired by Marvel films are quite varied. For younger fans, there are role-playing toys. Kids can don their own Infinity gauntlet and act out their favorite scenes and moments. These gauntlets are typically one-size-fits-all and made from either plastic or rubber-like synthetics. For kids interested in a Thanos or Iron Man costume, the gauntlet is an important component, but a completed look will require a mask as well.
Action figures
Some fans may be more interested in action figures featuring Thanos wearing his gauntlet. These may be simpler toys appealing to youngsters with various points of articulation or more detailed figurines designed for display. While Thanos is the primary wearer of the gauntlet, both Hulk and Iron Man put on the Nano Gauntlet, so some toys may depict them wielding the Infinity Stones as well.
What to look for in a quality Infinity Gauntlet toy
Interactivity
While some wearable Infinity gauntlets may be just one complete piece, some higher-end options may add an element of interactivity. For example, there are certain products where the stones are affixed using magnets, allowing kids to remove them and put them back in a dramatic fashion, just like Thanos.
Some Infinity gauntlets may be battery-powered, offering stimulating sights and sounds for users. Because the gauntlet is populated with six colorful stones, some options may light each gem individually.
Collectibles
Older fans may be interested in collectible items that are solely intended to be put on display. These will be more detailed and typically made of higher-quality materials. The collectibles may be simply the gauntlet or a character wearing it.
Specifically, Hasbro and Funko make quality collectible action figures. Hasbro’s array will be a detailed, authentic representation standing anywhere from 6 to 12 inches tall. Meanwhile, Funko boasts a line of uniform vinyl figurines with exaggerated heads and stand under 4 inches tall. Their extensive lineup of Marvel figurines includes Thanos, Iron Man and Hulk, all wearing the gauntlet.
Reputable seller
An Infinity gauntlet toy in particular and Marvel toys, in general, are highly popular, which unfortunately invites fabrication. Always buy Marvel toys from trusted, reputable sellers.
How much you can expect to spend on an Infinity Gauntlet toy
Simpler Infinity gauntlet toys for younger kids, as well as some action figures, may cost from $10-$20, but more advanced toys, including LEGO sets and options that light up, may cost from $50-$100.
Infinity Gauntlet toy FAQ
Is an Infinity Gauntlet an appropriate toy for a child?
A. Marvel films and comics appeal to a wide age range, including many adolescents. While the films and stories can sometimes be violent, they’re often bloodless and tempered. The movie in which the gauntlet takes center stage is particularly dark and sad, however, the sequel is more inspiring. Parents are the best judge as to whether their children should watch the movies, all of which are rated PG-13.
What other Marvel toys go with the Infinity gauntlet?
A. The Infinity gauntlet is just one weapon from a specific villain; kids may be eager to collect other role-playing accessories and toys to recreate their favorite moments and use their imagination. Thor’s hammer Mjolnir as well as Captain America’s vibranium shield are among two of the most popular accessories. Giant Hulk gloves are also sought after by kids who want to embrace Bruce Banner’s green alter ego.
What’s the best Infinity Gauntlet toy to buy?
Top Infinity Gauntlet toy
What you need to know: This beautiful LEGO set appeals to both kids and adults alike and culminates in a stunning display piece.
What you’ll love: This cleverly designed LEGO set comprises almost 600 pieces, welcoming youngsters and adult fans to build alone or together. Includes a stable base and a plaque, and the fingers even move. Stands at 12.5 inches tall.
What you should consider: Quite expensive. Build may not be challenging enough for adults.
Where to buy: Sold by Amazon
Top Infinity Gauntlet toy for the money
What you need to know: A simpler toy, this Nano gauntlet will delight youngsters with its sight and sounds.
What you’ll love: This Iron Man gauntlet appeals to aspiring young heroes; it lights up and makes noise. Infinity stones are bright and eye-catching. Fits most kids’ hands comfortably. Affordably-priced.
What you should consider: Fingers don’t move. Requires batteries.
Where to buy: Sold by Amazon
Worth checking out
Marvel Legends Endgame Gauntlet
What you need to know: A high-end Nano gauntlet, this interactive option is fun to play with as well as put on display.
What you’ll love: This gauntlet fits snugly on most hands and moves and flexes in order to recreate popular moments from the film. Stones light up and glow, and the gauntlet plays sounds. It can also lock into a fist to be put on display.
What you should consider: Considerably expensive. Some fans may prefer Thanos’ gauntlet.
Where to buy: Sold by Amazon
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Anthony Marcusa writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved. | https://www.wfla.com/reviews/br/toys-games-br/hobby-collectibles-br/best-infinity-gauntlet-toy/ | 2022-04-11T07:17:35 | 0 | https://www.wfla.com/reviews/br/toys-games-br/hobby-collectibles-br/best-infinity-gauntlet-toy/ |
Which Halloween game is best?
As Halloween approaches, you may be looking for a fun way to get into the holiday spirit. Luckily, there are numerous Halloween-themed games that are great for parties, families or even just hanging out by yourself. For example, the Ravensburger Horrified: Universal Monsters Strategy Board Game is fun for children 10 and up and supports up to five players at a time.
What to consider before you buy a Halloween game
Types of Halloween games
Halloween is a holiday many people look forward to all year. Due to its popularity, there are Halloween-themed games in nearly every format you could think of. Some of the most popular Halloween games come in the form of Halloween board games that allow you to strategize and play with multiple players using spooky pieces and themes. Halloween trivia games are another favorite for those who love to learn about all things Halloween, and console and PC gamers alike will be excited to learn there is no shortage of Halloween video games available as well.
Age range
Halloween is a great time for getting scared, but many kids may not want to be scared in the same way as adults. For this reason, it’s a good idea to look at a game’s recommended age range before purchasing so you don’t accidentally buy something too scary for younger audiences.
Halloween games for teens
Scavenger hunts, mystery boxes and bobbing for apples can all be tons of fun, but many teens may feel like they’re too old for these types of games. Many teenagers prefer playing video games and role-playing games that they can play with their friends. Luckily, spooky games like “Luigi’s Mansion 3” feature fun, two-player co-op modes that teens are sure to enjoy.
What to look for in a quality Halloween game
Replay value
When buying any game, one of the first things you should consider is whether or not it will be a fun, replayable game. Some Halloween-themed games, such as pin the tail on the donkey style games, will likely lose their appeal after only one or two play sessions. On the other hand, fun Halloween video games, board games and trivia games are likely to be enjoyable for quite some time after Halloween is over.
Spooky thematic elements
Thematic elements are essential when it comes to Halloween games. You’ll often get the most bang for your buck if you buy a game that is undoubtedly Halloween-themed without being so on the nose that it isn’t fun outside of Halloween. Some good examples of spooky thematic elements include ghosts, monsters, murder mysteries, fear of the dark and witchcraft.
Interesting design
Because Halloween is a holiday aimed at all ages, there are numerous design styles to represent the various ghouls, ghosts and other creatures commonly associated with Halloween. If you’re buying a Halloween game for teens, they aren’t likely to be impressed by cartoonish takes on ghosts and monsters. On the other hand, some teens and even adults prefer games that don’t take themselves too seriously or try too hard to be scary.
How much you can expect to spend on a Halloween game
Many Halloween board games will run you about $10-$25, whereas Halloween-themed video games tend to cost around $50-$60.
Halloween game FAQ
Are there any Halloween games I can make myself?
A. There are several fun Halloween games you can make yourself, such as bobbing for apples, haunted scavenger hunts and number guessing jars that use candy corn.
How can I incorporate Halloween games into my Halloween party?
A. One of the best ways to incorporate Halloween games into your party is by having a contest where the players with the highest scores receive fun, Halloween-themed prizes or candy for winning.
What’s the best Halloween game to buy?
Top Halloween board game
Ravensburger Horrified: Universal Monsters Strategy Board Game
What you need to know: This Halloween board game has players work together to defend the town against monsters such as Dracula, a mummy and the Creature from the Black Lagoon.
What you’ll love: This cooperative board game is a nice break from the usual competitive play that most games are built around. Fans of classic monster movies will get a kick out of the many references to vintage horror films.
What you should consider: Some of the pieces are flimsy and may bend after a few uses.
Where to buy: Sold by Amazon
Top Halloween video game
What you need to know: This Nintendo Switch title puts players in control of a frightened Luigi as he solves puzzles and catches ghosts to save his friends.
What you’ll love: “Luigi’s Mansion 3” features top-notch graphics, and the puzzles and gameplay are fun for players of all ages. Once players beat the first set of missions, they unlock a Luigi-clone named Gooigi and a 2-player co-op mode that makes the game even more fun.
What you should consider: “Luigi’s Mansion 3” doesn’t feature Y-axis inversion, which is essential for many players.
Where to buy: Sold by Amazon and Kohl’s
Top Halloween trivia game
What you need to know: This in-depth horror trivia game features tons of questions from both mainstream and obscure horror films.
What you’ll love: This trivia game can be played either one-on-one or with teams. The Horror Trivia Card Game has 150 different cards with 300 trivia questions. A wide range of cards are featured and even include questions about lesser-known horror movies.
What you should consider: If you aren’t a horror movie buff, you may find this game to be too challenging.
Where to buy: Sold by Amazon
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Cody Stewart writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved. | https://www.wfla.com/reviews/br/toys-games-br/holiday-costumes-br/the-best-halloween-game/ | 2022-04-11T07:17:43 | 1 | https://www.wfla.com/reviews/br/toys-games-br/holiday-costumes-br/the-best-halloween-game/ |
Which bounce houses are best?
A bounce house set up at your party will definitely make a statement and amaze both parents and children. Most people rent a bounce house for a special occasion, as they want to save up or avoid cluttering their storage room or garage. While buying a bounce house can be a significant investment, the margin between buying and renting is smaller than you’d think. There are several high-quality models out on the market that can be enjoyed 365 days a year.
The perfect bounce house is fun and engaging for kids and easy to use for adults. Particularly, the Bounceland Royal Palace has a compact footprint but can still accommodate five children. Here’s what to consider when shopping for a bounce house.
What to know before you buy a bounce house
Residential vs. commercial
When most people think of bounce houses, they think of giant unwieldy commercial models. The type that you might find at a county fair or a neighborhood block party. These commercial bounce houses are meant for heavy use by dozens of children over a long period of time.
This guide focuses on residential bounce houses. They’re just as fun, but they’re considerably smaller and intended for private use by a few children at a time. The other big difference is price. Commercial bounce houses cost several thousands of dollars, while residential bounce houses cost several hundreds.
Dimensions
Residential bounce houses can be used both indoors and outdoors. If using outdoors, be sure to secure your bounce house to the ground with stakes to prevent it from blowing away in the wind. In addition, measure the space where your bounce house will go before you buy. Make sure you have a few extra feet beyond that for the air blower.
If buying in-store, note the size of the box as well. This will give you a ballpark idea of how much storage room you’ll need. If buying online, you should be able to find the dimensions of the box somewhere in the item description.
Inflation method
Basic bounce houses use an air pump to inflate just like an air mattress. Like larger commercial models, mid-range and high-end bounce houses use an air blower that constantly runs to ensure proper inflation. While air blowers can be noisy, they’re the better option because they ensure your bounce house won’t deflate during play.
You may notice very small holes around the seams of your bounce house. This is normal and not a sign of a manufacturing defect. These holes let out a tiny amount of air so your bounce house doesn’t explode while attached to the air blower.
What to look for in a quality bounce house
Bounce floor size
Bounce floor size is the amount of space your children will have to play within the bounce house itself. This is different from the overall dimensions of the bounce house. A bigger bounce house does not necessarily mean a bigger bounce floor size.
Most bounce houses are suitable for kids up to 12 years old. If you buy a bounce house when your children are young enough, they can enjoy it for years. However, if you have older children, it may make more sense to rent for a single occasion than to buy if you have older children, knowing they’ll soon grow out of it.
Weight limit and capacity
Bounce houses have an overall weight limit that varies by manufacturer and design. Residential models can generally support 250-500 pounds. Also, keep an eye on overall capacity. Residential bounce houses can be used by anywhere from 2-5 children at one time.
It may be tempting to try out your child’s bounce house for yourself. Yet, don’t. The material used to make residential bounce houses is not as thick as the material used to make commercial bounce houses. They are not meant to support individual jumpers with adult weights.
Design and extras
Bounce houses are colorful and fun, but some models go beyond that with actual designs like a castle, a pirate ship or a tropical jungle. Some may contain one or more slides, and some of these slides can be used with water. Other bounce houses will have games or other interactive features built into the walls.
For adults, some models will come with a carrying or storage case for added convenience. What’s more, keep an eye out for bounce houses that come with their own air pumps.
How much you can expect to spend on a bounce house
Small bounce houses for toddlers that inflate like an air mattress can be found for $50-$150. Most residential models for children up to 12 years old fall between $200-$500. High-end residential bounce houses that approach the size of commercial models can easily fetch $1,000-$2,500.
Bounce house FAQ
How long does it take to inflate and deflate a bounce house?
A. Inflation time will depend on the size of your model. Most take 2-5 minutes to fully inflate. Be sure to tether your bounce house to the ground if using outside. Deflation should take 4-10 minutes. Some models have zipper compartments you can open so the air escapes faster. Make certain there are no children or pets in your bounce house before deflating.
How should I store my bounce house?
A. You should store your bounce house in a cool, dark place after each use. A hard plastic storage box in the garage is perfect. Leaving your bounce house deflated in the backyard leaves it open to sun and water damage that will decrease its service life. It could also become a tripping hazard.
What’s the best bounce house to buy?
Top bounce house
What you need to know: This bounce house includes a slide and can accommodate up to five children.
What you’ll love: Adorable castle design. Features a safety net and removable sunshade. Long slide for the overall size of the unit.
What you should consider: Fabric weakens easily in the sun. Needs to be tied down with stakes so it doesn’t fly away.
Where to buy: Sold by Amazon
Top bounce house for the money
ACTION AIR Inflatable Bounce House Jumping Castle with Slide
What you need to know: A basic bounce house at a fair price.
What you’ll love: Wide slide that spans the length of the entire house. Accommodates up to three kids and 250 pounds total.
What you should consider: Fabric feels thin compared to more expensive models. On the smaller side.
Where to buy: Sold by Amazon and Wayfair
Worth checking out
Costway Inflatable Jungle Bounce House Kids Dual Slide Jumping Castle
What you need to know: A unique jungle-themed bounce house with two separate slides.
What you’ll love: Five children up to 300 pounds can play at the same time. Design features palm trees and cute kangaroos.
What you should consider: Doesn’t come with its own air blower, a drawback considering the price.
Where to buy: Sold by Home Depot
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Frank Paiva writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved. | https://www.wfla.com/reviews/br/toys-games-br/outdoor-toys-br/best-bounce-house/ | 2022-04-11T07:17:51 | 0 | https://www.wfla.com/reviews/br/toys-games-br/outdoor-toys-br/best-bounce-house/ |
Which Nintendo Switch fitness game is best?
Nintendo Switch is the system that gets players moving, but did you know it can boost your activity level even more with fitness games? That’s right. These days, you can get a full-body workout from video games.
There is a broad range of Nintendo Switch fitness games, including low-impact dancing games as well as intense, heart-pumping boxing and sports games. If you’re looking for a well-rounded, head-to-toe workout, a top choice for many is Nintendo “Ring Fit Adventure”.
What to know before you buy a Nintendo Switch fitness game
Regular games vs. fitness games?
The Nintendo Switch uses motion-sensitive Joy-Con controllers, which deliver immersive gaming experiences that go beyond button-mashing. In many Nintendo Switch games, players manipulate Joy-Con controllers to go fishing, swing a sword or block hits. Despite hand and arm engagement, most of these games can be played entirely from seated positions.
Fitness games for the Nintendo Switch, however, get players on their feet and keep them moving. In these games, Joy-Con controllers are manipulated to simulate true-to-life exercise moves, like punching, disco dancing or stretching. Some Switch fitness games come with accessories, like gloves or rings, to make gameplay more realistic. All things considered, most players break a sweat with most of these games.
Get in shape with Nintendo Switch fitness games
Nintendo Switch fitness games may help some individuals reach their activity and exercise goals. According to Mayo Clinic, adults should get at least 150 minutes of moderate aerobic activity every week. If you play some of these games a few times a week, it’s easy to meet or exceed 150 minutes. Moving around playing Nintendo Switch games also contributes to daily step count goals.
What to look for in a quality Nintendo Switch fitness game
Levels of difficulty
Nintendo Switch fitness games offer several difficulty levels, typically ranging from beginner to expert, to accommodate all players. In most games, the more you progress through the game or win challenges, the sooner you’ll level up and unlock new content or features. Some games allow players to adjust difficulty levels between rounds or challenges.
In-game tutorials
To keep Switch fitness games as user-friendly as possible, many of them feature in-game tutorials. Almost all games have opening tutorials explaining how to use Joy-Con controllers or accessories when you begin the game. Other games have on-screen guidance during every challenge or board, such as dancing figures demonstrating choreography.
Multiplayer modes
Some Nintendo Switch fitness players are single-player-only, like “Ring Fit Adventure,” whereas games like “Just Dance” or “Fitness Boxing” offer multiplayer modes. Certain games let you play with up to six players who can take turns using Joy-Con controllers. Other games also have online multiplayer modes, where players compete with others virtually.
Downloadable content
If you’re playing Switch fitness games online, you may be able to enjoy downloadable content, or DLC. This refers to additional content you can add to existing games, including new characters, skins, extra levels or specialty items. There is free DLC available for certain games, whereas for others, you’ll need to purchase DLC either through game-specific marketplaces or subscriptions.
How much you can expect to spend on Nintendo Switch fitness games
Nintendo Switch fitness games range in price from $19-$70. Older versions of certain games cost $30 and below, whereas new releases run closer to $50. Games that come with additional accessories arrive at the top of the price range.
Nintendo Switch fitness game FAQ
Can I use my smartwatch or fitness tracker while playing Nintendo Switch fitness games?
A. Yes, and some of these devices may have preset programs for certain types of exercise, like dancing or strength training, for more accurate tracking. Playing one of these games also keeps you on your feet and contributes to your step count.
What ESRB ratings do Nintendo Switch fitness games have?
A. ESRB ratings inform adults about the age appropriateness of video game content. The rating is located in the lower left corner of game boxes and features content descriptors, like comic mischief or mild lyrics, that explain why the game has received a particular rating. Most Nintendo Switch fitness games are rated E or E10, both of which are considered kid-friendly.
What’s the best Nintendo Switch fitness game to buy?
Top Nintendo Switch fitness game
What you need to know: This unique game comes with a Pilates-inspired ring and leg strap that holds Joy-Con controllers to offer in-depth full-body workouts.
What you’ll love: The game lets players run through a fantasy world fighting bosses using true-to-life exercises. It offers a diverse variety of workouts to accommodate players of all fitness and skill levels. The challenges include tutorials to guide users through basic movements.
What you should consider: It’s more expensive than most Switch games, and some players feel challenges are repetitive.
Where to buy: Sold by Amazon
Top Nintendo Switch fitness game for the money
“Just Dance 2021” for Nintendo Switch
What you need to know: Ideal for all-ages fun, this popular dance game invites players to rock, head-to-toe, to popular songs.
What you’ll love: The game offers multiplayer modes for up to six players. The choreography is easy to follow, but it’s still challenging enough to make players sweat. The well-rounded song assortment includes picks across all genres, including some Disney tunes and radio hits.
What you should consider: Several players were disappointed to learn they had to subscribe to unlock the full song library.
Where to buy: Sold by Amazon
Worth checking out
Nintendo “Fitness Boxing 2: Rhythm & Exercise”
What you need to know: While this boxing game is often thought to be geared toward upper-body exercises, it actually offers a full-body workout.
What you’ll love: The boxing challenges are suitable for beginners as well as experienced fighters. It incorporates dance moves into boxing for dynamic workouts that involve more footwork and movement. It has a small learning curve and is considered a user-friendly option.
What you should consider: Some players reported the game has occasional glitches that detract from gameplay.
Where to buy: Sold by Amazon
Sign up here to receive the BestReviews weekly newsletter for useful advice on new products and noteworthy deals.
Sian Babish writes for BestReviews. BestReviews has helped millions of consumers simplify their purchasing decisions, saving them time and money.
Copyright 2022 BestReviews, a Nexstar company. All rights reserved. | https://www.wfla.com/reviews/br/toys-games-br/video-games-br/best-nintendo-switch-fitness-games/ | 2022-04-11T07:18:00 | 0 | https://www.wfla.com/reviews/br/toys-games-br/video-games-br/best-nintendo-switch-fitness-games/ |
featured agate Daily Journal high school baseball rankings, April 11 Brad Locke Brad Locke Senior sports reporter Author twitter Author email Apr 11, 2022 1 hr ago Comments Facebook Twitter WhatsApp SMS Email Oxford right fielder Thomas Rayburn catches a short fly ball against Tupelo last Tuesday. The Chargers swept a three-game series from the Golden Wave. Thomas Wells | Daily Journal Facebook Twitter WhatsApp SMS Email Print Save DAILY JOURNAL BASEBALL RANKINGSTeam (Class) | W-L | Pvs1. East Union (2A) | 19-3 | 12. Oxford (6A) | 17-6 | 23. Amory (3A) | 18-3 | 34. Nettleton (3A) | 17-6 | 45. Saltillo (5A) | 19-5 | 66. Mooreville (4A) | 15-6 | 57. Lafayette (5A) | 17-5 | 98. New Albany (4A) | 14-8 | NR9. Vardaman (1A) | 14-2 | NR10. Pine Grove (2A) | 15-6 | NR brad.locke@journalinc.com Facebook Twitter WhatsApp SMS Email Print Save Tags High School Baseball Rankings Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today Recommended for you Please enable JavaScript to view the comments powered by Disqus. comments powered by Disqus Newsletters Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. The Daily You'll receive our top headlines each morning, seven days a week, as well as each weekday afternoon. News Alerts & Top Stories Get news sent to your inbox as it happens, as well as our top stories each week. The Session Get weekly recaps during Mississippi's annual legislative session, plus breaking alerts, from our state politics team. You must select at least one email list. Please enter a valid email address. Sign up All Newsletters
Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today | https://www.djournal.com/sports/high-school/daily-journal-high-school-baseball-rankings-april-11/article_17f23a09-5711-514e-86ee-04652cee5b02.html | 2022-04-11T07:21:07 | 0 | https://www.djournal.com/sports/high-school/daily-journal-high-school-baseball-rankings-april-11/article_17f23a09-5711-514e-86ee-04652cee5b02.html |
featured agate Daily Journal high school softball rankings, April 11 Brad Locke Brad Locke Senior sports reporter Author twitter Author email Apr 11, 2022 2 hrs ago Comments Facebook Twitter WhatsApp SMS Email Pitcher Layla Owens and catcher Chloe McClain have helped get Itawamba AHS into this week's softball rankings. ABBY LODEN Facebook Twitter WhatsApp SMS Email Print Save DAILY JOURNAL SOFTBALL RANKINGSTeam (Class) | W-L | Pvs1. Booneville (3A) | 15-5 | 12. Kossuth (3A) | 14-5 | 23. Saltillo (5A) | 16-2-1 | 44. Mantachie (3A) | 19-4 | 55. Tishomingo Co. (4A) | 17-4 | 36. East Webster (2A) | 17-4 | 67. Itawamba AHS (4A) | 12-6-1 | NR8. Corinth (4A) | 14-5-1 | 89. Pine Grove (1A) | 18-3 | 910. Pontotoc (4A) | 16-5 | 7 brad.locke@journalinc.com Facebook Twitter WhatsApp SMS Email Print Save Tags High School Softball Rankings Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today Recommended for you Please enable JavaScript to view the comments powered by Disqus. comments powered by Disqus Newsletters Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. The Daily You'll receive our top headlines each morning, seven days a week, as well as each weekday afternoon. News Alerts & Top Stories Get news sent to your inbox as it happens, as well as our top stories each week. The Session Get weekly recaps during Mississippi's annual legislative session, plus breaking alerts, from our state politics team. You must select at least one email list. Please enter a valid email address. Sign up All Newsletters
Brad Locke Senior sports reporter Brad is a senior sports reporter and columnist. Author twitter Author email Follow Brad Locke Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today | https://www.djournal.com/sports/high-school/daily-journal-high-school-softball-rankings-april-11/article_07a67f36-65e4-5e77-acf5-9b2e47bbb3cf.html | 2022-04-11T07:21:13 | 1 | https://www.djournal.com/sports/high-school/daily-journal-high-school-softball-rankings-april-11/article_07a67f36-65e4-5e77-acf5-9b2e47bbb3cf.html |
Man accused of beating roommate over mosquito argument
DALLAS (CNN) - A Texas man is facing aggravated assault charges after allegedly beating his roommate over an argument about mosquitoes.
Victor Shavers, 43, reportedly admits he hit the man he shares a bedroom with when they began arguing over what mosquitoes look like. The roommate says the attack began when the verbal argument escalated.
The man says Shavers grabbed a wooden stick and beat him in the head with it before he was able to get a metal baseball bat to defend himself. He used that bat to hit Shavers in the head several times.
Both men were treated for their injuries at the hospital. The roommate required multiple stitches on his face.
Police arrested Shavers on an outstanding warrant and also charged him with assault.
A judge ordered him to be held Tuesday on a $28,000 bond.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.1011now.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ | 2022-04-11T07:31:36 | 1 | https://www.1011now.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ |
GUANGZHOU, China, April 10, 2022 /PRNewswire/ -- The 131st Canton Fair will be held online from April 15-24. According to Maggie Pu, Deputy Director General of the Foreign Affairs Office of the Canton Fair, a slew of highly-expected new products will be released in the machinery exhibition section this year.
As one of the most-visited exhibition sections at the Canton Fair, Machinery at the Canton Fair boasts big numbers in exhibits and turnover. Once incompetent, China's machinery industry has drastically developed under the "innovation-driven" strategy.
China's machinery industry is well-diversified. Fierce competition in the international market stimulates enterprises to take more seriously the product quality and costs and the capability to develop new products. Responding to the demands, enterprises have invested manpower and resources in strengthening the R&D of core technologies, which directly accelerated the transformation and upgrading of China's machinery manufacturing industry.
In recent years, high-end equipment, including ultra-high voltage power transmission and distribution equipment, ten-million tonnage level oil refining equipment, and one-million tonnage level large ethylene equipment were developed, breaking the foreign company dominance. Emerging industries, such as robotics, have seen breakthroughs in motion control and high-performance servo drives. General machinery, agriculture machinery, small processing machinery and industrial parts have also formed a complete industrial chain. According to the German Mechanical Engineering Industry Association(VDMA), in 2020, China overtook Germany in the world rankings of machinery and equipment export with the lion's share of 15.8% at €165 billion.
The Canton Fair brings together competent machinery manufacturing enterprises. Each session, leading exhibitors such as Guangzhou Tech-Long Packaging Machinery Co., Ltd., Hubei Tri-Ring Metal-Forming Equipment Import & Export Co., Ltd., and Hualian Machinery Group Co., Ltd. exhibited their new products at the Fair. New products include various intelligent equipment of different sizes, such as photoelectric complementary generator sets, new intelligent agricultural machinery, and digital silent inverter generator.
With the implementation of the "14th Five-Year Plan" for the Machinery Industry Development, China's pertinent sectors will embrace much progress. The infrastructure boom in "Belt and Road Initiative" (BRI) countries, together with the Regional Comprehensive Economic Partnership(RCEP) taking effect, renders a broad stage for China's machinery industry to quickly become internationally advanced. As a bond of friendship and a bridge for trade, the Canton Fair is witnessing the evolution of China's manufacturing and machinery industries.
Visit https://www.cantonfair.org.cn/en-US/register/index#/foreign-email for more opportunities.
View original content:
SOURCE Canton Fair | https://www.1011now.com/prnewswire/2022/04/10/canton-fair-2022-intelligent-manufacturing-upgrade-empowers-rapid-evolution-chinas-machinery-industry/ | 2022-04-11T08:06:27 | 1 | https://www.1011now.com/prnewswire/2022/04/10/canton-fair-2022-intelligent-manufacturing-upgrade-empowers-rapid-evolution-chinas-machinery-industry/ |
DAYTON, Tenn., April 10, 2022 /PRNewswire/ -- Jason Christie left Dayton Municipal Park on Championship Sunday just 6 ounces out of the lead with a crystal-clear plan for where he wanted to start.
But thick fog created by temperatures that had plunged into the 30s overnight changed that plan — and ultimately played a huge role in his eighth career victory with B.A.S.S.
To let the fog clear, Christie stopped on a bank he hadn't fished all week and quickly put a solid limit in his livewell. He culled up a few ounces throughout the day until he reached a five-bass limit of 15 pounds, 12 ounces that helped him win the Guaranteed Rate Bassmaster Elite at Chickamauga Lake with a four-day total of 73-7.
"The fog is why I won," said Christie, who is a little more than a month removed from winning the Academy Sports + Outdoors Bassmaster Classic presented by Huk on Lake Hartwell. "I went through one fogbank at about 25 mph going to where I was going to start. But then I hit another fogbank and I saw a boat wave that I knew didn't come from one of our guys, so I just immediately peeled off to an area that I fished three or four years ago in another event."
After a warm start on Thursday, Days 2 and 3 were the polar opposite with cloudy skies, temperatures in the 40s and a spattering of rain, sleet and snow. But the low-light conditions played into the hands of Christie, who fished all week with a 1/2-ounce Booyah Covert Spinnerbait (chartreuse, white and blue with a white Yum Swim'n Dinger as a trailer), a bladed jig and the same War Eagle Jiu-Jigsu Jig (green pumpkin) he used at the Classic.
The conditions made another sharp turn Sunday, with the return of the sun, calm winds and a high temperature near 70 degrees. But Christie once again took advantage of a short window of low visibility aided by the early morning fog.
"I knew the spot I stopped at had had a lot of traffic, but I figured I would just go in there and fish until the fog lifted," Christie said. "But really it set up perfectly because it was shaded and had all the right stuff."
While much of the field was still navigating the fog, Christie caught a quick limit, taking the unofficial lead on BassTrakk by 8 a.m. and never relinquishing it.
"That was the key, just getting off to a good start," he said. "What was weird is every day those fish have been tight to cover. But the first big one I caught today was halfway back to the boat. Then the next bite was about the same — and that's how I ended up catching them.
"I think the bait would come by the cover, and they were sitting right out in front of it."
The win provided a bit of redemption for Christie, who followed his Classic victory with a 93rd-place finish at the next Elite Series event at Santee Cooper Lakes — one of the worst finishes of his career. He said the same stubbornness that cost him at Santee Cooper Lakes might have helped him to the victory on Chickamauga.
"I certainly don't like to make excuses," he said. "But during practice for Santee, I was doing every interview, every podcast about the Classic win — I didn't turn anyone down. I still thought I was on a good deal there and that I would catch them. But I was too stubborn to give up on it when it didn't work.
"That's just like today. The fishing was a lot tougher than it had been the last two days, but I stuck with what I was doing."
Like Christie, Mississippi pro Brock Mosley stayed with the program he had been using all week, alternating between a bladed jig, a jig, a Senko and a spinnerbait. But with a modest limit of 11-14, he finished second with a four-day total of 69-15.
It marked his fifth career second-place finish on the Elite Series and the third time he's finished one spot behind Christie.
"I caught plenty of fish today, but I just didn't run into any big fish," Mosley said. "I thought as good as I was catching them, everybody else was probably catching them too. So late in the day, I decided to run down the lake and try to catch a couple of big ones on a big swimbait.
"Looking back, I probably should have just stuck with what I was doing."
Phoenix Boats Big Bass of the Day honors went to Arizona pro Clifford Pirch for a 5-4 largemouth. Wisconsin pro Pat Schlapper won Phoenix Boats Big Bass of the Week with the 10-5 he caught Thursday.
Hawaiian Matty Wong failed to make the Top 10 cut for Championship Sunday, placing 14th with 48-5. But he earned the VMC Monster Bag of the Week award for the 25-13 limit he weighed in Friday.
Christie took home $3,000 for being the highest-placing entrant in the Toyota Bonus Bucks program, and Mosley earned $2,000 for being the second-highest placing entrant.
As part of the Yamaha Power Pay program, Christie also earned $4,000 for winning while Australian Carl Jocumsen claimed an additional $1,500 for being the second-highest placing entrant.
Ed Loughran III won the $1,000 BassTrakk Contingency award for the most accurate weight reporting.
With a 33rd-place finish, Florida pro John Cox maintained his lead in the Progressive Insurance Bassmaster Angler of the Year standings with 353 points. Idaho pro Brandon Palaniuk moved into second with 343, followed by Pirch (338), David Mullins of Tennessee (321) and Drew Benton of Georgia (321).
Wisconsin pro Jay Przekurat leads the Falcon Rods Bassmaster Rookie of the Year race with 293 points, followed by Joseph Webster of Alabama (249) and Tennessee pro Jacob Foutz (200).
The tournament was hosted by Rhea County, City of Dayton, Tenn., and Fish Dayton.
2022 Bassmaster Elite Series Platinum Sponsor: Toyota
2022 Bassmaster Elite Series Premier Sponsors: Bass Pro Shops, Berkley, Humminbird, Mercury, Minn Kota, Nitro Boats, Power-Pole, Progressive Insurance, Ranger Boats, Rapala, Skeeter Boats, Yamaha
2022 Bassmaster Elite Series Supporting Sponsors: AFTCO, Daiwa, Garmin, Huk Performance Fishing, Marathon, Strike King, Triton Boats, VMC
2022 Bassmaster Conservation Partners: AFTCO, Yamaha Rightwaters
Media Contact: Emily Harley, B.A.S.S. Communications Manager, 205-313-0945, eharley@bassmaster.com
View original content to download multimedia:
SOURCE B.A.S.S. | https://www.1011now.com/prnewswire/2022/04/10/christie-rights-his-ship-wins-bassmaster-elite-series-event-chickamauga-lake/ | 2022-04-11T08:06:38 | 1 | https://www.1011now.com/prnewswire/2022/04/10/christie-rights-his-ship-wins-bassmaster-elite-series-event-chickamauga-lake/ |
NEW YORK, April 10, 2022 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the "Class Period") of the important April 18, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Acutus Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Acutus Medical class action, go to https://rosenlegal.com/submit-form/?case_id=3255 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) a material percentage of the AcQMap systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, Acutus Medical's products; (2) a material percentage of the AcQMap systems under evaluation had been installed in locations where Acutus Medical did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system's operations; (3) as a result, Acutus Medical was in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (4) Acutus Medical's management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on Acutus Medical's 2021 financial results; and (5) Acutus Medical's risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing Acutus Medical. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Acutus Medical class action, go to https://rosenlegal.com/submit-form/?case_id=3255 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View original content to download multimedia:
SOURCE Rosen Law Firm, P.A. | https://www.1011now.com/prnewswire/2022/04/10/final-deadline-notice-rosen-top-ranked-law-firm-encourages-acutus-medical-inc-investors-with-losses-secure-counsel-before-important-april-18-deadline-securities-class-action-afib/ | 2022-04-11T08:06:45 | 1 | https://www.1011now.com/prnewswire/2022/04/10/final-deadline-notice-rosen-top-ranked-law-firm-encourages-acutus-medical-inc-investors-with-losses-secure-counsel-before-important-april-18-deadline-securities-class-action-afib/ |
Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate
No New Safety Signals Observed
Longest Follow-Up of Patients Treated With a KRASG12C Inhibitor
THOUSAND OAKS, Calif., April 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib)*. The two-year follow-up data will be presented orally as part of a clinical trials plenary session at the American Association for Cancer Research (AACR) annual meeting on April 10, 2022. LUMAKRAS is the first and only KRASG12C inhibitor to-date to show long-term clinical benefit and overall survival in patients with NSCLC harboring the KRAS G12C mutation.
"With regulatory approvals in nearly 40 countries and thousands of patients treated, LUMAKRAS, the only approved KRASG12C inhibitor, is a transformative targeted therapy for the treatment of patients living with KRAS G12C-mutated NSCLC," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "We are pleased with these latest results from the CodeBreaK 100 study, which represent the longest follow-up of patients treated with a KRASG12C inhibitor and confirm rapid, deep and durable responses in patients receiving LUMAKRAS."
In this long-term, two-year analysis of 174 heavily pre-treated patients (172 with baseline measurable lesion(s)), LUMAKRAS demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7% and median duration of response (DOR) of 12.3 months. Five patients achieved complete responses and 65 patients achieved partial responses. The results also showed median progression-free survival (PFS) of 6.3 months and overall survival (OS) of 12.5 months with 32.5% of patients still alive at two years. No new safety signals for LUMAKRAS were identified with the long-term follow-up.
"Since the FDA approval almost a year ago, LUMAKRAS has changed the treatment paradigm for patients with advanced non-small cell lung cancer who harbor the KRAS G12C mutation," said Grace Dy, M.D., chief, thoracic oncology, Roswell Park Comprehensive Cancer Center. "The durable efficacy and positive benefit-risk profile seen in the two-year analysis of CodeBreaK 100 highlight the important role this innovative targeted therapy can offer long-term."
In May 2021, LUMAKRAS was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval. LUMAKRAS is now approved in 39 countries.
*LUMAKRAS is marketed as LUMYKRAS® (sotorasib) in the European Union, the United Kingdom and Switzerland.
About LUMAKRAS®/LUMYKRAS® (sotorasib)
Amgen took on one of the toughest challenges of the last 40 years in cancer research by developing LUMAKRAS/LUMYKRAS, a KRASG12C inhibitor.1 LUMAKRAS/LUMYKRAS has demonstrated a positive benefit-risk profile with rapid, deep, and durable anticancer activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation with a once daily oral formulation.2
Amgen is progressing the largest and broadest global KRASG12C inhibitor development program with unparalleled speed and exploring more than 10 sotorasib combination regimens, including triplets, with clinical trial sites spanning five continents. To date, over 4,000 patients around the world have received LUMAKRAS/LUMYKRAS through the clinical development program and commercial use.
In May 2021, LUMAKRAS was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval. LUMAKRAS/LUMYKRAS is also approved in the European Union, Japan, United Arab Emirates, South Korea and Switzerland and in Australia, Brazil, Canada, and Great Britain under the FDA's Project Orbis. Through Project Orbis, Amgen also has Marketing Authorization Applications (MAAs) for sotorasib in review in Israel and Singapore. Additionally, Amgen has submitted MAAs in Argentina, Colombia, Hong Kong, Kuwait, Malaysia, Mexico, Qatar, Saudi Arabia, Taiwan, Thailand and Turkey.
LUMAKRAS/LUMYKRAS is also being studied in multiple other solid tumors.3
About Non-Small Cell Lung Cancer and the KRAS G12C Mutation
Lung cancer is the leading cause of cancer-related deaths worldwide, and it accounts for more deaths worldwide than colon cancer, breast cancer and prostate cancer combined.4 Overall survival rates for NSCLC are improving but remain poor for patients with advanced disease and 5-year survival is only 7% for those with metastatic disease.5
KRAS G12C is the most common KRAS mutation in NSCLC.6 About 13% of patients with NSCLC harbor the KRAS G12C mutation.7 Unmet medical need remains high and treatment options are limited for NSCLC patients with the KRAS G12C mutation whose first-line treatment has failed to work or has stopped working. The outcomes with other approved therapies are suboptimal, with a median progression-free survival of approximately four months following second-line treatment of KRAS G12C-mutated NSCLC.8
About CodeBreaK
The CodeBreaK clinical development program for Amgen's drug sotorasib is designed to study patients with an advanced solid tumor with the KRAS G12C mutation and address the longstanding unmet medical need for these cancers.
CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors.9 Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 2 study was centrally assessed objective response rate. The Phase 2 trial in NSCLC enrolled 126 patients, 124 of whom had centrally evaluable lesions by RECIST at baseline.2 The Phase 2 trial in colorectal cancer (CRC) is fully enrolled and results have been published.10
CodeBreaK 200, the global Phase 3 randomized active-controlled study comparing sotorasib to docetaxel in KRAS G12C-mutated NSCLC completed enrollment of 345 patients. Eligible patients had previously treated, locally advanced and unresectable or metastatic KRAS G12C-mutated NSCLC. The primary endpoint is progression-free survival and key secondary endpoints include overall survival, objective response rate, and patient-reported outcomes.11
Amgen also has several Phase 1b studies investigating sotorasib monotherapy and sotorasib combination therapy across various advanced solid tumors (CodeBreaK 101) open for enrollment.12 A Phase 2 randomized study will evaluate sotorasib in patients with stage IV KRAS G12C-mutated NSCLC in need of first-line treatment (CodeBreaK 201).13
For information, please visit www.hcp.codebreaktrials.com.
LUMAKRAS® (sotorasib) U.S. Indication
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
LUMAKRAS® (sotorasib) Important U.S. Safety Information
Hepatotoxicity
- LUMAKRAS can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
- Among 357 patients who received LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
- Monitor liver function tests (ALT, AST and total bilirubin) prior to the start of LUMAKRAS every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
- Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction.
Interstitial Lung Disease (ILD)/Pneumonitis
- LUMAKRAS can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS was discontinued due to ILD/pneumonitis in 0.6% of patients.
- Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified.
Most Common Adverse Reactions
- The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough.
Drug Interactions
- Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products.
- Inform patients to avoid proton pump inhibitors and H2 receptor antagonists while taking LUMAKRAS.
- If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS 4 hours before or 10 hours after a locally acting antacid.
Please see LUMAKRAS full Prescribing Information.
About Amgen Oncology
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer.
For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
At Amgen, we're advancing oncology at the speed of life™.
For more information, follow us on www.twitter.com/amgenoncology.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Jessica Akopyan, 805-440-5721 (media)
Arvind Sood, 805-447-1060 (investors)
LUMAKRAS, LUMYKRAS, Otezla, and Advancing Oncology at The Speed of Life are trademarks of Amgen Inc.
1 Canon J, et al. Nature. 2019;575: 217–223.
2 Skoulidis F, et al. N Engl J Med. 2021;384:2371-2381.
3 Hong DS, et al. N Engl J Med. 2020;383:1207-1217.
4 Sung H, et al. CA Cancer J Clin. 2021; 71:209-249.
5 American Cancer Society. Lung Cancer Survival Rates. 2021. Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed on March 7, 2022.
6 Arbour KC, et al. Clin Cancer Res. 2018; 24:334-340.
7 Nassar AF, et al. N Engl J. Med. 2021;384:185-187.
8 Spira Al, et al. Lung Cancer. 2021;159 :1-9.
9 ClinicalTrials.gov. CodeBreaK 100. Avalable at: https://clinicaltrials.gov/ct2/show/NCT03600883 . Accessed on March 7, 2022.
10 Fakih MG, et al. Lancet Oncol. 2022;23:115-124.
11 ClinicalTrials.gov. CodebreaK 200. Available at: https://clinicaltrials.gov/ct2/show/NCT04303780 . Accessed on March 7, 2022.
12 ClinicalTrials.gov. CodeBreaK 101. Available at: https://clinicaltrials.gov/ct2/show/NCT04185883 . Accessed on March 7, 2022.
13 ClinicalTrials.gov. CodeBreaK 201. Available at: https://clinicaltrials.gov/ct2/show/NCT04933695. Accessed on March 7, 2022.
View original content to download multimedia:
SOURCE Amgen | https://www.1011now.com/prnewswire/2022/04/10/lumakras-sotorasib-codebreak-100-study-shows-two-year-overall-survival-325-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/ | 2022-04-11T08:06:53 | 0 | https://www.1011now.com/prnewswire/2022/04/10/lumakras-sotorasib-codebreak-100-study-shows-two-year-overall-survival-325-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/ |
CAMBRIDGE, Mass., April 10, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late-breaking data at the American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, LA, April 8-13, 2022.
The data presented at AACR 2022 illustrate that Myeloid has designed and developed two novel therapeutic platforms, ATAK™ CAR receptors and in vivo mRNA programming, to target and activate the ability of myeloid cells to attack cancer by immune reprogramming. Myeloid cells are a primary orchestrator of immune response and accumulate naturally within solid tumors, in some cases representing up to seventy-five percent of the tumor mass. Myeloid's adaptations of mRNA for the myeloid compartment are expanding the impact of these cells within in vivo experiments.
Myeloid's novel class of CARs, known as ATAK™ Receptors, combine tumor recognition with multiple proprietary innate-immune signaling domains. Myeloid scientists have screened multiple unexplored combinations of innate-immune signals and uncovered optimal multi-signal pathways. The combination of cancer recognition binders with these novel intracellular signaling domains allows myeloid cells to be reprogrammed with previously unexplored combinations of immune signals, leading to tumor killing and broad systemic anti-tumor responses.
Myeloid's novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in selective uptake and expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models. These data demonstrate the potential for Myeloid's technology to program cells directly in vivo.
"At this year's AACR meeting, we are pleased to present significant progress across our platforms that showcase the ability of myeloid cells to orchestrate broad immune responses through in vivo mRNA programming and our next-generation ATAK™ CARs," said Bruce McCreedy, Ph.D., Chief Scientific Officer of Myeloid. "These data support our plans to initiate clinical trials to evaluate the safety and activity of several novel drug product candidates within the next year, expanding our existing clinical pipeline."
Details of the late-breaking poster presentations:
Title: "In vivo programming of myeloid cells by mRNA-mediated delivery of novel Fc alpha fusion receptor activates anti-tumor immunity"
Session: Late-Breaking Research: Clinical Research 1
Date and Time: Sunday Apr 10, 2022 1:30 PM - 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 17
Title: "ATAK receptors, a new class of chimeric antigen receptors that harness innate immunity in myeloid cells to target cancer"
Session: Late-Breaking Research: Clinical Research 1
Date and Time: Sunday Apr 10, 2022 1:30 PM - 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 17
Abstracts and full session details can be accessed through the AACR meeting planner once available: AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating the fields of RNA, immunology and medicine, the Company's proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. For more information, visit https://www.myeloidtx.com/.
Investor and Media Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
858-914-1962
View original content to download multimedia:
SOURCE Myeloid Therapeutics, Inc. | https://www.1011now.com/prnewswire/2022/04/10/myeloid-therapeutics-presents-late-breaking-data-aacr-2022-demonstrating-ability-its-atak-receptors-vivo-delivery-mrna-attack-cancer-by-immune-reprogramming/ | 2022-04-11T08:07:00 | 1 | https://www.1011now.com/prnewswire/2022/04/10/myeloid-therapeutics-presents-late-breaking-data-aacr-2022-demonstrating-ability-its-atak-receptors-vivo-delivery-mrna-attack-cancer-by-immune-reprogramming/ |
Potentially game changing impact investment program aimed at fundamentally disrupting the fight against kidney disease
NEW YORK, April 10, 2022 /PRNewswire/ -- The National Kidney Foundation (NKF) today, announced the launch of the NKF Innovation Fund, a new impact investment program aimed at fundamentally disrupting the fight against kidney disease.
"The kidney health landscape is broken and lacks needed innovation," said Kevin Longino, Chief Executive Officer of NKF and a kidney transplant patient. "Dialysis has been the go-to treatment for more than half a century. Fifty years without major progress is unacceptable. About 37 million Americans have kidney disease and many crash into kidney failure and require dialysis before ever being diagnosed. We need a fundamental change in how we deal with kidney disease. Our Innovation Fund will provide donors with a unique opportunity to see their dollars support companies pursuing the most promising therapies, treatments and prevention methods that offer the potential to transform kidney care."
The NKF Innovation Fund's goal is to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve. The fund will primarily invest in early to mid-stage companies that are developing innovative, patient-centric kidney therapies. The NKF Fund is modeled after similar vehicles used by other leading patient organizations to spur industry to develop transformative treatments with other diseases. NKF believes kidney patients deserve no less.
NKF's Innovation Fund is already attracting interest from major donors and innovator companies. In March, the Fund made one of its first investments. Kuleana Technology, located in Seattle, Washington, is a spinoff from the University of Washington and closely aligned with both the Center for Dialysis Innovation at the University of Washington, and with the Northwest Kidney Centers. The company is developing a groundbreaking portable hemodialysis device that will not require connection to an external water source. The new technology will be more effective than current dialysis since it will allow patients to dialyze on the go, enabling whenever, wherever dialysis for millions of patients around the world living with kidney failure.
"Our vision is very straightforward," added Longino. "We are going after the full spectrum of kidney disease. With the NKF Innovation Fund we want to prevent kidney disease, eliminate the transplant wait list, and provide better, safer treatments for dialysis patients so they can live fuller and more productive lives. That's the prism we're looking through for every investment we make, and I think our first investment into this space shows just how serious we are."
"We are excited and enthusiastic to be partnering with the National Kidney Foundation in this pioneering effort to impact the lives of people living with advanced kidney disease. Like NKF, we recognize the large unmet need to create transformative dialysis therapies that are safer, more effective, give patients freedom and mobility, in order to significantly improve their quality of life", said Dr. Jonathan Himmelfarb, President and CEO of Kuleana Technology.
For more information about the NKF Innovation Fund visit kidney.org/innovationfund. To learn more about kidney disease and how to maintain optimal kidney health visit www.kidney.org/.
About Kidney Disease
In the United States, 37 million adults are estimated to have kidney disease, also known as chronic kidney disease—and approximately 90 percent don't know they have it. 1 in 3 American adults are at risk for chronic kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of African American, Hispanic, American Indian, Asian, or Pacific Islander descent are at increased risk for developing the disease. African Americans are almost 4 times more likely than White Americans to have kidney failure. Hispanics are 1.3 times more likely than non-Hispanics to have kidney failure.
About National Kidney Foundation
The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org.
View original content to download multimedia:
SOURCE The National Kidney Foundation | https://www.1011now.com/prnewswire/2022/04/10/new-national-kidney-foundation-innovation-fund-seeks-accelerate-kidney-disease-therapies/ | 2022-04-11T08:07:07 | 0 | https://www.1011now.com/prnewswire/2022/04/10/new-national-kidney-foundation-innovation-fund-seeks-accelerate-kidney-disease-therapies/ |
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma (STS).
Olaratumab was originally developed by Lilly as a (non-radiolabelled) monoclonal antibody targeting Platelet Derived Growth Factor Receptor Alpha (PDGFRα). PDGFRα is expressed in multiple tumour types including STS. STS is generally a radiation susceptible cancer that may be inherently amenable to systemic radionuclide therapy and olaratumab's ability to target PDGFRα makes it a highly novel and potentially exciting candidate for use as a radionuclide targeting agent. The exclusive worldwide licence will allow Telix to repurpose olaratumab as a targeting agent for radiopharmaceutical imaging and therapy of cancer. Olaratumab has an established safety profile that underpins its potential use as a radionuclide targeting agent.
Material terms of the agreement
Under the terms of the agreement Telix will pay Lilly an upfront payment of US$5M (~AU$6.7M) for the grant of an exclusive licence to Lilly's intellectual property related to the development of a radiolabelled olaratumab, as well as access to material for use by Telix in initial pre-clinical and early-phase clinical studies in application to potential uses for the diagnosis and treatment of human cancers.
Lilly may be eligible for up to US$225M (~AU$301M) in payments based upon the achievement of pre-specified development, regulatory and commercial milestones. Lilly would also be eligible to receive industry standard royalties on net sales. The agreement also includes an option for Lilly to be granted an exclusive licence to a radiolabelled companion diagnostic which would be developed by Telix. If exercised, Lilly will pay Telix US$5M (~AU$6.7M) and up to US$30M (~AU$40.1M) in potential development milestones, as well as industry standard royalties.
The agreement has typical termination rights for breach and related corporate issues. Telix retains termination rights typical to licence agreements of this nature to enable the Company to exit the agreement based on a development or commercial basis.
Building on Telix's track record in acquiring and commercialising assets
Telix Group CEO and Managing Director, Dr. Christian Behrenbruch said, "This in-licence transaction with Lilly is a valuable – and rare – opportunity to acquire an asset which has demonstrated clinical safety. In our pre-transaction diligence and research, we have identified that a radiolabelled version of olaratumab could be efficacious in patients with STS, particularly as it is a highly radiation-sensitive cancer. The safety data generated by Lilly in relation to the original development program significantly de-risks the program for Telix. We anticipate that early clinical translation with a radiolabeled olaratumab as an imaging agent may also provide valuable clinical information as to whether this asset has potential therapeutic efficacy, demonstrating the advantage of Telix's "theranostic" approach.
"This acquisition mirrors the approach that Telix has taken in building its existing pipeline by in-licencing or acquiring assets that have already been proven to be safe for use in humans that can be harnessed as novel radiolabelled targeting agents. This partnership also demonstrates the value that Telix can bring as a capable partner with the expertise in radiopharmaceutical development and manufacturing, to help repurpose or expand the use of promising candidates to better target, find and treat cancer."
About Soft Tissue Sarcoma (STS)
Soft tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers, with more than 50 histological subtypes. In the United States, it is estimated that 13,040 new cases and 5,150 deaths were caused by STS in 2019, representing 0.75% of overall cancer incidence and 0.84% of overall cancer mortality.1 In Europe, nearly 23,600 new STS cases rose annually, and the crude incidence rate was 4.7 per 100,000.2 Approximately 39,900 new STS cases occurred nationwide in China in 2019, accounting for 1.05% of overall cancer incidence.3 The crude incidence rate was 2.91/100,000 and generally increased with age. Standard treatment for soft tissue sarcoma includes surgery, radiation therapy and/or chemotherapy. For patients with advanced, unresectable, or metastatic disease, treatment typically involves chemotherapy with single agents (e.g., doxorubicin) or anthracycline-based combination regimens. However, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months.
About olaratumab
Olaratumab (previously sold under the brand name, Lartruvo®) was originally developed as a monoclonal antibody targeting PDGFRα. Olaratumab was granted "Accelerated Approval" in the US and "Conditional Approval" in the EU based on Phase 2 trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy. Olaratumab was voluntarily withdrawn from the market by Lilly following the failure of the Phase 3 ANNOUNCE clinical trial, in which olaratumab did not improve survival for patients.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, Illuccix® (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),4 and by the Australian Therapeutic Goods Administration (TGA).5 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe6 and Canada.7
This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.
Legal Notices
This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).
View original content to download multimedia:
SOURCE Telix Pharmaceuticals Limited | https://www.1011now.com/prnewswire/2022/04/10/telix-pharmaceuticals-announces-licence-agreement-with-lilly-olaratumab/ | 2022-04-11T08:07:14 | 1 | https://www.1011now.com/prnewswire/2022/04/10/telix-pharmaceuticals-announces-licence-agreement-with-lilly-olaratumab/ |
LONDON, 10 April 2022 /PRNewswire/ -- Tetragon announces the final results of the "modified Dutch auction" tender offer to purchase a portion of the outstanding non-voting shares of Tetragon for a maximum aggregate payment of $50,000,000 in cash. The tender offer expired at 11:59 p.m. (ET) on 7 April 2022.
J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) acted as dealer manager for the tender offer and Computershare Investor Services PLC acted as tender agent for the tender offer. As dealer manager, J.P. Morgan determined the final purchase price at which Tetragon will purchase shares in the tender offer. As tender agent, Computershare determined the final proration factor.
In accordance with the terms of the tender offer, Tetragon has accepted for purchase 4,291,157 non‑voting shares at a purchase price of $9.75 per share. The aggregate cost of this purchase is $41,838,780.75, excluding fees and expenses relating to the tender offer. A total of 4,291,157 Tetragon non-voting shares were properly tendered and not properly withdrawn at or below the purchase price of $9.75 per share.
Tetragon will promptly make payment for the shares validly tendered and accepted for purchase, which is expected to occur on or about 14 April 2022.
About Tetragon:
Tetragon is a closed-ended investment company that invests in a broad range of assets, including public and private equities and credit (including distressed securities and structured credit), convertible bonds, real estate, venture capital, infrastructure, bank loans and TFG Asset Management, a diversified alternative asset management business. Where appropriate, through TFG Asset Management, Tetragon seeks to own all, or a portion, of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit, equity, interest rate, inflation and real estate cycles. The company's non-voting shares are traded on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V., and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at www.tetragoninv.com.
This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU) ("EU MAR") and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).
This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.
J.P. Morgan Securities plc, which is authorised by the UK Prudential Regulation Authority and regulated by the UK Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Tetragon and for no one else in connection with the tender offer and will not be responsible to anyone (whether or not recipient of the tender offer) other than Tetragon for providing the protections afforded to the clients of J.P. Morgan Securities plc or for providing advice in relation to the tender offer.
View original content:
SOURCE Tetragon Financial Group Limited | https://www.1011now.com/prnewswire/2022/04/10/tetragon-financial-group-limited-announcement-final-results-tender-offer-purchase-tetragon-non-voting-shares/ | 2022-04-11T08:07:21 | 1 | https://www.1011now.com/prnewswire/2022/04/10/tetragon-financial-group-limited-announcement-final-results-tender-offer-purchase-tetragon-non-voting-shares/ |
ST. LOUIS, April 10, 2022 /PRNewswire/ -- Global packaging leader TricorBraun announced today that it has entered into an agreement to acquire PB Packaging ("PB"), a wholly-owned business of Pro-Pac Packaging Limited (ASX: PPG) ("Pro-Pac"), expanding its presence in Australia.
One of Australia's leading providers of plastic and glass packaging, PB is a one-stop shop for rigid packaging needs, serving customers in the health, industrial, food, and automotive industries.
"We are excited to grow our business in Australia, offering customers expanded solutions and supply chain options," said Court Carruthers, president and CEO, TricorBraun. "The PB Packaging team's dedication to innovation, quality, and exceptional customer service make them an ideal fit. We are pleased to welcome PB Packaging to the TricorBraun family, and we look forward to investing in its continued growth."
TricorBraun established its footprint in the region with its acquisition of Cormack Packaging in September 2021.
PB's current leadership team will join TricorBraun and all 140 PB team members will be offered positions with the company. Effective with the closing of the transaction, PB will operate as PB Packaging, a TricorBraun company. The company will continue to operate as a stand-alone business.
"We are delighted that TricorBraun will acquire PB and that all Rigid team members will be offered positions with TricorBraun," said Tim Welsh, CEO and managing director, Pro-Pac. "TricorBraun is a natural home for the PB business, and we look forward to completing the transaction expeditiously."
"Over the last 32 years, we've solidified our reputation as one of the most respected distributors of packaging materials and services in Australia," said Andrew Allsop, executive general manager, PB Packaging. We look forward to continuing our service to customers, with TricorBraun's support, resources, and investments in our growth."
Since its founding, TricorBraun has partnered with management teams to successfully acquire and further accelerate growth for 34 packaging companies globally.
The transaction is expected to close in the second quarter of 2022, subject to the Australian Foreign Investment Review Board approval and satisfaction of other customary completion conditions.
About PB Packaging
PB Packaging is the Rigid division of the Pro-Pac Group (PPG) of companies, one of Australia's largest publicly listed packaging companies. Established in 1990, PB Packaging has continuously evolved to meet the varying and diverse needs of its customers, offering a comprehensive product range of locally-moulded and imported products.
About Pro-Pac Packaging
Pro-Pac Packaging Limited (ASX: PPG) is an innovative Flexibles, Industrial Specialty Packaging and Rigid packaging company with a diversified distribution and manufacturing network throughout Australia and New Zealand. Headquartered in Melbourne, Pro-Pac delivers bespoke packaging solutions for a broad group of blue-chip and SME clients in the industrial, food and beverage, health, agriculture and manufacturing sectors. For further information, please visit www.ppgaust.com.au.
About TricorBraun
Founded in 1902, TricorBraun is a global packaging leader and North America's largest distributor of primary packaging. We provide innovative solutions across a wide array of customer end markets in plastic, glass, and aluminum containers, closures, dispensers, tubes, and flexibles. Our award-winning Design & Engineering Center provides forward-thinking design, driven by consumer insight and creative solutions. We leverage our global supply chain expertise, expansive and sustainable footprint, and unmatched purchasing power to identify the best sourcing partners and cost-effective solutions for our customers. TricorBraun is comprised of more than 1,700 packaging professionals operating from more than 75 locations across the Americas, Europe, Asia, and Australia.
View original content to download multimedia:
SOURCE TricorBraun | https://www.1011now.com/prnewswire/2022/04/10/tricorbraun-acquire-pb-packaging-expanding-its-presence-australia/ | 2022-04-11T08:07:28 | 0 | https://www.1011now.com/prnewswire/2022/04/10/tricorbraun-acquire-pb-packaging-expanding-its-presence-australia/ |
The company will present the preclinical data of five novel drug candidates at AACR 2022 (on April 8-13).
Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008.
SHANGHAI and HONG KONG, April 10, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the publication of five posters that will be presented during the upcoming 2022 American Association for Cancer Research Annual Meeting (AACR 2022), taking place from April 8th to April 13th in New Orleans in person or via virtual attendance.
(https://www.aacr.org/professionals/meetings/myaacr-support/ )
"The preclinical studies that we are presenting at AACR 2022 provide a window into five innovative programs in Antengene's pipeline," said Bo Shan, Ph.D., Chief Scientific Officer of Antengene. "These programs target areas that we believe are very important in cancer drug development: Tumor microenvironment (TME) regulators (ATG-037), pathway inhibitors (ATG-018, ATG-022 and ATG-008), and ADCs (ATG-022). These studies have been instrumental in guiding our clinical development plans for each program, including selection of combination partners and biomarkers, that could be used to predict efficacy or improve the proportion of patients who respond to treatment. We are very pleased to share these results with the oncology community."
Details of the posters and corresponding abstracts are shown below:
ATG-037, a highly potent small molecule CD73 inhibitor has superior activity of reversing immunosuppression in higher-AMP environments compared with anti-CD73 antibodies
Abstract: 2576
Session: Cell Cycle, Replication Inhibitors, and Immunotherapy Agents
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 21
This study was designed to compare the T-cell rescue activity of ATG-037, a highly potent and selective oral small molecule inhibitor of CD73, and two CD73 blocking antibodies. CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression. In vitro assays were used to assess each compound's ability to inhibit CD73 enzyme activity and reverse AMP/adenosine mediated T-cell suppression. ATG-037 demonstrated more potent and complete inhibitory activity of cell surface CD73 in this study.
As shown in Figure, the authors found that ATG-037 had a stronger ability to restore T-cell function in higher-AMP environments compared with other clinical anti-CD73 antibodies. These data highlight the potential therapeutic advantages of small molecule inhibitors of CD73 over blocking antibodies. ATG-037 is being evaluated by Antengene in a Phase I trial as monotherapy and in combination with anti-PD-1 antibody in patients with locally advanced or metastatic solid tumors.
The novel ATR inhibitor ATG-018 is efficacious in preclinical cancer models
Abstract: 2604
Session: DNA Damage Response and Repair
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 22
In this study, the preclinical pharmacology data set supporting the development of ATG-018, a small molecule ATR inhibitor, was reviewed. Inhibiting ATR kinase (ataxia telangiectasia and Rad3 related kinase) leads to increased accumulation of double-strand breaks, particularly meaningful for tumor cells which rely on DNA damage response (DDR). ATG-018 was tested in a panel of 142 tumor cell lines and three CDX mouse models to assess anti-tumor efficacy and to identify potential predictive biomarkers. ATG-018 was a potent inhibitor of in vitro ATR activity inhibition and cell proliferation without significant impact on normal peripheral blood mononuclear cell (PBMCs) viability.
In addition, a series of genetic alterations were discovered that correlated with ATG-018 sensitivity and could be potential predictive biomarkers. As shown in Figure, the authors found that ATG-018 demonstrated potent in vivo efficacy in solid tumor/hematologic cancer models with certain DDR-related mutations. These data showed the potential of ATG-018 in synthetic lethality with homologous recombination deficiencies and promising application in a wide range of indications. With single-agent activity and no impact on PBMCs viability, ATG-018 may be well positioned for use in mono- or combination therapy in a wide range of tumors that rely on DDR. Development of a set of predictive biomarkers could enable its use as a precision-medicine. Antengene intends to file the first IND for ATG-018 in 2022.
ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts
Abstract: 1143
Session: Preclinical and Clinical Pharmacology
Date and Time: 9:00 AM – 12:30 PM CST, April 11, 2022
Venue: Poster Section 25
In this preclinical study, ATG-022, an antibody-drug conjugate targeting Claudin18.2 (CLDN18.2), was evaluated in several gastric cancer patient-derived xenograft (PDX) models, to assess whether it had potential across a range of CLDN18.2 expression levels. Human CLDN18.2 is ectopically expressed in a large number of gastric and pancreatic cancers. Monoclonal antibody targeting CLDN18.2 demonstrated a promising clinical benefit when used in combination with chemotherapy. However, it showed suboptimal efficacy in patients with low CLDN18.2 levels.
In this study presented in the AACR, ATG-022 is reported to show high affinity (sub-nanomolar grade) against CLDN18.2 and demonstrated potent in vitro and in vivo antitumor effects, with in vivo efficacy observed in CLDN18.2 low expression PDX models. As shown in Figure, ATG-022 demonstrated much better in vivo efficacy compared with benchmark ADC. In addition, ATG-022 was highly specific for CLDN18.2, with virtually no effect on cells expressing CLDN18.1. In addition, ATG-022 has almost no impact on body weight, a proxy for safety. The authors concluded that ATG-022 shows promise for treating gastric cancer patients with a broad range of CLDN18.2 expression levels, a significant unmet need. Antengene is conducting preclinical studies for ATG-022.
Synergistic effects of the combination of Kras (G12C) with SHP2, ERK 1/2, mTORC1/2 or XPO1 inhibition for the treatment of Kras (G12C) mutated cancer
Abstract: 2679
Session: Signaling Pathway Inhibitors
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 25
This preclinical study was conducted to identify combination therapy regimen that could overcome the short progression free survival that is a characteristic of KRAS G12C inhibitors (linked to acquired resistance). The study evaluated the anti-tumor activity of ATG-012, a KRAS G12C inhibitor, with four other agents that are involved in the multiple pathways impacted by RASi: i) an SHP2 inhibitor (ET0038), ii) an ERK 1/2 kinase inhibitor (ATG-017), iii) an mTORC1/2 kinase inhibitor (ATG-008) or iv) the XPO-1 inhibitor, Selinexor, in preclinical solid tumor CDX models.
While ATG-012 monotherapy induced dose-dependent tumor growth inhibition at day 27, as shown in Figure, the authors also found strong in vivo synergism in 2-agent combinations. In particular, ATG-012 and clinical stage ERK inhibitor (ATG-017) demonstrate strong in vitro and in vivo synergism, suggesting potential clinical application which may overcome the rapid resistance of KRAS inhibitors. These data open the door to a range of combination partners for ATG-012 that could be fine-tuned to address drug resistance and potentially improve progression-free survival by matching tumor type/histology and combination partner for patients with the KRAS G12C mutation. Antengene is conducting preclinical studies for ATG-012.
Identification of MUC5B mutation as a positive predictive biomarker for mTORC1/2 inhibition by ATG-008 in lung cancer
Abstract: 4032
Session: Molecular Pharmacology
Date and Time: 9:00 AM – 12:30 PM CST, April 13, 2022
Venue: Poster Section 26
This study was designed to evaluate whether MUC5B could serve as a positive predictive biomarker for mTORC1/2 inhibition by ATG-008 (Onatasertib) in lung cancer. ATG-008 is a dual mTOR complex 1/2 kinase inhibitor. The mTOR complex regulates cell growth, metabolism, proliferation and survival. While the mTOR pathway is frequently deregulated in cancers, efficacy of mTOR inhibitors in lung cancer has been modest. In the study, 31 lung cancer cell lines were treated with ATG-008 to determine dose response and to correlate the gene mutation, amplification and expression with sensitivity to ATG-008.
As shown in Figure, the authors found that the presence of the MUC5B mutation correlates with more potent anti-tumor efficacy of ATG-008 in vitro and in vivo in lung cancer CDX models. The mucin MUC5B has a critical protective role in normal lung and has been identified as prognostic marker in multiple tumor types. One observation highlighted in the poster is that MUC5B is also mutated in melanoma, endometrial, colorectal, esophogastric and cervical cancers, vastly expanding the potential clinical utility of MUC5B mutation as the predictive biomarker for ATG-008. ATG-008 is being evaluated by Antengene in multiple Phase I and II clinical trials.
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 23 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010/XPOVIO® in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.
Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2020, and subsequent filings with the Hong Kong Stock Exchange.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000
View original content to download multimedia:
SOURCE Antengene Corporation Limited | https://www.1011now.com/prnewswire/2022/04/11/antengene-announces-publication-five-posters-2022-american-association-cancer-research-aacr-annual-meeting/ | 2022-04-11T08:07:35 | 1 | https://www.1011now.com/prnewswire/2022/04/11/antengene-announces-publication-five-posters-2022-american-association-cancer-research-aacr-annual-meeting/ |
TAIPEI, Taiwan, R.O.C., April 11, 2022 /PRNewswire/ -- ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711, "ASEH" or the "Company"), announces its unaudited consolidated net revenues for March and 1st quarter of 2022.
Consolidated net revenues (unaudited)
Pro Forma Basis**
Net revenues for ATM assembly, testing and material business are as follows:
atm net revenues (unaudited)
Pro Forma Basis**
*This press release is intended to comply with Taiwan regulatory requirements.
** Pro forma basis excludes the 4 disposed China Sites.
Safe Harbor Notice:
This press release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People's Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2021 Annual Report on Form 20-F filed on March 29, 2022.
Investor Relations Contact:
View original content:
SOURCE ASE Technology Holding Co., Ltd. | https://www.1011now.com/prnewswire/2022/04/11/ase-technology-holding-co-ltd-announces-monthly-net-revenues/ | 2022-04-11T08:07:42 | 0 | https://www.1011now.com/prnewswire/2022/04/11/ase-technology-holding-co-ltd-announces-monthly-net-revenues/ |
BOLIDEN, Sweden, April 11, 2022 /PRNewswire/ -- Ongoing geotechnical investigations in Aitik show the need to eventually change to a new dam construction method to ensure long-term disposal of tailings. In addition, there is a need to strengthen the current dam construction to meet the best international industry standards. The investments over the next two years are expected to lead to increased investments of a total of SEK 5 billion, of which SEK 1 billion in 2022.
- A high level of dam safety is always our top priority. The new direction naturally entails challenges in the short term, but it also creates long-term opportunities in Aitik and a clear direction for how the business can be developed going forward, says Mikael Staffas, President and CEO of Boliden.
Normally, the dam structures at Aitik's tailings pond are built and filled in line with production. In connection to ongoing geotechnical surveys for future dam heightening, areas with poorer soil conditions than previously estimated have been identified. Additional dam heightening and deposition of tailings against dams in these areas has therefore been suspended. In a first step, existing dam structures will now be strengthened and certain infrastructure will need to be moved. This is estimated to take about two years, after which dam heightenings and deposition in this area can be resumed.
Production in Aitik is not expected to be affected during this time as tailings can continue to be deposited in other parts of the tailings pond. The measures depend on environmental permits and other approvals, but work can be started prior to the permitting process.
For 2022, the total investments in the Group are now expected to increase from previously communicated just over SEK 10 billion to just over SEK 11 billion.
This information is information that Boliden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Director Group Communication, at 08:00 CET on April 11, 2022.
For further information, please contact:
Klas Nilsson, Director Group Communications, phone: +46 70-453 65 88
Mail: klas.nilsson@boliden.com
Due to this communicated press release, a telephone conference for analysts will be held today at 09.00 Stockholm time zone. From Boliden, Mikael Staffas, President and CEO and Håkan Gabrielsson, CFO, participate.
To participate, please call 5 minutes before the opening of the conference:
- from Sweden +46 856642651
- from United Kingdom +44 3333000804
- from United States +1 6319131422
PIN Code: 69409035#
The presentation will be held in English
Boliden is a metals company with a focus on sustainable development. Our roots are Nordic, our market global. Our core competence lies within the fields of exploration, mining, smelting and metal recycling. Boliden has around 6,000 employees and an annual turnover of around SEK 70 billion. The share is listed in the Large Cap segment on NASDAQ OMX Stockholm.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Boliden | https://www.1011now.com/prnewswire/2022/04/11/decision-adjust-dam-construction-aitik/ | 2022-04-11T08:07:48 | 0 | https://www.1011now.com/prnewswire/2022/04/11/decision-adjust-dam-construction-aitik/ |
- Valour has been admitted to The Financial Services Standards Association (in German: Verein zur Qualitätssicherung von Finanzdienstleistungen, "VQF"), a self-regulatory organization.
- The membership assures people that all DeFi Europe AG ("DeFi Europe") trade operations are compliant with Swiss anti-money laundering legislation and provides a regulatory stamp of approval strengthening the Company's trust as an issuer of digital assets
- The membership marks Valour as the first and only ETP issuer with admission to VQF association and it also enables the company to offer digital assets directly to businesses and institutions.
TORONTO, April 11, 2022 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (NEO: DEFI) (GR: RMJR) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that Valour Inc. ("Valour"), its wholly owned subsidiary and a pioneer in digital asset exchange traded products ("ETPs"), has been approved for a Swiss VQF membership through its Switzerland-based entity DeFi Europe.
The Swiss VQF membership was awarded by VQF, a self-regulatory association for the financial industry in Switzerland. The SRO is supervised by the country's official watchdog, the Swiss Financial Market Supervisory Authority ("FINMA").
DeFi Europe is a wholly owned subsidiary of Valour Inc. based in Zug, Switzerland. With the approval, DeFi Europe can now operate as a broker for digital assets, fully compliant with Swiss anti-money laundering legislation, enabling the company to offer access and liquidity in digital assets to businesses and institutions. The membership provides a regulatory stamp of approval strengthening the Company's trust as an issuer of digital assets. Valour becomes the first and only ETP issuer with admission to the VQF association.
"We see a tremendous amount of development across the broker landscape with continued adoption and demand for ETPs and digital assets," said Tommy Fransson, CEO of Valour. "In addition to ETPs, the most innovative brokers are searching for the possibility to offer crypto directly to their clients. With our state of the art infrastructure already in place, in combination with the transparency and trust that is a guiding principle for us at Valour, we see this as our next phase to leverage our existing operations that will enable us to support our counterparts."
"We continue to focus on providing transparency and utility to investors," said Russell Starr, CEO of DeFi Technologies. "Receiving admission to the VQF association further strengthens our value proposition and validates our ambition to be a leading provider of digital assets. We believe this will be an important step in our roadmap to access an even larger part of the institutional market."
Learn more about DeFi Technologies and Valour at defi.tech and valour.com.
The Financial Services Standards Association (in German: Verein zur Qualitätssicherung von Finanzdienstleistungen - VQF) is a self-regulatory organization. In Switzerland, the Swiss Financial Market Supervisory Authority (FINMA) is the Swiss government body responsible for financial regulation of financial institutes/intermediaries such as banks, insurances, broker-dealers, funds as well as SRO's.
DeFi Europe is a wholly owned subsidiary of Valour Inc. based in Zug, Switzerland. Once approved, DeFi Europe will be operating as a broker for virtual assets, fully compliant with Swiss anti-money laundering legislation and enable the company to offer access and liquidity in virtual assets.
Valour Inc. issues exchange-listed financial products that enable retail and institutional investors to access investment in disruptive innovations, such as digital assets, in a simple and secure way. Established in 2019 and based in Zug, Switzerland, Valour is a wholly owned subsidiary of DeFi Technologies Inc. (NEO:DEFI) (GR: RMJ.F) (OTC: DEFTF). For more information on Valour, visit www.valour.com.
DeFi Technologies Inc. is a technology company bridging the gap between traditional capital markets and decentralized finance. Our mission is to expand investor access to industry-leading decentralized technologies which we believe lie at the heart of the future of finance. On behalf of our shareholders and investors, we identify opportunities and areas of innovation, and build and invest in new technologies and ventures in order to provide trusted, diversified exposure across the decentralized finance ecosystem. For more information or to subscribe to receive company updates and financial information, visit https://defi.tech/.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to: the DeFi Europe's Swiss VQF membership; the business plans for DeFi Europe; the growth and adoption of decentralized finance; the pursuit by DeFi Technologies of business opportunities; the development of future ETPs and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited to, regulatory approval of DeFi Europe; the growth and development of the DeFi and cryptocurrency sector; rules and regulations with respect to DeFi; regulatory approval of ETPs and future adoption of Valour's ETPs. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
THE NEO STOCK EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
View original content to download multimedia:
SOURCE DeFi Technologies, Inc. | https://www.1011now.com/prnewswire/2022/04/11/defi-technologies-subsidiary-valour-approved-swiss-vqf-membership/ | 2022-04-11T08:07:55 | 1 | https://www.1011now.com/prnewswire/2022/04/11/defi-technologies-subsidiary-valour-approved-swiss-vqf-membership/ |
STOCKHOLM, April 11, 2022 /PRNewswire/ --
- Ericsson suspends affected business in Russia
- Records a SEK 0.9 b. provision in first quarter 2022
In late February, Ericsson (NASDAQ: ERIC) suspended all deliveries to customers in Russia. In the light of recent events and of European Union sanctions, the company will now suspend its affected business with customers in Russia indefinitely. Ericsson is engaging with customers and partners regarding the indefinite suspension of the affected business. The priority is to focus on the safety and well-being of Ericsson employees in Russia and they will be placed on paid leave.
As a consequence, Ericsson records a SEK 0.9 b. provision in first quarter 2022 for impairment of assets and other exceptional costs. No staff redundancy cost is included. The provision will be recorded in Other Operating Expenses in Segment Networks. Around one third of this amount will impact cashflow.
NOTES TO EDITORS:
FOLLOW US:
Subscribe to Ericsson press releases here.
Subscribe to the Ericsson Blog here.
https://www.twitter.com/ericsson
https://www.facebook.com/ericsson
https://www.linkedin.com/company/ericsson
MORE INFORMATION AT:
Ericsson Newsroom
media.relations@ericsson.com
(+46 10 719 69 92)
investor.relations@ericsson.com
(+46 10 719 00 00)
About Ericsson
Ericsson enables communications service providers to capture the full value of connectivity. The company's portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson's investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Ericsson | https://www.1011now.com/prnewswire/2022/04/11/ericsson-suspends-business-russia-indefinitely-records-provision-q1-2022/ | 2022-04-11T08:08:02 | 0 | https://www.1011now.com/prnewswire/2022/04/11/ericsson-suspends-business-russia-indefinitely-records-provision-q1-2022/ |
SPRING, Texas, April 11, 2022 /PRNewswire/ -- ExxonMobil introduced today its new Exceed™ S performance polyethylene (PE) resins, which deliver industry-leading combinations of stiffness and toughness while being easy to process. Utilizing the company's latest innovations in polymer science, the new PE platform provides opportunities to reduce the complexity of film formulations and designs while improving film performance, conversion efficiency, and packaging durability versus current market references.
Modern film design is a story of increasing complexity and compromise between performance and processability that is accepted to ensure durable packaging and high customer satisfaction. Multi-component resin blends in coextruded and laminated films with high layer counts are common-place. Every step of producing and converting printed film into durable packaging is prone to complexity-induced inefficiency, scrap and human mistakes. What if your resin could help simplify all of this?
"Exceed™ S performance PE resins deliver simplicity without compromise," said Tom Miller, Exceed™ S marketing manager at ExxonMobil. "With Exceed S, converters can obtain high levels of performance with easy processing, stiffness and toughness with less blending, and resin solutions that can simplify operations and improve package durability. In short, it is a platform of performance polyethylene grades designed to do so much, so simply."
Innovative converters can rethink film design with Exceed™ S performance PE by…
- Creating stiff, tough functional layers to maximize performance
- Leveraging increased performance to help facilitate solutions with sustainability benefits
- Reducing the need to add HDPE for stiffness or LDPE for processing
- Creating flatter, less extensible films to increase print and package line efficiency
- Delivering more durable flexible packaging, contributing to consumer satisfaction and helping to reduce food waste
The first three commercially available grades of Exceed™ S resins are designed to ensure low melt pressure and high output on blown film lines. The combined benefits allow the creation of a broad range of packaging and film applications:
- Large-format heavy duty sacks used in industry and agriculture along with silo bags for farming can benefit from increased puncture, impact and tear resistance. Exceed™ S resin's combination of low melt pressure and high extrusion output can also help increase converter's production capacity.
- In primary packaging, non-laminated coextruded films used in pouches and bags containing liquid, food, or other goods can benefit from improved toughness and are less likely to break when transported or dropped. For example, multi-wall bladders used in hot-filled bag-in-box packaging exhibit exceptional resistance to heat-induced blocking and flex cracking.
- PE//PE laminates with improved stiffness, toughness and bag drop survival can help facilitate larger pouch sizes and accommodate bulkier, heavier contents, helping to expand market usage of mechanically recyclable packaging.*
In these types of applications, the outstanding mechanical properties of Exceed™ S resins can be used to increase film performance, maintain comparable performance at a thinner gauge, produce more durable mono-material products, or incorporate high percentages of recycled content. Providing such solutions are part of ExxonMobil's four-pronged approach of using performance polymers to help facilitate solutions with sustainability benefits.
"ExxonMobil has been at the forefront of polyethylene innovation for nearly thirty years," said David Hergenrether, vice president for polyethylene at ExxonMobil. "The new Exceed™ S platform embodies our most advanced product and process development informed by deep, long-standing partnerships with our customers."
"The innovation opportunities that Exceed™ S performance polyethylene offers have already resulted in successful collaborations with more than 75 customers globally working on more than 100 different applications. We look forward to collaborating with our customers on new opportunities to advance their products."
Learn more about ExxonMobil's Exceed™ S solutions, visit: https://www.exxonmobilchemical.com/pe
View original content to download multimedia:
SOURCE Exxon Mobil Corporation | https://www.1011now.com/prnewswire/2022/04/11/exxonmobil-introduces-new-exceed-s-performance-polyethylene-enabling-converters-rethink-film-design-simpler-solutions/ | 2022-04-11T08:08:09 | 1 | https://www.1011now.com/prnewswire/2022/04/11/exxonmobil-introduces-new-exceed-s-performance-polyethylene-enabling-converters-rethink-film-design-simpler-solutions/ |
RADNOR, Pa., April 10, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Astra Space, Inc. ("Astra") (NASDAQ: ASTR) f/k/a Holicity Inc. ("Holicity") (NASDAQ: HOL). The action charges Astra with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Astra's materially misleading statements to the public, Astra investors have suffered significant losses.
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE
CLICK HERE TO SUBMIT YOUR ASTRA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/astr-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=tal&utm_content=astra
LEAD PLAINTIFF DEADLINE: APRIL 11, 2022
CLASS PERIOD: FEBRUARY 2, 2021 AND DECEMBER 29, 2021
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com
ASTRA'S ALLEGED MISCONDUCT
Astra operates as an operational space launch company. On June 30, 2021, Astra and Holicity, a special purpose acquisition company, merged.
On February 2, 2021, Holicity filed a Form 8-K, which attached a press release dated February 2, 2021 entitled "Astra to become the first publicly traded space launch company on NASDAQ via merger with Holicity" which announced the merger with Astra. The February 2, 2021 8-K also attached an investor presentation which included slides touting Astra's ability to "[l]aunch anywhere in the world in 24 hours", its timeline, and its potential market.
The truth emerged on December 29, 2021, when market researcher Kerrisdale Capital released a report entitled "Astra Space, Inc (ASTR): Headed for Dis-Astra" (the Kerrisdale Report"), which alleged myriad issues with Astra. Specifically, the Kerrisdale Report stated that "[m]anagement habitually describes Astra as having the flexibility to launch from 'anywhere in the world,' which is simply not true" reasoning that "[in] the US, Astra can only launch from an FAA-licensed commercial spaceport approved for vertical launch. There are only 5 such sites (plus SpaceX's private Boca Chica spaceport) located in the U.S." The Kerrisdale Report also stated that Astra's "main competitors will soon be launching larger 1,000kg+ payload rockets while Astra has yet to overcome developmental hurdles necessary to successfully launch even a single satellite into any of the emerging broadband mega-constellations." Further, the Kerrisdale Report stated that "[c]onversations with an individual familiar with Astra's rocket design and manufacturing suggest investors may have to endure an uncomfortably high rate of failure as the company ramps to a targeted monthly launch cadence in 2022." Finally, the Kerrisdale Report stated that "[w]hile others in the industry like Rocket Lab are developing well-suited, best-in-class technology, enabling a variety of TAM-expanding missions, Astra is settling for suboptimal acquired technology with only niche applications."
Following this news, Astra's share price fell $1.10 per share, or approximately 14%, to close at $6.61 per share on December 29, 2021.
WHAT CAN I DO?
Astra investors may, no later than April 11, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member Kessler Topaz Meltzer & Check, LLP encourages Astra investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View original content to download multimedia:
SOURCE Kessler Topaz Meltzer & Check, LLP | https://www.1011now.com/prnewswire/2022/04/11/final-deadline-kessler-topaz-meltzer-amp-check-llp-reminds-investors-lead-plaintiff-deadline-securities-fraud-class-action-lawsuit-filed-against-astra-space-inc-fka-holicity-inc-astr/ | 2022-04-11T08:08:15 | 0 | https://www.1011now.com/prnewswire/2022/04/11/final-deadline-kessler-topaz-meltzer-amp-check-llp-reminds-investors-lead-plaintiff-deadline-securities-fraud-class-action-lawsuit-filed-against-astra-space-inc-fka-holicity-inc-astr/ |
SAN FRANCISCO and SUZHOU, China, April 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase I study for IBI322 (anti-CD47 /PD-L1 bispecific antibody) in patients with advanced solid tumors were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Poster No. CT513).
This is a first-in-human, phase Ia/Ib dose escalation/expansion study of IBI322 monotherapy in patients with advanced solid tumors who failed standard of care treatment. 58 subjects were enrolled in the study, 16 of which (27.6%) had previously received PD-1/L1 treatment. The highlights for the study results were as follows:
- 20 patients with various advanced solid tumors at active doses of IBI310 ≥10 mg/kg group were evaluable per RECISTv1.1, 4 achieved PR, with investigator assessed ORR 20%.
- Among 9 patients with NSCLC treated at active doses of IBI310 ≥10 mg/kg group, 3 achieved PR, with investigator assessed ORR 33.3% and the DCR 88.9%.
- IBI322 was well tolerated and showed a favorable safety profile. Treatment related adverse events (TRAEs) occurred in 74.1% (43/58) patients, most frequent TRAEs including anemia, platelet count decreased, pyrexia. The majority of the TRAEs were in grade 1-2. No treatment related death occurred as the cut-off date.
Phase Ia dose expansion study with IBI322 monotherapy has kept updating with longer follow-up after the cut-off date. Preliminary response and disease control have been observed in specific indications (such as SCLC). More clinical data will be mature and presented in the future.
Furthermore, given that IBI322 has demonstrated promising efficacy signals and favorable safety and tolerability profile, phase Ib trial has been conducted to further explore the safety and efficacy of IBI322 in multiple indications.
Professor Jie Wang, principal investigator of the study, Chief of Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, stated: "Immune checkpoint inhibitors (ICI) have shown promising efficacy in various tumor types, but many clinical challenges still remain. With the increasing prescription of ICI in first-line setting, many patients developed into ICI resistance or has poor response rate in clinical practice. Therefore, it is of great clinical significance to develop next generation bi-specific immune checkpoint inhibitors. CD47 is one of the most promising targets in immunotherapy. With innovate bispecific antibody development technology, IBI322 showed favorable safety and preliminary efficacy signals in subjects who had failed previous standard treatment, which increased our confidence in the subsequent expansion cohort study."
Dr. Hui Zhou, Vice President of Innovent, stated: "IBI322 is a bispecific antibody that specifically targeting recombinant anti-differentiation cluster 47 (CD47) and anti-programmed death ligand 1 (PD-L1).IBI322 is independently developed by Innovent Biologics and the company owns global proprietary rights. We are very excited to observe preliminary efficacy and manageable safety profile in patients with advanced malignancy who failed standard of care treatment. We will continue to proceed the phase Ib expansion cohort study and further explore the safety and efficacy of IBI322 in multiple indications. By developing a comprehensive and advanced pipeline of next generation immune checkpoint inhibitors, we hope to bring clinical benefit to more patients."
About IBI322
IBI322 is a recombinant anti-human CD47/PD-L1 bispecific antibody developed by Innovent Biologics. As a bispecific antibody, IBI322 targets CD47 on the surface of tumor cells, blocks SIRPα/CD47 pathway and activates macrophages to attack the tumor cells. Furthermore, IBI322 target PD-L1 on the surface of tumor cells, blocks the PD-1/PD-L1 pathway, which counteracts the inhibition of T cells and activates the T cells to attack the tumor cells. By inhibiting two different targets, IBI322 can not only activate both innate immune pathway and adaptive immune pathway, which provides synergistic effect, but also reduce the red blood cell destruction. IBI322 has received IND approvals from both the NMPA and the U.S. FDA and has been actively developed globally.
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 32 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 7 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection), PEMAZYRE® (pemigatinib), olverembatinib (BCR ABL inhibitor) and Cyramza® (ramucirumab), 1 asset under NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials, and an additional 19 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
Disclaimer:
1. This indication is still under clinical study, which hasn't been approved in China.
2. Innovent does not recommend any off-label usage.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:
SOURCE Innovent Biologics | https://www.1011now.com/prnewswire/2022/04/11/innovent-release-phase-1-results-ibi322-anti-pd-l1cd47-bispecific-antibody-patients-with-advanced-solid-tumors-aacr-annual-meeting-2022/ | 2022-04-11T08:08:22 | 0 | https://www.1011now.com/prnewswire/2022/04/11/innovent-release-phase-1-results-ibi322-anti-pd-l1cd47-bispecific-antibody-patients-with-advanced-solid-tumors-aacr-annual-meeting-2022/ |
PALO ALTO, Calif., April 11, 2022 /PRNewswire/ -- Ladder, the company offering flexible life insurance in minutes, today released "Crocodile," the second installation of its "So Good" brand campaign — a series of humorous and memorable films built around the unique consumer insight that almost 1 in 2 couples with life insurance joke about taking each other out for the payout.
Created in partnership with creative/culture agency FRED & FARID Los Angeles and award-winning director and costume designer Casey Storm (of Spike Jonze and David Fincher credits), the new film stars the Ladder mom unleashing another inventive plot on her beloved husband: this time with the ruse of a romantic parental rendezvous and a little help from a crocodile. Once again, dad escapes the outlandish trap (mostly) unphased, retorting "I'm ok, guys!" with his signature happy-go-lucky demeanor.
With the continuation of this daring campaign and its innovative digital life insurance product, Ladder is cementing its position as the unavoidable disruptor in life insurance — attracting a new generation of consumers and flipping traditional life insurance rhetoric on its head to create easy and open conversations within families.
To champion these conversations, the "Crocodile" spot leads to a landing page with additional videos featuring the So Good cast: a delightful series of father-daughter interview sessions that cover the basics of life insurance. By centering these discussions, Ladder is further shifting life insurance away from a taboo topic to appreciating it as a crucial part of every family dynamic.
"We feel so lucky to have such an amazing client partner. They understand the power of creativity and are willing to take risks and to be bold and disruptive. We hope to continue to capitalize on the success of the campaign with many more films," says FRED & FARID Los Angeles creative agency.
"I love this campaign," says Casey Storm. "For me as a director, the scripts and the campaign are a home run. I've heard how effective the last campaign was and I'm sure this next devilish round will be equally successful at raising brand awareness and making people smile."
"Crocodile is about more than the next installment in our campaign," says Olivia Borsje, VP of Marketing at Ladder. "It's representative of the way Ladder is revolutionizing life insurance for customers — not only through product and distribution innovation, but also through brand. Giving digital consumers a fresh way to re-engage with the category is fundamental to achieving our mission of making life insurance as affordable, accessible, and beloved as it should be."
Ladder's "Crocodile" spot is now live across the country on digital platforms and TV networks.
About Ladder
Ladder is the next generation life insurance company. Offering flexible term coverage in minutes that can save policyholders up to 40%*, Ladder uses an all-digital architecture and real-time underwriting to make life insurance as accessible, affordable, and beloved as it should be. The company is headquartered in Palo Alto, CA and offers coverage up to $8M in all 50 states. To learn more, visit ladderlife.com.
About FRED & FARID
FRED & FARID is a creative/culture agency producing meaningful ideas, grounding brands into culture. Based in Los Angeles, New York, Paris, Shanghai, FRED & FARID's culture is a peculiar mix of the French sense of craft and taste, the Chinese sense of tactic and digital, and the American sense of vision and strategy. The agency focuses on creative consulting, brand strategy, branding, content & social activation, and has produced 1800+ creative campaigns for 250+ brands in 33+ industries, winning 1200+ awards and 30+ industry titles – including Cannes Grand Prix and D&AD 3rd Independent Network.
Media Contact
Liana Corwin, media@ladderlife.com
Jalila Levesque, jalila.levesque@fredfarid.com
Assets
"CROCODILE" FILM: https://www.youtube.com/watch?v=W7sQnmwGsbc
KEY VISUAL: https://www.dropbox.com/sh/9exdup3hhqnb4ew/AADvrGxzUh2ZNzRISIYibz3ta?dl=0
101 FILMS: https://www.ladderlife.com/so-good
KEY VISUALS: https://www.dropbox.com/sh/a6vctsyvgp8wr2a/AACBC9egEJa8u92223b1g-bQa?dl=0
Credits
Title of Ad: "CROCODILE"
Brand: Ladder
VP of Marketing: Olivia Borsje
Brand Marketing Manager: Casey Dubie
Director of Communications: Liana Corwin
Agency: FRED & FARID Los Angeles
Chief Creative Officers: Fred & Farid
Creative Director: Chelsea Steiger
Account Director: Sarah Silberstein
Copywriter: Ciana Alessi
Executive Producer: Amanda Van Caneghem
Strategy Director: Eileen Zhao
Head of Global Communications: Jalila Levesque
Business Affairs Lead: Michelle Fink
Production Company: Production Company Productions
Director: Casey Storm
Executive Producer: Rob Hatch-Miller
Executive Producer: Puloma Basu
Executive Producer: Tom Scharpling
DP: Jake Polonsky
Producer: Rob Hatch-Miller
Producer: Puloma Basu
Editorial: EXILE
Editor: Matt Murphy
Assistant Editor: Ersin Dogruer
Executive Producers: CL Kumpata, Jennifer Locke
Post Producer: Samantha Axelrod
Company 3 Color
Senior Colorist: Sean Coleman
Senior Color Producer: Matt Moran
Executive Producer Color: Connor Callaghan
Company 3 Finish
Lead Flame Artist: Brian Conlon
Flame Artists: Kelly Bumbarger, Sean Wilson, Cecile F. Tescon
Roto Artists: Pam Gonzales, Marianne Magne
Senior Finishing Producer: Paula S. Jiménez
Executive Producer Finish: Connor Callaghan
Music by Human
Head of Sync and A&R Kamela Anderson
Creative Director Craig DeLeon
Composer Jon Hubbell
Sound Design & Mix: Lime Studios
Mixer: Sam Casas
Executive Producer:Susie Boyajan
Disclosure
Ladder Insurance Services, LLC (CA license # OK22568; AR license # 3000140372) distributes term life insurance products issued by multiple insurers – for further details see ladderlife.com. All insurance products are governed by the terms set forth in the applicable insurance policy. Each insurer has financial responsibility for its own products.
*Savings in premium compared with the same customer maintaining their full coverage amount for the policy term. Savings attained by decreasing coverage every three years over the policy's full term on a $1.4M, 20 year policy. Prices valid as of June 15, 2021.
View original content to download multimedia:
SOURCE Ladder; FRED & FARID Los Angeles | https://www.1011now.com/prnewswire/2022/04/11/ladder-releases-crocodile-spot-second-chapter-so-good-campaign/ | 2022-04-11T08:08:28 | 0 | https://www.1011now.com/prnewswire/2022/04/11/ladder-releases-crocodile-spot-second-chapter-so-good-campaign/ |
BEIJING, April 11, 2022 /PRNewswire/ -- Recently, Realsee, a world-leading space digitalization integrated solution provider, officially entered into strategic cooperation with Realestate.com.kh, a real estate portal platform in Cambodia. The partnership will facilitate the sharing of technology and allow both parties to jointly explore new ways to advance the digitalization of real estate.
As a pioneer in digital space capture and processing, Realsee has taken the lead in the large-scale application of 3D reconstruction technology in China. Realsee has not only developed VR hardware acquisition equipment applicable to a range of industries and use cases, but also launched VR inspection, and AI-design functionality. These products have revolutionized the real estate transaction experience for homebuyers and sellers around the world. As of the end of 2021, Realsee had completed the 3D reconstruction of more than 18.44 million physical spaces generating more than 1.6 billion VR views annually.
Built on its advantages in technological leadership and low cost digital space solutions, Realsee has been adopted by more than 100 brands across 27 countries. After formalizing cooperation with Realsee, Realestate.com.kh will fully integrate a range of digital real estate solutions into its network, creating digital twins for potentially tens of thousands of new and existing properties. Realsee's VR solutions offer users the ability to experience lifelike restorations of properties, providing a high level of detail include property dimensions, orientation, surrounding environment – all seamlessly accessed through mobile or web browser.
In the era of COVID-19, VR is making property inspections safer, faster, and easier. Thomas O'Sullivan, CEO of Realestate.com.kh, pointed out that, "Customers usually prefer online housing inspection at present. VR-based housing inspection created by Realsee integrates everything into a 3D space with a more immersive panoramic effect and provides customers with an immersive house inspection experience. This cooperation with Realsee will not only provide a truly improved experience for offline property seekers, but also create significant benefits and value for real estate developers and brokers."
View original content:
SOURCE Realsee | https://www.1011now.com/prnewswire/2022/04/11/realestatecomkh-partners-with-realsee-transform-real-estate-emerging-markets/ | 2022-04-11T08:08:35 | 0 | https://www.1011now.com/prnewswire/2022/04/11/realestatecomkh-partners-with-realsee-transform-real-estate-emerging-markets/ |
- Underscoring its commitment to world-class technology, DAZN has recruited Sandeep Tiku to drive innovation and lead the next phase of platform development
- Sandeep is internationally recognised as a world-class technologist and innovator
LONDON, April 11, 2022 /PRNewswire/ -- DAZN Group, the global sports entertainment company, today announces that Sandeep Tiku will be joining the company as Chief Technology Officer.
Sandeep will lead DAZN's global technology and product teams to drive the next phase of development for its core sports streaming media platform as it integrates new experiences to become an interactive sports entertainment ecosystem and expands into new markets.
Having spent over 20 years designing and developing transformational technology and complex platforms for B2C digital products, Sandeep is recognised as a global technology leader and respected innovator.
Sandeep's impeccable track record in building complex technology, coupled with his entrepreneurial spirit and customer-centric approach, will be invaluable to DAZN.
His appointment follows the launch of DAZN X, the company's innovation lab, and underscores DAZN's ongoing investment in world-class technology and commitment to an exceptional fan experience as it integrates richer and more interactive content for fans to enjoy alongside live sports.
Sandeep joins from Entain, a FTSE 100 global gaming and entertainment company, where he was most recently Chief Operating Officer, and oversaw the technology and operations that supports a portfolio of brands in over 30 markets. During his eight years at Entain, Sandeep was instrumental in developing their industry-leading global platform to be robust and scalable.
CEO of DAZN Group Shay Segev said, "Having worked alongside Sandeep for many years at Entain, I know that he is an exceptional and visionary technologist and the right person to lead DAZN's technology teams. He will be invaluable as we expand our offering with even more ways to entertain and engage sports fans and forge ahead with transforming the global sports market."
Sandeep Tiku said, "To join a company like DAZN that has boundless ambitions and puts the customer at the heart of everything it does, is fantastic. With their vision and my tech experience, the potential is phenomenal. I look forward to working with Shay and the global technology teams to grow DAZN's platform as a true destination for sports fans across the world."
Photo - https://mma.prnewswire.com/media/1793931/DAZN_Sandeep_Tiku.jpg
Logo - https://mma.prnewswire.com/media/1097249/DAZN_Gr
View original content to download multimedia:
SOURCE DAZN | https://www.1011now.com/prnewswire/2022/04/11/sandeep-tiku-join-dazn-group-chief-technology-officer/ | 2022-04-11T08:08:42 | 1 | https://www.1011now.com/prnewswire/2022/04/11/sandeep-tiku-join-dazn-group-chief-technology-officer/ |
Stock price doubles in value
HONG KONG, April 11, 2022 /PRNewswire/ -- Hong Kong Aerospace Technology Group Limited (HKATG; 01725. HK) announced its strategic cooperation with the Company and Shandong Institute of Industrial Technology for the construction and operation of the first high-resolution agricultural satellite constellation (''Golden Bauhinia — Qilu Satellite Constellation'') on 4 April. It is known that the first phase of the project comprising 9 satellites and the first experiment satellite is expected to be launched in July 2022, and the remaining eight operational satellites with 8-band multi-spectral observation capability will be launched in December 2022.
After the news came out, a huge amount of smart money poured into HKATG, its stock soared for 4 consecutive days between 4 April and 8 April. HKATG recorded a four-day gaining streak from its latest low of HK$12.2, in addition to crossing above 10-day and 20-day exponential moving average (EMA), the stock, a new high in three months was made during intraday trading on 8 April. HKATG surged by more than 100% in a few days, and the trading volume moved against the market which up to nearly 800,000 shares, with a capital of HKD 16.83 million involved and an amazing momentum.
According to the Flow of Funds, several foreign and local banks have been increasing their holdings in the past few days, showing confidence in HKATG's prospects. Previously, HKATG announced its collaboration with the College of Engineering of the City University of Hong Kong (''CityU''), the parties have entered into a letter of intent (the ''LOI'') concerning the strategic cooperation in the research and development of advanced satellite technology and related applications in Hong Kong, covering communication systems, antenna technology, advanced materials, data processing, and energy management. With the dominant position in the local commercial aerospace market, HKATG is well-positioned for endless business opportunities.
Annual Results Not Fully Reflected Upcoming Profits
HKATG announced the consolidated annual results for the year ended 31 December 2021, though the gross profit recorded a year-over-year decline of approximately 25.2%, smart investors seem to be aware that last year's results did not reflect several strategic agreements signed by the company since the beginning of 2022, so they bought immediately while the stock price pulled back.
If you read the company's annual report carefully, it is not difficult to analyze the reasons that influence HKATG's gross profit in 2021. The company's key construction, the Satellite Operation Control, and Application Centre at the AMC Premises put into operation last year, which has led to an increase in operating costs while representing a milestone in the production capacity expansion. It is worth mentioning that, according to the latest annual results, the company's net impairment losses on financial assets as of 31 December 2021 have narrowed significantly, from RMB 5,122,000 in 2020 to RMB 131,000 in 2021, the result is quite encouraging.
An exclusive aerospace manufacturer in HK
According to the management of HKATG, the company will gradually put into production batches of optical remote sensing satellites, these satellites will have different types of payloads such as multi-spectral and synthetic aperture radar and can comprehensively provide satellite remote sensing data and products that integrate different bands. The company also announced earlier that those 25 satellites are planned to be launched in 2022 for the "Golden Bauhinia Constellation'', and the ''Golden Bauhinia Satellite No. 1 (04)'' is also ready to launch. With the launch of small satellites in batches, HKATG is expected to realise the on-orbit verification of miniaturized aerospace systems, laying the foundation for next year's business constellation development.
''Golden Bauhinia Satellite No. 1 (04)'' is another pilot satellite of the "Golden Bauhinia Constellation", on the one hand, the satellite will conduct on-orbit testing and verification of micro-miniature remote sensing payloads, and on the other hand, the data generated during the satellite's in-orbit operation will be widely used in agricultural monitoring, disaster prevention, and mitigation, as well as comprehensive urban management and watershed control.
Taking the supporting role in the development of Hong Kong into an international innovation and technology hub, HKATG certainly has a market-dominating position with explosive growth potential in the upcoming years and beyond.
View original content:
SOURCE Hong Kong Aerospace Technology Group | https://www.1011now.com/prnewswire/2022/04/11/smart-money-pours-into-hkatg/ | 2022-04-11T08:08:49 | 1 | https://www.1011now.com/prnewswire/2022/04/11/smart-money-pours-into-hkatg/ |
Stay up-to-date with the latest Korean dramas on Rakuten Viki and watch all-new episodes with subtitles available in more than 150 different languages. Subscribe to Viki Pass and enjoy exclusive shows in HD, completely ad-free.
SAN MATEO, Calif., April 11, 2022 /PRNewswire/ -- April is going to be an exciting month for kdrama fans. Viki presents a line-up of new and exclusive dramas that are sure to satisfy viewers of all ages. From Queendom 2 to Again My Life, viewers can watch the latest episodes online on Viki's website.
Top Korean Drama Picks to Watch This April
Starring Lee Joon Gi and Kim Ji Eun, Again My Life is a crime and mystery Korean drama that follows a hardworking prosecutor who gets killed while investigating a politician suspected of corruption. Kim Hee Woo (Lee Joon Gi) gets another shot at life and tries to discover the truth about what happened to him.
Viewers looking for a romance Korean drama to watch can look forward to Sh**ting Stars (Shooting Stars). Top star, Gong Tae Sung (Kim Young Dae), is viewed as a kind and polite young man in the public's eyes. However, he has a different personality off-screen. As the PR team head, Oh Han Byeol (Lee Sung Kyung) always employs her excellent speech and crisis management skills to maintain Tae Sung's image. Despite their endless bickering, the two gradually develops feelings for each other.
Another must-watch Korean drama is From Now, Showtime! starring Park Hae Jin and Jin Ki Joo. Park Hae Jin plays a famous magician, Cha Cha Woong, who is able to see ghosts. Go Seul Hae (Jin Ji Joo) is a passionate police officer that shares the same ability but is afraid of using it. With Hae Jin's ghostly retinue, they start to work together to catch fiendish criminals.
Check Out More Exciting Shows
Apart from these new Korean dramas, viewers can also watch Queendom 2, a Korean reality survival show that pits six all-female acts against each other in a series of musical challenges. Viewers can look forward to exciting performances as the competitors battle it out to win the crown.
Additionally, viewers can also watch Japanese dramas like Promise Cinderalla – now available on Viki. When her husband reveals that he has met another woman, Katsuragi Hayama (Nikaido Fumi) leaves the house only to be robbed of the money she has. Homeless and penniless, she meets Issei (Maeda Gordon). The bratty high school student offers her a place to stay, only if she plays a game with him.
Watch Korean Dramas Online with Subtitles Free
Viki offers a wide range of genres, including romance, action and comedy. Viewers can watch shows for free or subscribe to Viki for an ad-free experience and be entertained anytime, anywhere. Dramas and movies on Viki are also subtitled in a variety of language options. Viewers can look forward to enjoying their favorite shows in English, French, Traditional Chinese and more.
About Rakuten Viki:
Rakuten Viki is a premier destination for Asian entertainment, offering the best and most accessible selection of Asian movies and shows, including dramas, variety and award shows, and originals across many popular genres. Reaching more than 55 million fans in 190 countries, Rakuten Viki's content is translated into 150+ languages by a community of avid fans. Viki, Inc. as well as Soompi, an entertainment news community, is a part of the Rakuten Group (TSE: 4755), a global leader in e-commerce and internet services that empower individuals, communities, businesses, and society.
View original content to download multimedia:
SOURCE Rakuten Viki | https://www.1011now.com/prnewswire/2022/04/11/watch-these-new-korean-dramas-online-rakuten-viki-this-april/ | 2022-04-11T08:08:56 | 1 | https://www.1011now.com/prnewswire/2022/04/11/watch-these-new-korean-dramas-online-rakuten-viki-this-april/ |
TAMPA, Fla. (WFLA) – You might need long sleeves or even a light jacket this morning, but temperatures climb quickly through the day. We’ll just need t-shirts and sunglasses by the afternoon.
After that cool start, highs reach the mid 80s today, which is above average, but the humidity stays quite low. Expect plenty of blue sky and sunshine today.
It won’t be as cool tonight with lows in the low 60s. Tuesday should be even warmer with highs in the upper 80s. Humidity slowly builds, but it should still feel comfortable tomorrow and Wednesday.
By Thursday, a cold front stalls just to our north and introduces a few showers back into the forecast. We have a 20% chance Thursday and a 30% chance Friday. Widespread storms are not expected, but a few passing showers will develop.
The front remains to our north into next week, so highs stay above average in the mid to upper 80s. | https://www.wfla.com/weather/forecast/warming-up-quickly-today/ | 2022-04-11T08:10:58 | 1 | https://www.wfla.com/weather/forecast/warming-up-quickly-today/ |
Man accused of beating roommate over mosquito argument
DALLAS (CNN) - A Texas man is facing aggravated assault charges after allegedly beating his roommate over an argument about mosquitoes.
Victor Shavers, 43, reportedly admits he hit the man he shares a bedroom with when they began arguing over what mosquitoes look like. The roommate says the attack began when the verbal argument escalated.
The man says Shavers grabbed a wooden stick and beat him in the head with it before he was able to get a metal baseball bat to defend himself. He used that bat to hit Shavers in the head several times.
Both men were treated for their injuries at the hospital. The roommate required multiple stitches on his face.
Police arrested Shavers on an outstanding warrant and also charged him with assault.
A judge ordered him to be held Tuesday on a $28,000 bond.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wflx.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ | 2022-04-11T08:22:53 | 0 | https://www.wflx.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ |
Police say a man is dead after he was stabbed in front of a home on College Avenue in the Bronx on Sunday, April 10.
Investigators say it was around 2:30 p.m. when they found the victim with stab wounds to both legs. The man was later identified as Antonio Iglesias.
Iglesias was taken to NYC Health + Hospitals/Lincoln, where he was pronounced dead. There are no arrests, and the investigation is ongoing. | https://www.nbcnewyork.com/news/56-year-old-man-stabbed-to-death-bronx/3639609/ | 2022-04-11T08:32:22 | 0 | https://www.nbcnewyork.com/news/56-year-old-man-stabbed-to-death-bronx/3639609/ |
- Nio announced Sunday it would raise the prices for its three SUVs — the ES8, ES6 and EC6 — by 10,000 yuan ($1,572), effective May 10.
- A day earlier, on Saturday, Nio said it suspended production due to Covid-related restrictions in the last several weeks that halted production at suppliers' factories.
- Many other electric car companies, from Tesla to Xpeng, have raised prices in the last several weeks.
BEIJING — Chinese electric car company Nio said over the weekend it is raising prices and suspending production as the latest Covid wave added to supply chain challenges.
The company's Hong Kong-listed shares fell nearly 9% in Monday morning trading.
Nio announced Sunday it would raise the prices for its three SUVs — the ES8, ES6 and EC6 — by 10,000 yuan ($1,572), effective May 10. Prices for the recently launched ET7 and ET5 sedans would remain the same.
Raw material prices, particularly those for batteries, have risen "too much" this year with no downward trend in sight for the near term, CEO William Li said as part of the announcement, according to a CNBC translation of the Chinese statement.
"Originally [we] thought we could bear it, but now with this pandemic it's even harder to bear," he said. "We have no alternative but to raise prices. Please be understanding."
A day earlier, on Saturday, Nio said it suspended production due to Covid-related restrictions in the last several weeks that halted production at suppliers' factories.
Money Report
"Due to the impact of Covid on Changchun and Hebei, the supply of some of our auto parts has been cut off since mid-March," Li said. The company's production "managed to rely on auto parts inventory until last week."
He added that as a result of recent Covid outbreaks in Shanghai and Jiangsu province, many suppliers can't provide parts either.
The company began deliveries of its first sedan, the ET7, in late March. A second sedan, the ET5, is set to begin deliveries in September.
Industry-wide price hikes
In terms of monthly deliveries, Nio has lagged behind those of rival start-ups Xpeng — whose cars sell in a lower price range — and Li Auto — whose only model on the market comes with a fuel tank for charging the battery. All three companies delivered more cars in March than February despite supply chain challenges.
Nio was the last of the three start-ups to raise prices.
In March, Xpeng hiked prices for its cars by 10,100 yuan to 20,000 yuan, while Li Auto raised prices by 11,800 yuan. The moves follow Tesla and other electric car companies in the country that have raised prices in the last several weeks.
Covid-related disruptions have hit traditional automakers as well.
Volkswagen said Thursday its factories in Anting on the outskirts of Shanghai and Changchun in the northern province of Jilin remained closed through Friday, April 8.
China's producer price index rose by 1.1% in March from a month earlier and gained 8.3% from a year ago, according to official figures released Monday. The year-on-year increase topped expectations for a 7.9% increase forecast by a Reuters poll.
— CNBC's Arjun Kharpal contributed to this report. | https://www.nbcnewyork.com/news/business/money-report/chinese-electric-car-company-nio-hikes-prices-suspends-production/3639632/ | 2022-04-11T08:32:29 | 0 | https://www.nbcnewyork.com/news/business/money-report/chinese-electric-car-company-nio-hikes-prices-suspends-production/3639632/ |
Beneath the ancient beech forests of the Carpathian Mountains, a quiet monastery in the western Ukrainian village of Hoshiv has transformed itself into a giant playground for a dozen children who've been displaced by the war with their families.
Nuns at the Greek Catholic Congregation of the Sisters of the Holy Family, 100 kilometers (60 miles) from Lviv, have granted refuge to some 40 people fleeing fighting with Russian forces in eastern and central Ukraine.
The sound of birdsong and the gentle drone of prayers are a relief for 59-year-old Ryma Stryzhko, who fled from Kharkiv. “It seemed that the planes were flying in the middle of the house. And you could hear the sound of bombing,” she recalled. She often had to duck behind cars as she was going to buy bread or medicines.
“After what we saw, (the monastery) is a paradise.”
The monastery is in itself a symbol of resilience, built after Ukraine’s independence in the early 1990s. The previous monastery in the village had been closed by communist authorities while the area was part of the Soviet Union, and the nuns were sent to Siberia.
“All our prayers are now focused on peace in Ukraine, for our soldiers, for those innocent people who died, who were murdered,” said Sister Dominica, the head nun.
Before the war, the 17 nuns led a tranquil life. In addition to their religious duties and charitable work, they also grew mushrooms, made their own pasta and painted icons to decorate the chapel. Now, they run after young children, provide support and counseling to their mothers and cook daily for dozens of guests.
“Everything in the monastery is focused on prayer and order,” Sister Dominica explained. But when the Russian invasion began, they told local officials they could host up to 50 displaced people.
“We adjusted the prayer and work schedule to the people,” she said.
More Russia-Ukraine War Coverage
Many of the children who are now laughing and hugging the nuns arrived traumatized.
“In the beginning, they were a little reticent. This is a new place for them. They came from cities where (there is shooting), where there are constant (air raid) sirens,” she said.
But even among these peaceful surroundings, the nuns still get air raid alerts on their smartphones. They warn the rest of the residents by ringing the monastery bells — a less traumatic sound than the loud sirens in the cities — and direct them to the basement.
A makeshift chapel there is decorated with a painting of Mary and baby Jesus, a candle and a large cross made of branches. Mattresses, blankets and benches also line the basement. One of the walls had “The Prodigy” written in chalk, an apparent homage to the British dance-electronic band.
But even when there are no sirens, children happily use the cavernous underground space.
“We play, and read prayers," said Rostyslav Borysenko, a 10-year-old, who fled besieged Mariupol with his mother. “It helps.”
His mother is still anxiously awaiting news of relatives and friends who couldn't escape Mariupol, or were evacuated to eastern areas controlled by Russian-backed separatists.
Despite being thousands of kilometers from the frontlines, conversation at the dinner table mostly revolved around war.
While the families break bread in the dining room, the nuns dine separately in the library, at a long table under a painting of the Last Supper. Among them is 44-year-old Sister Josefa, who was evacuated from a Kyiv monastery on the first day of the war.
“It’s hard to leave the place you lived,” she said. “Although I can live here ... my heart is there. And I’m waiting to go back.”
Click here for complete coverage of the crisis in Ukraine.
Associated Press photojournalist Nariman El-Mofty contributed to this report. | https://www.nbcnewyork.com/news/national-international/after-what-we-saw-its-a-paradise-ukrainian-nuns-open-monastery-to-the-displaced/3639652/ | 2022-04-11T08:41:03 | 0 | https://www.nbcnewyork.com/news/national-international/after-what-we-saw-its-a-paradise-ukrainian-nuns-open-monastery-to-the-displaced/3639652/ |
BALTIMORE — Oriole Park at Camden Yards is bringing new bites to eat this season.
For the first time this year, Jimmy's Famous Seafood will be serving food at the park. It will be near the Section 72 concourse.
The restaurant will be serving up Crab cake egg rolls ($20), crab and shrimp rolls($20), crabby fries and Baltimore superfan Mo Gaba's favorite - the shrimp platter ($16).
In honor of Gaba's death, One dollar from every shrimp platter sold will benefit the Johns Hopkins Children's center.
If you're feeling spicy, The Hot Corner is a new stand. It will be on the lower concourse near sections 49-52. They'll be serving chicken tenders with three types of sauces and toppings including:
Buffalo Tenders: tenders tossed in Franks RedHot aioli and topped with crumbled blue cheese and scallions.
All American Tenders: tenders tossed in cheese sauce, topped with Applewood bacon and scallions.
Capital City Mambo Tenders: tenders tossed in Mambo sauce and topped with scallions and garlic aioli.
They will cost you $15 dollars each.
B&O Market along Eutaw Street has two new dishes. They will be offering crab dip pretzels($16) and a pepperoni pizza pretzel ($14).
Eutaw Street Burger Portable are now offering the Baltimore smash ($14). It's wo short-rib-and-chuck-blend patties topped with shaved onions, American cheese, and special sauce. | https://www.wmar2news.com/news/local-news/new-food-coming-to-orioles-park | 2022-04-11T08:43:46 | 0 | https://www.wmar2news.com/news/local-news/new-food-coming-to-orioles-park |
BALTIMORE — Another year of Orioles baseball is here. When you go to Oriole Park at Camden Yards this year, there are some policies you'll need to review before you head to the ballpark.
Fan Reminders:
• Cashless Policy: Oriole Park at Camden Yards will be a completely cashless ballpark in 2022. In conjunction
with this policy, there will be one “Reverse ATM” machine that can exchange cash to card for use at concession and merchandise stands. The machine is located on the Lower-Level Concourse adjacent to First Aid near Gate D.
• Digital Ticketing: Fans will be required to show tickets on their mobile device upon entry by utilizing the ballpark’s complimentary Wi-Fi network. Fans are encouraged to use the official MLB Ballpark app to buy and show tickets upon entry. For more information, Orioles.com/BallparkApp.
• Bag Policy: Bags will not be permitted at Oriole Park this season. Medically necessary, nursery bags, and clutch purses no larger than 5” x 7” will be permissible.
• Food & Beverage Policy: Fans are allowed to bring food and non-alcoholic beverages into Oriole Park this
year following the provided guidelines:
- All food and beverage must be contained in a clear plastic bag, no larger than one-gallon in size,
- One one-gallon size, sealable plastic bag is allowed per guest.
- Food items should resemble individual portions and not bulk items.
- Fans may bring in a factory-sealed, plastic, non-alcoholic beverage, no larger than 20 oz.
- Frozen water bottles are prohibited for safety purposes.
Gates to Oriole Park at Camden Yards will open two hours before first pitch Monday, at 1:05 p.m. Fans are encouraged to be in their seats and fans at home are encouraged to watch starting at 2:15 p.m for pregame festivities. | https://www.wmar2news.com/news/local-news/orioles-policies-at-camden-yards-this-year | 2022-04-11T08:43:52 | 1 | https://www.wmar2news.com/news/local-news/orioles-policies-at-camden-yards-this-year |
MANILA — Shrugging off his low rating in opinion polls, Philippine politician and former boxing star Manny Pacquiao says his impoverished roots make him the best person to be president, as he warned voters to avoid corruption-tainted candidates.
Pacquiao questioned why people supported Ferdinand Marcos Jr., the current frontrunner for the May 9 vote, pointing to the plundering of the country’s wealth during the harsh authoritarian rule of his late father and namesake.
“The root cause of our country’s problem is corruption and then we would vote for a candidate who has been tainted by corruption? What happened to us as a nation? Where is our intelligence?” Pacquiao said in an interview with Reuters late on Thursday.
Pacquiao is trailing in fourth place on 6% in the latest opinion poll, well behind Marcos, who is leading with 56%.
The incumbent senator has made fighting corruption a centerpiece of his campaign, vowing to strengthen efforts to recover billions of dollars missing since the fall of the Marcos dictatorship in 1986, as part his anti-graft platform.
Marcos’s family was accused of plundering an estimated $10 billion during his late father’s two-decade rule, spending it on jewelry, real estate and artworks including those of Pablo Picasso and Claude Monet.
“Why are we in poverty? Because we don’t have money? Wrong. Because of corruption,” Pacquiao said at his campaign headquarters.
Marcos’s camp did not immediately respond to a request for comment, but the candidate has previously said he cannot apologize for what his father did.
Pacquiao has also sparred with incumbent President Rodrigo Duterte over territorial disputes in the South China Sea. He said he would not be bullied by China if he won the presidency.
“I dare you, bother the Filipino fishermen and I’m the one you would have to face,” Pacquiao said in comments addressed at China. “To be bullied is not in my vocabulary.”
China reiterates its claims of sovereignty in the disputed waterway whenever Manila complains about its actions towards Filipino fishermen.
Duterte has faced criticism for not confronting China more over the conduct of its military, coast guard and fishing fleet in waters around the archipelago, arguing it was pointless since Manila was no match for Beijing’s military might.
If need be, Pacquiao vowed to deploy navy ships in the disputed waters to protect his country’s fishermen and said he valued his country’s relationship with the United States, which he called as “our best friend.”
The only man to hold boxing world titles in eight different divisions, Pacquiao retired from boxing in September after the sport brought him huge riches to propel him from humble beginnings as a dirt-poor youngster doing odd jobs to survive.
Pacquiao said he was unfazed by his low rating in polls, convinced the poor would deliver the votes for him on election day.
His impoverished beginnings made him the best person to take on the presidency, because he understood what it was like to be poor, he said.
“If we are going to discuss poverty, that is not a concept for Manny Pacquiao. I felt and lived that and that is why I want to lift the people out of poverty,” he said. | https://www.unionleader.com/news/back_page/manny-pacquiao-says-he-is-not-to-be-counted-out-of-presidential-race/article_74e47daf-deb4-5d52-9db7-128c0a2939c2.html | 2022-04-11T08:50:07 | 1 | https://www.unionleader.com/news/back_page/manny-pacquiao-says-he-is-not-to-be-counted-out-of-presidential-race/article_74e47daf-deb4-5d52-9db7-128c0a2939c2.html |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.unionleader.com/news/politics/voters/florida-s-desantis-catching-up-to-trump-in-campaign-cash/article_c74f1b71-abfc-5ad2-b1c9-eb0603edc7bd.html | 2022-04-11T08:50:13 | 1 | https://www.unionleader.com/news/politics/voters/florida-s-desantis-catching-up-to-trump-in-campaign-cash/article_c74f1b71-abfc-5ad2-b1c9-eb0603edc7bd.html |
Man accused of beating roommate over mosquito argument
DALLAS (CNN) - A Texas man is facing aggravated assault charges after allegedly beating his roommate over an argument about mosquitoes.
Victor Shavers, 43, reportedly admits he hit the man he shares a bedroom with when they began arguing over what mosquitoes look like. The roommate says the attack began when the verbal argument escalated.
The man says Shavers grabbed a wooden stick and beat him in the head with it before he was able to get a metal baseball bat to defend himself. He used that bat to hit Shavers in the head several times.
Both men were treated for their injuries at the hospital. The roommate required multiple stitches on his face.
Police arrested Shavers on an outstanding warrant and also charged him with assault.
A judge ordered him to be held Tuesday on a $28,000 bond.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wnem.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ | 2022-04-11T08:52:28 | 1 | https://www.wnem.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ |
Man accused of beating roommate over mosquito argument
DALLAS (CNN) - A Texas man is facing aggravated assault charges after allegedly beating his roommate over an argument about mosquitoes.
Victor Shavers, 43, reportedly admits he hit the man he shares a bedroom with when they began arguing over what mosquitoes look like. The roommate says the attack began when the verbal argument escalated.
The man says Shavers grabbed a wooden stick and beat him in the head with it before he was able to get a metal baseball bat to defend himself. He used that bat to hit Shavers in the head several times.
Both men were treated for their injuries at the hospital. The roommate required multiple stitches on his face.
Police arrested Shavers on an outstanding warrant and also charged him with assault.
A judge ordered him to be held Tuesday on a $28,000 bond.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.kttc.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ | 2022-04-11T09:01:22 | 1 | https://www.kttc.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ |
WEEKLY RECIPE
It’s time for a little comfort, and here is a sweet fix. Pound cakes are the pleasing plain-Janes of desserts: figurative no-nonsense confections that provide a welcome pick-me-up without wandering into sugary oblivion. In a world of bling and excess, these cakes are not to be underestimated. Their simplicity is their appeal, humbly playing it straight and ordinary, with no need to primp and accessorize.
A pound cake was traditionally constructed of a pound each of butter, sugar, eggs and flour (hence its name), which yielded an exceptionally large cake. Over time, the ingredients ratio has shifted and reduced according to preference, conveniently producing a single loaf or Bundt cake. Subtle tweaks and discreet flourishes are sometimes added, such as a dash of spice, a sprinkle of citrus zest, a shower of confectioners’ sugar or a drizzle of syrup. Adjustments and additions aside, in the end, the pound cake remains an unfailingly predictable and pleasing treat.
This recipe celebrates the end of the blood orange season. Any citrus is delicious in a pound cake, which is a natural canvas for the spark of citrus. Blood oranges are murkier and less bright than their navel brethren and add a deeper, fruity flavor to the cake. To match this depth, I swapped out some of the granulated sugar with light brown sugar and combined almond meal (flour) with all-purpose flour, yielding a denser, nuttier cake.
Blood Orange Pound Cake
Active time: 15 minutes
Total time: 1 hour and 15 minutes
Yield: Makes one loaf
Cake:
1 1/4 cups all-purpose flour
1/2 cup almond meal
1 teaspoon baking powder
1 teaspoon kosher salt
1 cup unsalted butter, softened
1/2 cup sugar
1/2 cup packed light brown sugar
3 large eggs
1/4 cup sour cream
Zest of 2 blood oranges
1/2 teaspoon vanilla extract
Syrup:
1/4 cup blood orange juice
1/4 cup sugar
Pinch of kosher salt
Heat the oven to 350 degrees. Butter a loaf pan and line the bottom with parchment.
Combine the flour, almond meal, baking powder and salt in a bowl and stir to blend.
In a bowl of an electric mixer fitted with a whisk attachment, mix the butter and sugars until light and fluffy. Add the eggs, one at time, mixing well after each addition. Add the sour cream, orange zest and vanilla and mix to combine. Add the flour mixture, and using a wooden spoon, mix to blend without overmixing.
Spoon the batter into the prepared loaf pan and smooth the top. Bake in the oven until a wooden skewer comes clean, about 1 hour.
While the cake is baking, heat the syrup ingredients over medium-low heat, stirring to dissolve the sugar.
When the cake is ready, remove from the oven and transfer to a rack. Prick the top of the cake with a wooden skewer and brush with some of the syrup. Cool 10 minutes, then remove the cake from the pan. Brush the cake on all sides with the syrup. Cool completely.
Serve dusted with confectioners’ sugar or whipped cream.
• This recipe is from Lynda Balslev, a cookbook author, food and travel writer, and recipe developer. She can be found at TasteFoodBlog.com | https://www.kokomotribune.com/news/features/stuff-we-like-monday-april-11-2022/article_7fadedfc-a6d0-11ec-bc91-2753aa58943b.html | 2022-04-11T09:14:13 | 1 | https://www.kokomotribune.com/news/features/stuff-we-like-monday-april-11-2022/article_7fadedfc-a6d0-11ec-bc91-2753aa58943b.html |
SEATTLE • When Morgan Fyfe Powell was a little girl living in Oxford, she tried all kinds of sports, but wasn't particularly good at any of them.
"I was the kid on the soccer field with a bow in my hair, picking wildflowers," said Powell, 27.
When she was in fourth grade, she began taking art lessons after school from Taylor Ricketts.
"I was creative as a kid, but I didn't think I'd ever be an artist," she said.
She was wrong.
Today, art is Powell's full-time job. She works out of a studio in the home she and her husband, Jesse, share in Seattle. But she hasn't abandoned her roots and will be bringing her talent to two art festivals in Northeast Mississippi this spring.
She'll be at the Double Decker Arts Festival in Oxford on April 23, and at the Gumtree Art and Wine Festival in Tupelo May 6-8.
"I'm so excited to do shows again, to meet people and show my work and get to learn other artists' stories," she said.
From art student to artist
Powell took some art classes in high school and found them to be a welcome challenge.
"I felt I was getting better, and I was encouraged by teachers, but art was just a hobby," Powell said.
In high school, she had created several paintings for her parents, Lea and Richard Fyfe of Oxford. Someone saw one and asked Powell if she'd paint something for them while she was a student at Ole Miss.
"I always had a little studio in my room in college," she said. "It was a healthy outlet for me. It let me be creative."
She accepted that commission. And then someone else saw that painting and asked her to do six pieces for an investment property.
"They were divine encounters," Powell said. "And it was a way for me to fund things in college that were fun without having to ask my parents for money."
Powell majored in social work, and after graduation, she moved to Seattle to take a job in marketing.
"I moved here for a boy, but I wouldn't admit that until after Jesse and I married," she said. "I used to say I moved here for work."
In Seattle, she continued to do artwork on the side as she worked full time.
"At the end of 2019, I was working some pretty long hours and weekends, and I realized I didn't love marketing," she said. "I knew I didn't want to do that for the long haul."
With some good advice and guidance, Powell quit her job and become a full-time artist at the beginning of 2020.
"It was an interesting journey," she said. "You build yourself up and are so excited for the transition. But then there's this pressure to create really good work – something I could be proud of."
So Powell began creating work without pressure. She just started showing up in her studio every day. If she created something she liked, wonderful. If she created something she didn't like, at least she'd showed up.
Her artwork soon took on a different look. She would begin a painting with a full layer of gold and silver leaf, then use heavy body acrylics over the gold.
"I had no idea when I was painting with gold what that meant, but I think I do now," she said. "When I moved to Seattle, I don't know if I could have found a place more different than the South. It's really gray here, and people keep to themselves. You don't meet people as easily, and they're not very warm. I decided if I'm not going to find that here, I'm going to be that here. When you put a painting with gold on it in a room, it reflects the light it's in. I feel like that's me."
'A good balance'
Powell specializes in two kinds of paintings: abstracts and landscapes. For the landscapes, she draws from the beauty of both the Pacific Northwest and the South.
"It's really easy to be inspired," she said. "I take what they represent from my point of view. I know what it's going to look like at the end of the painting, but it's hours and hours before I get there. What story do I really want this painting to tell?"
Powell will do a large batch of landscapes, then go back to abstracts.
"The abstracts are so freeing because I don't know what they're going to look like," she said. "So it's a good balance. It may take me years to finish one. I may work on 30 paintings at one time. I like the flow of constantly moving from one to another. And that's also a way not to waste paint."
Now that COVID-19 restrictions are lifting around the country, Powell is eager to participate in art shows again. She had applied to several in 2020, but they all got canceled. She was able to attend two shows in Seattle in 2021.
At the art festivals in Oxford and Tupelo this spring, Powell will have everything from 4-by-4-inch paintings to 48-by-60-inch paintings as well as stationery card prints.
"I want to have a range for people's space and budgets," she said. "I feel like art is an investment, not just financially, but also an investment in the space in your house."
Powell and her husband don't have a lot of wall space in their townhouse on a beach in Seattle. She has one painting hanging, and it isn't even one of her own.
"When we grow out of this house, I'd love to support other artists," she said. "I want to have their work on my walls." | https://www.djournal.com/lifestyle/arts-entertainment/oxford-native-turns-passion-for-painting-into-career/article_be55d5d2-7e43-560f-b988-ae537d984645.html | 2022-04-11T09:27:36 | 0 | https://www.djournal.com/lifestyle/arts-entertainment/oxford-native-turns-passion-for-painting-into-career/article_be55d5d2-7e43-560f-b988-ae537d984645.html |
Recycling
Tupelo residents living north of Main Street will have recycling pickup Wednesday. Residents south of Main Street will have pickup next Wednesday.
Government calendar
• The Lee County Board of Supervisors meet on the first and third Monday of every month at 9 a.m. at the Board of Supervisors office at 300 W. Main St., Tupelo, MS 38804.
• The Tupelo City Council meets on the first and third Tuesday of every month at 6 p.m. in the City Council chambers at Tupelo City Hall at 71 E. Troy St., Tupelo, MS 38804
All board of aldermen meetings at respective city halls:
Baldwyn • First Tuesday of the month at 6 p.m.
Guntown • First Tuesday of month
at 5:30 p.m.
Nettleton • First Monday of the month at 6:30 p.m.
Plantersville • First Tuesday of the month at 6 p.m.
Saltillo • First Tuesday of the month at 6 p.m.
Shannon • First Thursday of the month at 6 p.m.
Sherman • First Tuesday of the month at 6 p.m.
Verona • First Tuesday of the month at 6 p.m.
Meetings
• The AARP Chapter of Tupelo will meet the first Wednesday of each month in the Helen Foster Auditorium of the Lee County Library in Tupelo. The meeting is open to residents of Tupelo, Lee County and surrounding counties. Call Henry Cobb at (662) 231-3507 or Lonnice C. Mitchell at (662) 566-7818.
• Al-Anon is a mutual support group of peers who share their experience in applying the Al-Anon principles to problems related to the effects of a problem drinker in their lives. The Peace Seekers Al-Anon group meets at noon every Wednesday at Calvary Baptist Church Family Life Center, 501 W. Main St., in Tupelo. For more information, contact Bob W. at (662) 401-8094.
• American Legion Post 51 in Fulton meets at 6:30 p.m. the second Tuesday of each month. Bring a covered dish for supper. Call (662) 862-9230.
• BSF will begin its study on the Book of Genesis on Sept. 17, but because of COVID-19, we will begin online. Group leaders will contact you and help get you connected. Interested? Call 662-844-0427.
• Bible Study Fellowship for women meets Thursdays from 9 until 10:30 a.m. from September to May. Host church is The Orchard, 1379 Coley Road in Tupelo. For information, call (662) 844-0427 or visit bsfinternational.org.
• Biggersville Dulcimer Club meets at 5:30 p.m. the first and third Wednesday of each month at the Biggersville Pentecostal Church on Hwy. 45 N., Biggersville. Call (662) 287-1054.
• Boone Country Dulcimers meets at 6 p.m. the second and fourth Mondays of each month at the Landmark Community Assisted Living Center in the old high school at 701 W. Church St., Booneville. Call (662) 728-5448 or email forsmith@bellsouth.net.
• Concerned Citizens For Justice meets at 6 p.m. the second and fourth Thursday of each month at The A.M. Strange Library, North Spring Street, Tupelo. Call James Brim (662) 871-2531.
• Conservative Women In Action (CWIA) meets from noon to 2 p.m. the second Tuesday of each month at McAlister’s Deli of Tupelo. CWIA is a group of women dedicated to “Making a Difference, One Change at a Time.”
• Crosstown Dulcimer Guild meets from 6 to 8 p.m. the first and third Mondays of each month at Tupelo Baptist Church, 1406 Eckford St. Call (662) 842-8318.
• The Fairfield Dulcimer Club meets at 6 p.m. the first and third Thursday of each month at the Fairfield Presbyterian church in Blue Springs. For more information, call (662) 534-8822.
• The Gathering is held at the Carolina United Methodist Church Fellowship Hall on the first Tuesday of each month from 9 a.m. until 2 p.m. There are community speakers, devotions, potluck lunch, and bingo and dominoes. Contact Patti Powell at (662) 760-7308.
• The Green Tee Neighborhood Association meets from 6 to 7 p.m. the second Monday of each month at the Boys and Girls Club on Willie Moore Road. For more information, call Gladys Betts (662) 566-2075.
• GumTree Quilters Guild meets at 6:30 p.m. the first Tuesday of each month at All Saints’ Episcopal Church, 608 W. Jefferson St., Tupelo. All those interested in the art of quilting are encouraged to attend. For more information, contact president Carolyn Terry at (512) 864-4018 or gumtreequilters@gmail.com; or Marcelle Bethany aat (662) 680-3160.
• Gum Tree Woodworkers Club meets the first Tuesday of each month at 6 p.m. at Old West Fish and Steak Restaurant. All area woodworkers are invited to attend.
• Indivisible Northeast Mississippi: Non-partisan, grass-roots organization of politically progressive voters in the First Congressional District. We follow the Indivisible.com guide. Indivisible meets the second Tuesday of each month at the Link Center (West entrance off Douglas Street) at 5:30 p.m. Meeting begins at 6 p.m. Call MJ at (251)-597-7979 for information.
• The Kiwanis Club of Tupelo meets at noon every Friday at the Tupelo Country Club. For more information, visit http://www.tupelokiwanis.org/.
• The Lee Acres Neighborhood Association meets the third Thursday of every month, except in December. Meetings are held at Lawndale Presbyterian Church in Tupelo at 6 p.m. For more information, call Donna Wardlaw at 662-372-1277.
• The Lee County Community Civitan Club meets at 9 a.m. the second Saturday of each month at Verona City Hall. For more information, contact Sherry Garrett at (662) 231-4377.
• The Lee County Republican Club meets at 6 p.m. the second Monday of each month (except December) at Bar-B-Q by Jim restaurant, 203 Commerce St., in Tupelo.
• The Lee County Section of the National Council of Negro Women meets at 6 p.m. the second Monday of each month at the A.M. Strange Library on North Spring Street in Tupelo.
• The Lee County Shriners meets the first Tuesday of each month at the Shrine Club in Tupelo. Meetings include a meal and a program.
• The Magnolia Dulcimer Club meets at 6 p.m. the first and third Monday of each month at the First Presbyterian Church, 919 Shiloh Road, Corinth. Call Larry Kendall at (662) 728-4675 or Jan Pike at (662) 665-1871 or email janicepike85@yahoo.com.
• The Marine Corps League, G.H. Vaughn Detachment, meets at 7 p.m. the second Monday of each month. Call (662) 272-5292 or (662) 327-4016.
• Mindful Moments Mindfulness Group meets from 6 until 7:30 p.m. every Tuesday in the group room at Conscious Healing Therapies, 302 S. Spring St., in Tupelo. Free, but love offerings are accepted for donations to the community. For more information, call (662) 841-8020.
• National Active and Retired Federal Employees will not meet again until September.
• Newborns in Need meets from 9 a.m. to 2 p.m. the second Saturday of each month at the Saltillo City Hall and the fourth Friday of each month at the Lee County Baptist Association. They provide sleepers, gowns, handmade quilts and blankets, burial layettes and other necessary items for babies facing health or economic crisis. Open to the public, the group asks that people bring sewing machines, sergers and scissors, and a covered dish and drink for lunch.
• Northeast Mental Health-Mental Retardation Commission meets at noon the last Thursday of each month at the Chemical Dependency Unit, 920 Boone St., in Tupelo.
• Oxford Dulcimer Club meets at 6 p.m. the second and fourth Thursday of each at Peace Lutheran Church in Oxford. Call (662) 234-3571.
• Pontotoc Ridge Dulcimer Club meets at 6 p.m. the first and third Thursday of each month at the Pontotoc Library. Call (662) 489-5724.
• The Presley Heights Neighborhood Association meets at 6:30 p.m. the second Tuesday of each month at the J.T. Neely Building at Veterans Park.
• The Ratliff R.C.D.C. meets at 7 p.m. the first Monday of each month. A potluck supper will be held at the beginning of the meeting. Visitors are welcome.
• Richmond Lodge 97 Free and Accepted Masons meets at 7 p.m. the first Tuesday of each month at the Lodge Hall in the Evergreen community.
• Rotary Club of Tupelo meets every Monday at noon, except for holidays, at Calvary Baptist Church, 501 Main Street, Tupelo. Contact (662) 231-2995 or info@tupelorotary.com.
• Rotary Satellite Meeting is from 5:30 until 6 p.m. the first and third Tuesdays at Bulldog Burger in Tupelo. Contact (662) 231-1401 or info@tupelorotary.com.
• Senior citizens meet at 10 a.m. the first Monday of each month at the New Site Volunteer Fire Department.
• Tippah Dulcimer Guild meets at 6 p.m. the second and fourth Tuesday of each month at the Ripley Public Library. Every fifth Tuesday, the guild meets at 6 p.m. at Shirley’s Restaurant in Ripley. Call (731) 609-9349.
• The Tupelo Ballroom Dance Club meets from 7:30 to 9 p.m. every Monday at The Dance Studio at 108 N. Spring St., next to Sprint Print. The dances, which are at the beginning level, are free and open to the public.
• Tupelo Christian Women’s Club, sponsored by Stonecroft Ministries of Kansas City, Mo., is a club where women connect with God, each other and their communities through meetings and Bible studies. The club meets at 11:30 a.m., with a lunch buffet at 11 a.m., the second Tuesday of each month at the Tupelo Country Club. Call (662) 844-5258 or (662) 869-5784.
• Tupelo Duplicate Bridge Club meets at 1 p.m. every Monday, Wednesday and Friday at the Bel-Air Center in Tupelo. Call Suzi Rogers at (662) 346-4284 or Jeremy Herndon at (662) 321-1261.
• Tupelo Evening Civitan Club meets at 6:30 p.m. the first and third Tuesday of each month at American Legion Post 49. Call (662) 871-8994 or (662) 213-3024 or email kppro77@gmail.com.
• The Tupelo Kennel Club meets at 6 p.m. the second Tuesday of each month at McAlister’s Restaurant in Tupelo. For more information, call Tere Woody at (662) 416-1392.
• The Tupelo Lions Club meets at noon every Tuesday at New China Buffet, 3877 N. Gloster St., in Tupelo. For more information, call (662) 231-2565.
• Tupelo Luncheon Civitan Club meets at 11:30 a.m. every Thursday at The Anchor Church in Verona. Call Marla Elmore at (662) 397-6747 for more information.
• Tupelo Parks and Recreation Department’s Young at Heart Club meets from 6:30 to 9 p.m. at the Bel-Air Center in Tupelo every Thursday, except on 5th Thursdays. Casual dress. The meeting includes live music and dancing. Admission is $5 for a regular meeting and $7 for a catered meeting. No smoking or drinking allowed. For additional information, call (662) 587-3514.
• Veterans of Foreign Wars will meet the second Tuesday of each month at 6:30 p.m. at 1748 Mitchell Road in Tupelo, for a free meal followed by meeting. For more information, call (662) 842-8732. We need your involvement. | https://www.djournal.com/print-features/monday-meetings-for-april-11/article_ea83962c-5ae3-5f3c-8c4d-3e28f831e6b0.html | 2022-04-11T09:27:42 | 0 | https://www.djournal.com/print-features/monday-meetings-for-april-11/article_ea83962c-5ae3-5f3c-8c4d-3e28f831e6b0.html |
Banning Russian oil imports could give Biden more leeway
The U.S. Senate has voted unanimously to ban any oil imports from Russia (Gaston Gazette, 4/8/22).
This will probably increase the price we pay at the gas pumps only a little, because Russia sources a small fraction of the oil we import.
The bill is mostly a symbolic gesture, but by also ending normal trade relations with Russia, the Senate enables President Biden to raise tariffs on other Russian products such as steel and aluminum.
This is news welcomed by domestic producers of oil, steel and aluminum, since it makes their products more affordable in comparison.
Make no mistake — tariffs are paid for by domestic consumers, not foreign producers. Not only are US consumers harmed (by having to pay increased prices for goods subject to tariffs), but also foreign workers who produce those goods have less gainful employment.
Will this make employees in those Russian industries like us more or like us less? You do the math.
David Hoesly is a resident of Gastonia. | https://www.gastongazette.com/story/opinion/2022/04/10/banning-russian-oil-imports-could-give-biden-more-leeway/9537316002/ | 2022-04-11T09:32:13 | 0 | https://www.gastongazette.com/story/opinion/2022/04/10/banning-russian-oil-imports-could-give-biden-more-leeway/9537316002/ |
This content is only available to subscribers.
Support Local Journalism
$1 for 6 Months.
Your subscription supports:
Are you a subscriber with digital access?
Sign in to your accountAre you a subscriber without digital access?
Activate your digital accountAre you a subscriber without digital access?
Activate your digital accountThis content is only available to subscribers.
Support Local Journalism
$1 for 6 Months.
Your subscription supports:
Are you a subscriber with digital access?
Sign in to your accountAre you a subscriber without digital access?
Activate your digital account | https://www.gastongazette.com/restricted/?return=https%3A%2F%2Fwww.gastongazette.com%2Fstory%2Fnews%2F2022%2F04%2F11%2Fsouth-fork-sampler-adventure-race-running-biking-kayaking-gaston-gazette-janiya-winchester%2F9438684002%2F | 2022-04-11T09:32:27 | 1 | https://www.gastongazette.com/restricted/?return=https%3A%2F%2Fwww.gastongazette.com%2Fstory%2Fnews%2F2022%2F04%2F11%2Fsouth-fork-sampler-adventure-race-running-biking-kayaking-gaston-gazette-janiya-winchester%2F9438684002%2F |
WASHINGTON — You’ve likely heard a lot lately about Title 42, the pandemic-related public health policy that kept over a million migrants seeking asylum out of the U.S. last year.
President Biden has said that will end next month, on May 23rd, frustrating those who are concerned about a mass migration event at the border. So what is happening right now to prepare for the spike?
HISTORY OF SEEKING ASYLUM
Seeking asylum is permitted by U.S. law and is typically understood as escaping persecution from another country.
During the pandemic, however, the Trump and Biden administrations expanded the authority of the Department of Homeland Security to remove asylum-seeking individuals because of COVID-19 concerns.
That is what Title 42 is generally understood to be.
FRUSTRATION OVER CHANGE
“This isn’t our first time warning about this,” House Minority leader Kevin McCarthy (R-CA) told reporters on Capitol Hill at a recent briefing about Title 42.
"You are already seeing mayhem down at the border," McCarthy added.
The policy change, though, is frustrating conservatives like McCarthy, as well as moderate Democratic senators like Senator Mark Kelly and Kyrsten Sinema of Arizona, Senator Catherine Cortez Masto of Nevada and Senator Jon Tester of Montana.
Their concern is that more than 1.6 million migrants were expelled under Title 42 in the last year or so from the United States and in theory many will soon be able to try again, possibly overwhelming the border.
BIDEN ADMINISTRATION'S PLAN
So what do we know about President Biden's plan for the border after this controversial rule goes away next month?
For one the Department of Homeland Security is acknowledging an increase in numbers is “likely.”
As a result, preparations are underway to increase coordination with non-profits to ensure proper shelter and supplies. DHS is also creating new border facilities in key areas ahead of the expected surge.
The Department is also redirecting employees to the region to help with the processing of migrants. Additional preparations are underway so that air and ground transportation is available to send migrants to less crowded facilities should issues arise in one area.
WHY TITLE 42 IS ENDING?
If you are wondering why the policy is ending, Physicians for Human Rights recently testified in front of Congress saying COVID-19 should have never been an excuse to deny people help.
“These exclusionary practices are not now, and were not ever based on sound public health principles,” Dr. Adam Richards said.
Progressive groups have pressured the Biden administration to end Title 42 for over a year. Expect to hear more on the issue in the coming weeks.
A COVID-19 funding bill in Congress remains stalled because some in the Senate want the president to change his mind on Title 42. | https://www.wrtv.com/news/national-politics/what-is-title-42-and-what-is-being-done-to-address-an-expected-surge | 2022-04-11T09:36:57 | 0 | https://www.wrtv.com/news/national-politics/what-is-title-42-and-what-is-being-done-to-address-an-expected-surge |
Air Quality Alert for Southern Arizona
TUCSON, Ariz. (KOLD News 13) - The Arizona Department of Environmental Quality has issued an Air Quality Alert for the Tucson Metro Area, including the cities of Tucson, Green Valley, Marana and Vail. ADEQ also issued a PM-10 High Pollution Advisory for the Rillito (near Marana) area on Monday. An episode of strong and gusty winds is forecast to generate widespread blowing dust that may result in local PM- 10 concentrations that pose a health risk. Adverse health effects increase as air quality deteriorates. Coarse particulate matter - also known as PM-10 - is an air contaminant that can aggravate heart and lung disease conditions, especially in older adults, children, and those with asthma.
A decrease in physical activity is recommended. Consolidate your travel, stabilize loose soils, slow down or avoid travel on dirt roads, reduce or eliminate fireplace use, and avoid using gas-powered lawn equipment.
Copyright 2022 KOLD News 13. All rights reserved. | https://www.kold.com/2022/04/10/air-quality-alert-southern-arizona/ | 2022-04-11T09:40:45 | 0 | https://www.kold.com/2022/04/10/air-quality-alert-southern-arizona/ |
Elon Musk no longer joining Twitter’s board of directors
SAN FRANCISCO (AP) - Tesla CEO Elon Musk won’t be joining Twitter’s board of directors as previously announced. The tempestuous billionaire remains Twitter’s largest shareholder.
Twitter CEO Parag Agrawal tweeted the news, which followed a weekend of Musk tweets suggesting possible changes to Twitter, including making the site ad-free. Nearly 90% of Twitter’s 2021 revenue came from ads.
“Elon’s appointment to the board was to become officially effective on 4/9, but Elon shared that same morning that he would not be joining the board,” Agrawal wrote in a reposted note originally sent to Tesla employees. “I believe this is for the best.”
Agrawal didn’t offer an explanation for Musk’s apparent decision. He said the board understood the risks of having Musk as a member. But it, “believed having Elon as a fiduciary of the company, where he, like all board members, has to act in the best interests of the company and all our shareholders, was the best path forward,” he wrote.
Musk posted a few cryptic tweets late Sunday, including one showing a meme saying, “In all fairness, your honor, my client was in goblin mode,” followed by one saying “Explains everything.” Another, later tweet was of an emoji with a hand over its mouth.
He now has a 9% stake in Twitter, raising questions about how he might try to reshape the social media platform as Twitter’s biggest shareholder.
Musk’s 80.5 million Twitter followers make him one of the most popular figures on the platform, rivaling pop stars like Ariana Grande and Lady Gaga. But his prolific tweeting has sometimes gotten him into trouble, such as when he has used it to promote his business ventures, rally Tesla loyalists, question pandemic measures and pick fights.
In one famous example, Musk apologized to a British cave explorer who alleged the Tesla CEO had branded him a pedophile by referring to him as “pedo guy” in an angry — and subsequently deleted — tweet. The explorer filed a defamation suit, although a Los Angeles jury later cleared Musk.
He’s also been locked in a long-running dispute with the U.S. Securities and Exchange Commission over his Twitter activity. Musk and Tesla in 2018 agreed to pay $40 million in civil fines and for Musk to have his tweets approved by a corporate lawyer after he tweeted about having the money to take Tesla private at $420 per share. That didn’t happen but the tweet caused Tesla’s stock price to jump. His lawyer has contended that the SEC is infringing on Musk’s free speech rights.
Musk has described himself as a “free speech absolutist” and has said he doesn’t think Twitter is living up to free speech principles — an opinion shared by followers of Donald Trump and several right-wing political figures who’ve had their accounts suspended for violating Twitter content rules.
But what’s really has been driving Musk’s Twitter involvement isn’t clear. Other preoccupations with the service include arguing to make Twitter’s algorithm viewable by the public, widening the availability of “verified” Twitter accounts, and blasting a profile photo initiative involving non-fungible tokens, or NFTs.
Musk has also called “crypto spam bots,” which search tweets for cryptocurrency related keywords then pose as customer support to empty user crypto wallets, the “most annoying problem on Twitter.”
Twitter’s CEO and other board members have praised Musk, suggesting they might take his ideas seriously.
Agrawal’s initial actions since taking over from co-founder Jack Dorsey in November have involved reorganizing divisions without making major changes. The company has long lagged behind its social media rivals and boasts far fewer users.
Copyright 2022 The Associated Press. All rights reserved. | https://www.kold.com/2022/04/10/elon-musk-suggests-twitter-changes-including-accepting-dogecoin/ | 2022-04-11T09:40:52 | 1 | https://www.kold.com/2022/04/10/elon-musk-suggests-twitter-changes-including-accepting-dogecoin/ |
Kinder chocolate products recalled in US after salmonella cases reported in Europe
(Gray News) – Ferrero, Inc. is voluntarily recalling two of its Kinder chocolate products because of a possible salmonella contamination.
The company is recalling two Kinder products in the U.S. These include Kinder Happy Moments Chocolate Assortment and Kinder Mix Chocolate Treats basket.
Salmonella can cause serious and sometimes fatal infections in young children, frail or elderly people, and people with weakened immune systems, the FDA says.
Symptoms of salmonella infection in healthier people can include fever, diarrhea, nausea, vomiting and abdominal pain.
In rare cases, salmonella can produce more severe illnesses like arterial infections, endocarditis and arthritis.
Ferrero says the products are being recalled because they were manufactured in a facility where salmonella was detected.
There have been no reports of illness in the U.S. so far, the company says. The voluntary recall is due to an abundance of caution after Salmonella cases were reported by people in Europe who consumed chocolates from the same facility.
No other Kinder products in the U.S. were recalled.
Ferrero says it “deeply regrets the situation” and that it takes food safety “extremely seriously” and will continue to work with the FDA to address the situation.
If you’ve purchased either of the products, Ferrero says to not eat it and to contact the company’s customer service line sometime between 9 a.m. and 6 p.m. Monday through Friday EST at 1-800-688-3552 or via https://www.ferreronorthamerica.com/contact-US-residents.
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.kold.com/2022/04/10/kinder-chocolate-products-recalled-us-after-salmonella-cases-reported-europe/ | 2022-04-11T09:40:58 | 0 | https://www.kold.com/2022/04/10/kinder-chocolate-products-recalled-us-after-salmonella-cases-reported-europe/ |
Man ran over other man with car after argument, Phoenix police say
PHOENIX (3TV/CBS 5) -- Police say they’ve arrested a man who allegedly ran over a 62-year-old man near 12th Street and Northern Avenue in Phoenix late Friday night.
Phoenix police say they were called out to a parking lot in the area after hearing that a man had just been hit by a car. Officers learned that the victim had just been involved in an argument with the suspect, identified as 62-year-old Paul Scott. The victim died in the parking lot.
Investigators say Scott stayed at the scene and had asked someone to call police for help. He has been booked into jail on one count of First-Degree Murder. Authorities are asking someone who might have seen the altercation to call police at 602-262-6151 or through Silent Witness at 480-WITNESS.
Copyright 2022 KTVK/KPHO. All rights reserved. | https://www.kold.com/2022/04/10/man-ran-over-other-man-with-car-after-argument-phoenix-police-say/ | 2022-04-11T09:41:04 | 0 | https://www.kold.com/2022/04/10/man-ran-over-other-man-with-car-after-argument-phoenix-police-say/ |
National Siblings Day
TUCSON, Ariz. (KOLD News 13) - National Siblings Day is a celebrated every year on April 10. The holiday honors our brothers and sisters.
Siblings can be our best friends or our worst enemies. At times, siblings will provide us with our biggest competition, strongest encouragement and remind us of our most embarrassing moments.
In 1995, native New Yorker, Claudia Evart, founded National Siblings Day to honor and celebrate siblings. After losing her two siblings early in life in separate accidents, she knew how important siblings could be in our lives.
Evart created the Siblings Day Foundation, a tax-exempt organization, whose goals included the establishment of the national holiday. Evart selected April 10 in honor of her late sister, Lisette’s birthday.
Copyright 2022 KOLD News 13. All rights reserved. | https://www.kold.com/2022/04/10/national-siblings-day/ | 2022-04-11T09:41:11 | 1 | https://www.kold.com/2022/04/10/national-siblings-day/ |
Police investigate homicide in Tucson desert
Published: Apr. 10, 2022 at 3:58 PM MST|Updated: 10 hours ago
TUCSON, Ariz. (KOLD News 13) - Tucson police are investigating a homicide after a man’s body was found in a desert area on the city’s east side on Saturday, April 9.
Officers said they were called that morning to an area near East Sellarole Street and South Eastview Avenue, west of Houghton Road, where they found the body.
The victim was identified as 57-year-old Lionel Luwaiki Hoaeae, who was known to have frequented the area.
As of Sunday, police said, there were no suspects in custody.
Anyone who has information on Hoaeae’s death is asked to call 911 or call 88-CRIME to stay anonymous.
Copyright 2022 KOLD News 13. All rights reserved. | https://www.kold.com/2022/04/10/police-investigate-homicide-tucson-desert/ | 2022-04-11T09:41:17 | 0 | https://www.kold.com/2022/04/10/police-investigate-homicide-tucson-desert/ |
Singer Avril Lavigne tweets pic of engagement to Mod Sun
Published: Apr. 10, 2022 at 10:54 AM MST|Updated: 15 hours ago
(CNN) – Life is suddenly less “complicated” for pop star Avril Lavigne.
The 37-year-old Canadian singer announced on Twitter Thursday that she’s engaged to fellow musician Mod Sun.
Sun, whose real name is Derek Smith, popped the question with a heart-shaped diamond on a boat on the river Seine.
The irony is that the two met collaborating on Lavigne’s latest album titled “Love Sux.”
This would be the third marriage for Lavigne, whose previous husbands were also rock stars: Sum 41′s Deryck Whibley and Nickelback’s Chad Kroeger.
Mod Sun previously dated former Disney actor Bella Thorne.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.kold.com/2022/04/10/singer-avril-lavigne-tweets-pic-engagement-mod-sun/ | 2022-04-11T09:41:23 | 0 | https://www.kold.com/2022/04/10/singer-avril-lavigne-tweets-pic-engagement-mod-sun/ |
Suspected drunk driver runs red light, kills 2 riding a motorcycle in Apache Junction
Published: Apr. 9, 2022 at 9:01 PM MST
APACHE JUNCTION, AZ (3TV/CBS 5) - Two people riding a three-wheeled motorcycle have died after being hit by a car in Apache Junction Saturday night. The crash happened at the Superstition Boulevard and Ironwood Drive intersection, according to city officials.
Authorities say the driver of the car ran the red light and struck the motorcycle. Officials believe the driver was impaired. Drivers are asked to avoid the area. Police have not released the victim’s names or any information about the driver of the car. The investigation is ongoing.
Copyright 2022 KTVK/KPHO. All rights reserved. | https://www.kold.com/2022/04/10/suspected-drunk-driver-runs-red-light-kills-2-riding-motorcycle-apache-junction/ | 2022-04-11T09:41:30 | 1 | https://www.kold.com/2022/04/10/suspected-drunk-driver-runs-red-light-kills-2-riding-motorcycle-apache-junction/ |
‘The Simpsons’ to feature deaf character, use sign language for first time
(CNN) – For the first time in the show’s 33-year history, a deaf actor will be featured on “The Simpsons.”
The focus of the episode is on Lisa Simpson, who discovers her role model, late saxophonist Bleeding Gums Murphy, has a son who is deaf and needs a cochlear implant.
Deaf actor John Autry II plays the role of Monk Murphy on the episode, calling it “life-changing.”
The show’s characters use American sign language throughout the groundbreaking episode.
Even though “Simpsons” characters only have four fingers, the show consulted with sign language specialists to make sure visuals conveyed words correctly.
The storyline is loosely based on the life of the episode’s main writer, who says her brother is hearing impaired within a family that loves jazz music.
The episode was written before the film “Coda” won the Oscar for Best Picture two weekends ago.
The episode airs Sunday night.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.kold.com/2022/04/10/the-simpsons-feature-deaf-character-use-sign-language-first-time/ | 2022-04-11T09:41:36 | 1 | https://www.kold.com/2022/04/10/the-simpsons-feature-deaf-character-use-sign-language-first-time/ |
WATCH: Man pulled from raging river after attempted rescue of dog caught in current
LOS ANGELES, Calif. (KCAL/KCBS) – A good Samaritan is recounting his attempt to rescue a stranger’s dog from a river in California.
Dustin Leming, an iron worker, dropped 14 feet into the Los Angeles River to rescue a dog trapped in the raging current during a rain storm.
He risked his own life to save a stranger’s dog.
“Oh, that dog was scared,” he said.
The heroic effort left Leming in need of his own rescue.
“They did have to rescue me, and thank God they did,” he said.
As rescue helicopters circled above his home last week, Leming and his mom ran to the river out back and saw Scooby struggling to keep his furry head above the water.
When Leming saw the canine, he couldn’t help himself. He said he wanted to be a veterinarian so it was second nature to help an animal in need.
“I told her, I said ‘Look mom, that dog’s in the river. I’m going to the river. I’m gonna save that dog,’” he said. “And she goes, ‘You better not Dustin’ and I told her, ‘Look, I’m going in.”
But first, Leming had to run ahead of the dog.
“I think it was about a mile and a half down where I finally caught up to him,” Leming said.
When he finally got into the waist high water and got his arms around Scooby, the terrified German Shepherd sunk its teeth into his arms.
“That current, that current is stronger than you think,” Leming said.
He said it became too hard to hold on to the dog, and Scooby wiggled out of his arms and was eventually carried away by the current.
“I was like ‘Oh man, if that dog dies, I’m gonna be so sad,’” Leming said.
It was fortunately not a lost cause, and Scooby survived. The dog floated down the river to a shallow spot where rescue crews eventually got him to safety.
The next day, Scooby’s owner got to thank Leming for his attempted rescue.
“Thank you so much for all the love out there and support,” she said.
Leming said he’s just glad Scooby made it back home. He said there was no way the dog was going to drown on his watch.
“Everybody got their phones out and wanted to take videos but not take action,” Leming said. “I tried to help him out.”
Copyright 2022 KCAL,KCBS via CNN Newsource. All rights reserved. | https://www.kold.com/2022/04/10/watch-man-pulled-raging-river-after-attempted-rescue-dog-caught-current/ | 2022-04-11T09:41:45 | 1 | https://www.kold.com/2022/04/10/watch-man-pulled-raging-river-after-attempted-rescue-dog-caught-current/ |
Caught on camera: Man rescues driver after car plunges into Houston port
HOUSTON (KTRK) - A Texas man saved a driver from drowning after the man’s car plunged off a boat ramp in Houston.
The U.S. Coast Guard honored Cody Moore with one of its highest civilian honors for his lifesaving efforts on New Year’s Eve 2021 at the Lynchburg Ferry boat ramp in the Port of Houston. Surveillance video of the rescue was recently released.
Cody Moore and his family had just arrived at the nearby Monument Inn for dinner when the car came whizzing by and launched into the water. The father of five rushed to the car. He initially tried to talk to the driver, but a few moments later, he jumped in.
“When he said, ‘Call 911′ and I was running to the car to get something, I knew he was going in the water. I knew that he wouldn’t just stand by,” said Cody’s wife, Karen Moore.
Somehow, Cody Moore was able to convince the driver, in his 60s, to try and open the window.
As the car quickly sank, the man got out through the window. Cody Moore scooped him up and swam him to the shore.
Neighbors having dinner with the family captured the dramatic scene. They also used their shirts as a rope to get the two men onto the ramp.
Miraculously, nobody was seriously hurt.
“Whenever it happened, it seemed so surreal. I didn’t understand the gravity of it because he got out, he was soaking wet and we went and had dinner,” Karen Moore said.
While New Year’s Eve came and went, Cody Moore’s heroic efforts weren’t forgotten. The U.S. Coast Guard honored him Friday with a certificate of merit as his whole family watched with pride.
“It is really dangerous, and because he did it for someone else, I was really proud of him,” said Cody’s daughter, Ellen Moore.
Copyright 2022 KTRK via CNN Newsource. All rights reserved. | https://www.kold.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ | 2022-04-11T09:41:51 | 0 | https://www.kold.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ |
Man accused of beating roommate over mosquito argument
DALLAS (CNN) - A Texas man is facing aggravated assault charges after allegedly beating his roommate over an argument about mosquitoes.
Victor Shavers, 43, reportedly admits he hit the man he shares a bedroom with when they began arguing over what mosquitoes look like. The roommate says the attack began when the verbal argument escalated.
The man says Shavers grabbed a wooden stick and beat him in the head with it before he was able to get a metal baseball bat to defend himself. He used that bat to hit Shavers in the head several times.
Both men were treated for their injuries at the hospital. The roommate required multiple stitches on his face.
Police arrested Shavers on an outstanding warrant and also charged him with assault.
A judge ordered him to be held Tuesday on a $28,000 bond.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.kold.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ | 2022-04-11T09:41:58 | 0 | https://www.kold.com/2022/04/11/man-accused-beating-roommate-over-mosquito-argument/ |
Officers who pushed Floyd protester cleared by arbitrator
BUFFALO, N.Y. (AP) - An arbitrator has ruled that two Buffalo police officers didn’t violate the department’s use-of-force guidelines when they pushed a 75-year-old protester to the ground in June 2020 during racial injustice protests following the murder of George Floyd in Minneapolis.
The episode drew national attention when a news crew captured video of Martin Gugino being shoved by officers Robert McCabe and Aaron Torgalski in downtown Buffalo, as crowd control officers in riot gear cleared demonstrators for an 8 p.m. curfew.
Gugino, pushed backward, started bleeding after hitting his head on the pavement and spent about a month in the hospital with a fractured skull and brain injury.
In a decision Friday, arbitrator Jeffrey Selchick wrote, “Upon review, there is no evidence to sustain any claim that Respondents (police officers) had any other viable options other than to move Gugino out of the way of their forward movement.”
The level of force used by the officers was justified because Gugino refused to comply with orders to leave the scene and was acting erratically, and walked directly in front of McCabe, according to Selchick.
“The use of force employed by Respondents reflected no intent on their part to do more than to move Gugino away from them,” he wrote.
McCabe and Torgalski were suspended without pay and arrested within days of the incident, but last year a grand jury declined to indict them and charges were dropped.
An attorney for Gugino, who has sued the city, told the Buffalo News that the ruling has no bearing on the lawsuit.
“We are not aware of any case where this arbitrator has ruled against on-duty police officers, so his ruling here on behalf of the police was not only expected by us, but was certainly expected by the union and city who selected and paid him,” Melissa Wischerath told the newspaper.
Police Commissioner Joseph Gramaglia said in a statement he will reinstate the two officers to duty on Monday, the newspaper reported.
Email messages seeking comment were left Sunday with an attorney representing the city, which argued for the disciplinary charges, and with the Buffalo police union.
Copyright 2022 The Associated Press. All rights reserved. | https://www.kold.com/2022/04/11/officers-who-pushed-floyd-protester-cleared-by-arbitrator/ | 2022-04-11T09:42:05 | 0 | https://www.kold.com/2022/04/11/officers-who-pushed-floyd-protester-cleared-by-arbitrator/ |
Study finds higher homicide risk in homes with handguns
NEW YORK (AP) - Most U.S. gun owners say they own firearms to protect themselves and their loved ones, surveys show. But a study published last Monday suggests people who live with handgun owners are shot to death at a higher rate than those who don’t have such weapons at home.
“We found zero evidence of any kind of protective effects” from living in a home with a handgun, said David Studdert, a Stanford University researcher who was the lead author of the Annals of Internal Medicine study.
The study has several shortcomings. For example, the researchers said they could not determine which victims were killed by the handgun owners or with the in-home weapons. They couldn’t account for illegal guns and looked only at handguns, not rifles or other firearms.
The dataset also was limited to registered voters in California who were 21 and older. It’s not clear that the findings are generalizable to the whole state, let alone to the rest of the country, the authors acknowledged.
But some outside experts said the work was well done, important and the largest research of its kind.
“I would call this a landmark study,” said Cassandra Crifasi, a gun violence policy researcher at Johns Hopkins University. “This contributes to our understanding of the potential causal relationship between guns in the home and homicides,” she said.
California is unusual in that it offers gun ownership data and other information not obtainable in almost any other state. That allowed the researchers to follow millions of people over many years to try to better establish what happens when a person begins living in a home with handgun, they said.
The study focused on nearly 600,000 Californians who did not own handguns but began living in homes with handguns between October 2004 and December 2016 — either because they started living with someone who owned one or because someone in their household bought one.
The researchers calculated that for every 100,000 people in that situation, 12 will be shot to death by someone else over five years. In comparison, eight out of 100,000 who live in gun-free homes will be killed that way over the same time span.
“The rates are low” and the absolute risk is small, but it’s important to consider the increase in a person’s risk of being killed, Studdert said.
Those numbers suggest the risk rises 50%, but Studdert said it’s actually higher: In a separate calculation designed to better account for where people live and other factors, the researchers estimated the risk was actually more than twice as high.
Separately, the researchers found that those who lived with handgun owners had a much higher rate of being fatally shot by a spouse or intimate partner. The vast majority of such victims — 84% — were women, they said.
The study was confined to California, but the risk is likely even greater in states with less stringent gun laws and where gun ownership is more common, Crifasi said.
Previous research estimated that nearly 3% of U.S. adults became new gun owners between January 2019 and April 2021, which translates to about 7.5 million Americans. Of those, about 5.4 million previously lived in a home with no guns.
For decades, studies have shown guns in the home raise the risk of a violent death. Much of that work, including an earlier study by Studdert and his colleagues, focused on suicide.
The new study goes further in addressing the perception that handguns are still worthwhile because of the safety they provide against being murdered, some experts said.
“The reason people have guns in their home is for protection from strangers,” said David Hemenway, director of the Harvard University’s Injury Control Research Center. “But what this is showing that having a gun in the home is bad for people in the home.”
___
The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Copyright 2022 The Associated Press. All rights reserved. | https://www.kold.com/2022/04/11/study-finds-higher-homicide-risk-homes-with-handguns/ | 2022-04-11T09:42:14 | 1 | https://www.kold.com/2022/04/11/study-finds-higher-homicide-risk-homes-with-handguns/ |
DAYTON, Tenn., April 10, 2022 /PRNewswire/ -- Jason Christie left Dayton Municipal Park on Championship Sunday just 6 ounces out of the lead with a crystal-clear plan for where he wanted to start.
But thick fog created by temperatures that had plunged into the 30s overnight changed that plan — and ultimately played a huge role in his eighth career victory with B.A.S.S.
To let the fog clear, Christie stopped on a bank he hadn't fished all week and quickly put a solid limit in his livewell. He culled up a few ounces throughout the day until he reached a five-bass limit of 15 pounds, 12 ounces that helped him win the Guaranteed Rate Bassmaster Elite at Chickamauga Lake with a four-day total of 73-7.
"The fog is why I won," said Christie, who is a little more than a month removed from winning the Academy Sports + Outdoors Bassmaster Classic presented by Huk on Lake Hartwell. "I went through one fogbank at about 25 mph going to where I was going to start. But then I hit another fogbank and I saw a boat wave that I knew didn't come from one of our guys, so I just immediately peeled off to an area that I fished three or four years ago in another event."
After a warm start on Thursday, Days 2 and 3 were the polar opposite with cloudy skies, temperatures in the 40s and a spattering of rain, sleet and snow. But the low-light conditions played into the hands of Christie, who fished all week with a 1/2-ounce Booyah Covert Spinnerbait (chartreuse, white and blue with a white Yum Swim'n Dinger as a trailer), a bladed jig and the same War Eagle Jiu-Jigsu Jig (green pumpkin) he used at the Classic.
The conditions made another sharp turn Sunday, with the return of the sun, calm winds and a high temperature near 70 degrees. But Christie once again took advantage of a short window of low visibility aided by the early morning fog.
"I knew the spot I stopped at had had a lot of traffic, but I figured I would just go in there and fish until the fog lifted," Christie said. "But really it set up perfectly because it was shaded and had all the right stuff."
While much of the field was still navigating the fog, Christie caught a quick limit, taking the unofficial lead on BassTrakk by 8 a.m. and never relinquishing it.
"That was the key, just getting off to a good start," he said. "What was weird is every day those fish have been tight to cover. But the first big one I caught today was halfway back to the boat. Then the next bite was about the same — and that's how I ended up catching them.
"I think the bait would come by the cover, and they were sitting right out in front of it."
The win provided a bit of redemption for Christie, who followed his Classic victory with a 93rd-place finish at the next Elite Series event at Santee Cooper Lakes — one of the worst finishes of his career. He said the same stubbornness that cost him at Santee Cooper Lakes might have helped him to the victory on Chickamauga.
"I certainly don't like to make excuses," he said. "But during practice for Santee, I was doing every interview, every podcast about the Classic win — I didn't turn anyone down. I still thought I was on a good deal there and that I would catch them. But I was too stubborn to give up on it when it didn't work.
"That's just like today. The fishing was a lot tougher than it had been the last two days, but I stuck with what I was doing."
Like Christie, Mississippi pro Brock Mosley stayed with the program he had been using all week, alternating between a bladed jig, a jig, a Senko and a spinnerbait. But with a modest limit of 11-14, he finished second with a four-day total of 69-15.
It marked his fifth career second-place finish on the Elite Series and the third time he's finished one spot behind Christie.
"I caught plenty of fish today, but I just didn't run into any big fish," Mosley said. "I thought as good as I was catching them, everybody else was probably catching them too. So late in the day, I decided to run down the lake and try to catch a couple of big ones on a big swimbait.
"Looking back, I probably should have just stuck with what I was doing."
Phoenix Boats Big Bass of the Day honors went to Arizona pro Clifford Pirch for a 5-4 largemouth. Wisconsin pro Pat Schlapper won Phoenix Boats Big Bass of the Week with the 10-5 he caught Thursday.
Hawaiian Matty Wong failed to make the Top 10 cut for Championship Sunday, placing 14th with 48-5. But he earned the VMC Monster Bag of the Week award for the 25-13 limit he weighed in Friday.
Christie took home $3,000 for being the highest-placing entrant in the Toyota Bonus Bucks program, and Mosley earned $2,000 for being the second-highest placing entrant.
As part of the Yamaha Power Pay program, Christie also earned $4,000 for winning while Australian Carl Jocumsen claimed an additional $1,500 for being the second-highest placing entrant.
Ed Loughran III won the $1,000 BassTrakk Contingency award for the most accurate weight reporting.
With a 33rd-place finish, Florida pro John Cox maintained his lead in the Progressive Insurance Bassmaster Angler of the Year standings with 353 points. Idaho pro Brandon Palaniuk moved into second with 343, followed by Pirch (338), David Mullins of Tennessee (321) and Drew Benton of Georgia (321).
Wisconsin pro Jay Przekurat leads the Falcon Rods Bassmaster Rookie of the Year race with 293 points, followed by Joseph Webster of Alabama (249) and Tennessee pro Jacob Foutz (200).
The tournament was hosted by Rhea County, City of Dayton, Tenn., and Fish Dayton.
2022 Bassmaster Elite Series Platinum Sponsor: Toyota
2022 Bassmaster Elite Series Premier Sponsors: Bass Pro Shops, Berkley, Humminbird, Mercury, Minn Kota, Nitro Boats, Power-Pole, Progressive Insurance, Ranger Boats, Rapala, Skeeter Boats, Yamaha
2022 Bassmaster Elite Series Supporting Sponsors: AFTCO, Daiwa, Garmin, Huk Performance Fishing, Marathon, Strike King, Triton Boats, VMC
2022 Bassmaster Conservation Partners: AFTCO, Yamaha Rightwaters
Media Contact: Emily Harley, B.A.S.S. Communications Manager, 205-313-0945, eharley@bassmaster.com
View original content to download multimedia:
SOURCE B.A.S.S. | https://www.kold.com/prnewswire/2022/04/10/christie-rights-his-ship-wins-bassmaster-elite-series-event-chickamauga-lake/ | 2022-04-11T09:42:20 | 1 | https://www.kold.com/prnewswire/2022/04/10/christie-rights-his-ship-wins-bassmaster-elite-series-event-chickamauga-lake/ |
CAMBRIDGE, Mass., April 10, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late-breaking data at the American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, LA, April 8-13, 2022.
The data presented at AACR 2022 illustrate that Myeloid has designed and developed two novel therapeutic platforms, ATAK™ CAR receptors and in vivo mRNA programming, to target and activate the ability of myeloid cells to attack cancer by immune reprogramming. Myeloid cells are a primary orchestrator of immune response and accumulate naturally within solid tumors, in some cases representing up to seventy-five percent of the tumor mass. Myeloid's adaptations of mRNA for the myeloid compartment are expanding the impact of these cells within in vivo experiments.
Myeloid's novel class of CARs, known as ATAK™ Receptors, combine tumor recognition with multiple proprietary innate-immune signaling domains. Myeloid scientists have screened multiple unexplored combinations of innate-immune signals and uncovered optimal multi-signal pathways. The combination of cancer recognition binders with these novel intracellular signaling domains allows myeloid cells to be reprogrammed with previously unexplored combinations of immune signals, leading to tumor killing and broad systemic anti-tumor responses.
Myeloid's novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in selective uptake and expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models. These data demonstrate the potential for Myeloid's technology to program cells directly in vivo.
"At this year's AACR meeting, we are pleased to present significant progress across our platforms that showcase the ability of myeloid cells to orchestrate broad immune responses through in vivo mRNA programming and our next-generation ATAK™ CARs," said Bruce McCreedy, Ph.D., Chief Scientific Officer of Myeloid. "These data support our plans to initiate clinical trials to evaluate the safety and activity of several novel drug product candidates within the next year, expanding our existing clinical pipeline."
Details of the late-breaking poster presentations:
Title: "In vivo programming of myeloid cells by mRNA-mediated delivery of novel Fc alpha fusion receptor activates anti-tumor immunity"
Session: Late-Breaking Research: Clinical Research 1
Date and Time: Sunday Apr 10, 2022 1:30 PM - 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 17
Title: "ATAK receptors, a new class of chimeric antigen receptors that harness innate immunity in myeloid cells to target cancer"
Session: Late-Breaking Research: Clinical Research 1
Date and Time: Sunday Apr 10, 2022 1:30 PM - 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 17
Abstracts and full session details can be accessed through the AACR meeting planner once available: AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating the fields of RNA, immunology and medicine, the Company's proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. For more information, visit https://www.myeloidtx.com/.
Investor and Media Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
858-914-1962
View original content to download multimedia:
SOURCE Myeloid Therapeutics, Inc. | https://www.kold.com/prnewswire/2022/04/10/myeloid-therapeutics-presents-late-breaking-data-aacr-2022-demonstrating-ability-its-atak-receptors-vivo-delivery-mrna-attack-cancer-by-immune-reprogramming/ | 2022-04-11T09:42:27 | 1 | https://www.kold.com/prnewswire/2022/04/10/myeloid-therapeutics-presents-late-breaking-data-aacr-2022-demonstrating-ability-its-atak-receptors-vivo-delivery-mrna-attack-cancer-by-immune-reprogramming/ |
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma (STS).
Olaratumab was originally developed by Lilly as a (non-radiolabelled) monoclonal antibody targeting Platelet Derived Growth Factor Receptor Alpha (PDGFRα). PDGFRα is expressed in multiple tumour types including STS. STS is generally a radiation susceptible cancer that may be inherently amenable to systemic radionuclide therapy and olaratumab's ability to target PDGFRα makes it a highly novel and potentially exciting candidate for use as a radionuclide targeting agent. The exclusive worldwide licence will allow Telix to repurpose olaratumab as a targeting agent for radiopharmaceutical imaging and therapy of cancer. Olaratumab has an established safety profile that underpins its potential use as a radionuclide targeting agent.
Material terms of the agreement
Under the terms of the agreement Telix will pay Lilly an upfront payment of US$5M (~AU$6.7M) for the grant of an exclusive licence to Lilly's intellectual property related to the development of a radiolabelled olaratumab, as well as access to material for use by Telix in initial pre-clinical and early-phase clinical studies in application to potential uses for the diagnosis and treatment of human cancers.
Lilly may be eligible for up to US$225M (~AU$301M) in payments based upon the achievement of pre-specified development, regulatory and commercial milestones. Lilly would also be eligible to receive industry standard royalties on net sales. The agreement also includes an option for Lilly to be granted an exclusive licence to a radiolabelled companion diagnostic which would be developed by Telix. If exercised, Lilly will pay Telix US$5M (~AU$6.7M) and up to US$30M (~AU$40.1M) in potential development milestones, as well as industry standard royalties.
The agreement has typical termination rights for breach and related corporate issues. Telix retains termination rights typical to licence agreements of this nature to enable the Company to exit the agreement based on a development or commercial basis.
Building on Telix's track record in acquiring and commercialising assets
Telix Group CEO and Managing Director, Dr. Christian Behrenbruch said, "This in-licence transaction with Lilly is a valuable – and rare – opportunity to acquire an asset which has demonstrated clinical safety. In our pre-transaction diligence and research, we have identified that a radiolabelled version of olaratumab could be efficacious in patients with STS, particularly as it is a highly radiation-sensitive cancer. The safety data generated by Lilly in relation to the original development program significantly de-risks the program for Telix. We anticipate that early clinical translation with a radiolabeled olaratumab as an imaging agent may also provide valuable clinical information as to whether this asset has potential therapeutic efficacy, demonstrating the advantage of Telix's "theranostic" approach.
"This acquisition mirrors the approach that Telix has taken in building its existing pipeline by in-licencing or acquiring assets that have already been proven to be safe for use in humans that can be harnessed as novel radiolabelled targeting agents. This partnership also demonstrates the value that Telix can bring as a capable partner with the expertise in radiopharmaceutical development and manufacturing, to help repurpose or expand the use of promising candidates to better target, find and treat cancer."
About Soft Tissue Sarcoma (STS)
Soft tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers, with more than 50 histological subtypes. In the United States, it is estimated that 13,040 new cases and 5,150 deaths were caused by STS in 2019, representing 0.75% of overall cancer incidence and 0.84% of overall cancer mortality.1 In Europe, nearly 23,600 new STS cases rose annually, and the crude incidence rate was 4.7 per 100,000.2 Approximately 39,900 new STS cases occurred nationwide in China in 2019, accounting for 1.05% of overall cancer incidence.3 The crude incidence rate was 2.91/100,000 and generally increased with age. Standard treatment for soft tissue sarcoma includes surgery, radiation therapy and/or chemotherapy. For patients with advanced, unresectable, or metastatic disease, treatment typically involves chemotherapy with single agents (e.g., doxorubicin) or anthracycline-based combination regimens. However, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months.
About olaratumab
Olaratumab (previously sold under the brand name, Lartruvo®) was originally developed as a monoclonal antibody targeting PDGFRα. Olaratumab was granted "Accelerated Approval" in the US and "Conditional Approval" in the EU based on Phase 2 trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy. Olaratumab was voluntarily withdrawn from the market by Lilly following the failure of the Phase 3 ANNOUNCE clinical trial, in which olaratumab did not improve survival for patients.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, Illuccix® (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),4 and by the Australian Therapeutic Goods Administration (TGA).5 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe6 and Canada.7
This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.
Legal Notices
This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).
View original content to download multimedia:
SOURCE Telix Pharmaceuticals Limited | https://www.kold.com/prnewswire/2022/04/10/telix-pharmaceuticals-announces-licence-agreement-with-lilly-olaratumab/ | 2022-04-11T09:42:34 | 0 | https://www.kold.com/prnewswire/2022/04/10/telix-pharmaceuticals-announces-licence-agreement-with-lilly-olaratumab/ |
LONDON, 10 April 2022 /PRNewswire/ -- Tetragon announces the final results of the "modified Dutch auction" tender offer to purchase a portion of the outstanding non-voting shares of Tetragon for a maximum aggregate payment of $50,000,000 in cash. The tender offer expired at 11:59 p.m. (ET) on 7 April 2022.
J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) acted as dealer manager for the tender offer and Computershare Investor Services PLC acted as tender agent for the tender offer. As dealer manager, J.P. Morgan determined the final purchase price at which Tetragon will purchase shares in the tender offer. As tender agent, Computershare determined the final proration factor.
In accordance with the terms of the tender offer, Tetragon has accepted for purchase 4,291,157 non‑voting shares at a purchase price of $9.75 per share. The aggregate cost of this purchase is $41,838,780.75, excluding fees and expenses relating to the tender offer. A total of 4,291,157 Tetragon non-voting shares were properly tendered and not properly withdrawn at or below the purchase price of $9.75 per share.
Tetragon will promptly make payment for the shares validly tendered and accepted for purchase, which is expected to occur on or about 14 April 2022.
About Tetragon:
Tetragon is a closed-ended investment company that invests in a broad range of assets, including public and private equities and credit (including distressed securities and structured credit), convertible bonds, real estate, venture capital, infrastructure, bank loans and TFG Asset Management, a diversified alternative asset management business. Where appropriate, through TFG Asset Management, Tetragon seeks to own all, or a portion, of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit, equity, interest rate, inflation and real estate cycles. The company's non-voting shares are traded on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V., and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at www.tetragoninv.com.
This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU) ("EU MAR") and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).
This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.
J.P. Morgan Securities plc, which is authorised by the UK Prudential Regulation Authority and regulated by the UK Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Tetragon and for no one else in connection with the tender offer and will not be responsible to anyone (whether or not recipient of the tender offer) other than Tetragon for providing the protections afforded to the clients of J.P. Morgan Securities plc or for providing advice in relation to the tender offer.
View original content:
SOURCE Tetragon Financial Group Limited | https://www.kold.com/prnewswire/2022/04/10/tetragon-financial-group-limited-announcement-final-results-tender-offer-purchase-tetragon-non-voting-shares/ | 2022-04-11T09:42:41 | 1 | https://www.kold.com/prnewswire/2022/04/10/tetragon-financial-group-limited-announcement-final-results-tender-offer-purchase-tetragon-non-voting-shares/ |
ST. LOUIS, April 10, 2022 /PRNewswire/ -- Global packaging leader TricorBraun announced today that it has entered into an agreement to acquire PB Packaging ("PB"), a wholly-owned business of Pro-Pac Packaging Limited (ASX: PPG) ("Pro-Pac"), expanding its presence in Australia.
One of Australia's leading providers of plastic and glass packaging, PB is a one-stop shop for rigid packaging needs, serving customers in the health, industrial, food, and automotive industries.
"We are excited to grow our business in Australia, offering customers expanded solutions and supply chain options," said Court Carruthers, president and CEO, TricorBraun. "The PB Packaging team's dedication to innovation, quality, and exceptional customer service make them an ideal fit. We are pleased to welcome PB Packaging to the TricorBraun family, and we look forward to investing in its continued growth."
TricorBraun established its footprint in the region with its acquisition of Cormack Packaging in September 2021.
PB's current leadership team will join TricorBraun and all 140 PB team members will be offered positions with the company. Effective with the closing of the transaction, PB will operate as PB Packaging, a TricorBraun company. The company will continue to operate as a stand-alone business.
"We are delighted that TricorBraun will acquire PB and that all Rigid team members will be offered positions with TricorBraun," said Tim Welsh, CEO and managing director, Pro-Pac. "TricorBraun is a natural home for the PB business, and we look forward to completing the transaction expeditiously."
"Over the last 32 years, we've solidified our reputation as one of the most respected distributors of packaging materials and services in Australia," said Andrew Allsop, executive general manager, PB Packaging. We look forward to continuing our service to customers, with TricorBraun's support, resources, and investments in our growth."
Since its founding, TricorBraun has partnered with management teams to successfully acquire and further accelerate growth for 34 packaging companies globally.
The transaction is expected to close in the second quarter of 2022, subject to the Australian Foreign Investment Review Board approval and satisfaction of other customary completion conditions.
About PB Packaging
PB Packaging is the Rigid division of the Pro-Pac Group (PPG) of companies, one of Australia's largest publicly listed packaging companies. Established in 1990, PB Packaging has continuously evolved to meet the varying and diverse needs of its customers, offering a comprehensive product range of locally-moulded and imported products.
About Pro-Pac Packaging
Pro-Pac Packaging Limited (ASX: PPG) is an innovative Flexibles, Industrial Specialty Packaging and Rigid packaging company with a diversified distribution and manufacturing network throughout Australia and New Zealand. Headquartered in Melbourne, Pro-Pac delivers bespoke packaging solutions for a broad group of blue-chip and SME clients in the industrial, food and beverage, health, agriculture and manufacturing sectors. For further information, please visit www.ppgaust.com.au.
About TricorBraun
Founded in 1902, TricorBraun is a global packaging leader and North America's largest distributor of primary packaging. We provide innovative solutions across a wide array of customer end markets in plastic, glass, and aluminum containers, closures, dispensers, tubes, and flexibles. Our award-winning Design & Engineering Center provides forward-thinking design, driven by consumer insight and creative solutions. We leverage our global supply chain expertise, expansive and sustainable footprint, and unmatched purchasing power to identify the best sourcing partners and cost-effective solutions for our customers. TricorBraun is comprised of more than 1,700 packaging professionals operating from more than 75 locations across the Americas, Europe, Asia, and Australia.
View original content to download multimedia:
SOURCE TricorBraun | https://www.kold.com/prnewswire/2022/04/10/tricorbraun-acquire-pb-packaging-expanding-its-presence-australia/ | 2022-04-11T09:42:47 | 1 | https://www.kold.com/prnewswire/2022/04/10/tricorbraun-acquire-pb-packaging-expanding-its-presence-australia/ |
NASHVILLE, April 11, 2022 /PRNewswire/ -- AMBEST, the member-owned, nationwide network of independent truck stops and service centers, presented the 2021 Grand Prize Polaris Ranger XP900 to Kansas based driver and long-time AMBUCK$ cardholder Doug Jackson. The presentation was held on Wednesday April 6th, 2022, at AMBEST member location Midwest Travel Plaza in Cuba MO.
"The best phone call I get to make each year is when we call our AMBUCK$ grand prize lucky driver," says Steve Allen, CEO of AMBEST. "Drivers have responded and connected with the Polaris Ranger ATV, and we are excited to partner with Lucas Oil for the 14th consecutive year to present this amazing vehicle to Doug."
AMBUCK$ is the longest continuously running professional driver rewards program and gives over $30,000 in prizes and rewards to truck & motor coach drivers each year. Drivers swipe their AMBUCK$ loyalty card when they fuel at any AMBEST location or get work done at an AMBEST Service Center. Each swipe is an entry to win multiple prizes or even the annual grand prize valued at over $20,000.
"I remember looking at the grand prize banner and saying, 'No one ever wins these things.'" Says Doug Jackson, the lucky winner. "Like many truck drivers, I work hard and spend a lot of time on the road to build a better future for my family. Winning this is an amazing gift recognizing that hard work."
March 1st, AMBEST announced the 2022 Grand Prize is a 2022 Indian Super Chief Motorcycle. This will be the 15th year that AMBEST is partnering with Lucas Oil to co-sponsor a Grand Prize to be given to one lucky driver who swipes their AMBUCK$ card at one of over 500 AMBEST locations across the country.
About AMBEST
Founded in 1988, AMBEST is a member-owned, nationwide network of independent truck stops and service centers. Unlike big corporate companies, AMBEST locations are family owned businesses where you're likely to find the owner with his or her sleeves rolled up ready to take care of drivers anyway they can. AMBEST has over 500 Truck Stops and Service Centers across the United States.
Pictured: Steve Allen – CEO AMBEST, Doug Jackson– 2021 AMBUCK$ Grand Prize Winner
Contact Information:
AMBEST
Kevin Neely
Director of Marketing
kneely@am-best.com
615-777-9104
View original content to download multimedia:
SOURCE AMBEST | https://www.kold.com/prnewswire/2022/04/11/ambest-awards-ambuck-grand-prize-polaris-ranger-kansas-truck-driver/ | 2022-04-11T09:42:54 | 0 | https://www.kold.com/prnewswire/2022/04/11/ambest-awards-ambuck-grand-prize-polaris-ranger-kansas-truck-driver/ |
The company will present the preclinical data of five novel drug candidates at AACR 2022 (on April 8-13).
Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008.
SHANGHAI and HONG KONG, April 10, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the publication of five posters that will be presented during the upcoming 2022 American Association for Cancer Research Annual Meeting (AACR 2022), taking place from April 8th to April 13th in New Orleans in person or via virtual attendance.
(https://www.aacr.org/professionals/meetings/myaacr-support/ )
"The preclinical studies that we are presenting at AACR 2022 provide a window into five innovative programs in Antengene's pipeline," said Bo Shan, Ph.D., Chief Scientific Officer of Antengene. "These programs target areas that we believe are very important in cancer drug development: Tumor microenvironment (TME) regulators (ATG-037), pathway inhibitors (ATG-018, ATG-022 and ATG-008), and ADCs (ATG-022). These studies have been instrumental in guiding our clinical development plans for each program, including selection of combination partners and biomarkers, that could be used to predict efficacy or improve the proportion of patients who respond to treatment. We are very pleased to share these results with the oncology community."
Details of the posters and corresponding abstracts are shown below:
ATG-037, a highly potent small molecule CD73 inhibitor has superior activity of reversing immunosuppression in higher-AMP environments compared with anti-CD73 antibodies
Abstract: 2576
Session: Cell Cycle, Replication Inhibitors, and Immunotherapy Agents
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 21
This study was designed to compare the T-cell rescue activity of ATG-037, a highly potent and selective oral small molecule inhibitor of CD73, and two CD73 blocking antibodies. CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression. In vitro assays were used to assess each compound's ability to inhibit CD73 enzyme activity and reverse AMP/adenosine mediated T-cell suppression. ATG-037 demonstrated more potent and complete inhibitory activity of cell surface CD73 in this study.
As shown in Figure, the authors found that ATG-037 had a stronger ability to restore T-cell function in higher-AMP environments compared with other clinical anti-CD73 antibodies. These data highlight the potential therapeutic advantages of small molecule inhibitors of CD73 over blocking antibodies. ATG-037 is being evaluated by Antengene in a Phase I trial as monotherapy and in combination with anti-PD-1 antibody in patients with locally advanced or metastatic solid tumors.
The novel ATR inhibitor ATG-018 is efficacious in preclinical cancer models
Abstract: 2604
Session: DNA Damage Response and Repair
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 22
In this study, the preclinical pharmacology data set supporting the development of ATG-018, a small molecule ATR inhibitor, was reviewed. Inhibiting ATR kinase (ataxia telangiectasia and Rad3 related kinase) leads to increased accumulation of double-strand breaks, particularly meaningful for tumor cells which rely on DNA damage response (DDR). ATG-018 was tested in a panel of 142 tumor cell lines and three CDX mouse models to assess anti-tumor efficacy and to identify potential predictive biomarkers. ATG-018 was a potent inhibitor of in vitro ATR activity inhibition and cell proliferation without significant impact on normal peripheral blood mononuclear cell (PBMCs) viability.
In addition, a series of genetic alterations were discovered that correlated with ATG-018 sensitivity and could be potential predictive biomarkers. As shown in Figure, the authors found that ATG-018 demonstrated potent in vivo efficacy in solid tumor/hematologic cancer models with certain DDR-related mutations. These data showed the potential of ATG-018 in synthetic lethality with homologous recombination deficiencies and promising application in a wide range of indications. With single-agent activity and no impact on PBMCs viability, ATG-018 may be well positioned for use in mono- or combination therapy in a wide range of tumors that rely on DDR. Development of a set of predictive biomarkers could enable its use as a precision-medicine. Antengene intends to file the first IND for ATG-018 in 2022.
ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts
Abstract: 1143
Session: Preclinical and Clinical Pharmacology
Date and Time: 9:00 AM – 12:30 PM CST, April 11, 2022
Venue: Poster Section 25
In this preclinical study, ATG-022, an antibody-drug conjugate targeting Claudin18.2 (CLDN18.2), was evaluated in several gastric cancer patient-derived xenograft (PDX) models, to assess whether it had potential across a range of CLDN18.2 expression levels. Human CLDN18.2 is ectopically expressed in a large number of gastric and pancreatic cancers. Monoclonal antibody targeting CLDN18.2 demonstrated a promising clinical benefit when used in combination with chemotherapy. However, it showed suboptimal efficacy in patients with low CLDN18.2 levels.
In this study presented in the AACR, ATG-022 is reported to show high affinity (sub-nanomolar grade) against CLDN18.2 and demonstrated potent in vitro and in vivo antitumor effects, with in vivo efficacy observed in CLDN18.2 low expression PDX models. As shown in Figure, ATG-022 demonstrated much better in vivo efficacy compared with benchmark ADC. In addition, ATG-022 was highly specific for CLDN18.2, with virtually no effect on cells expressing CLDN18.1. In addition, ATG-022 has almost no impact on body weight, a proxy for safety. The authors concluded that ATG-022 shows promise for treating gastric cancer patients with a broad range of CLDN18.2 expression levels, a significant unmet need. Antengene is conducting preclinical studies for ATG-022.
Synergistic effects of the combination of Kras (G12C) with SHP2, ERK 1/2, mTORC1/2 or XPO1 inhibition for the treatment of Kras (G12C) mutated cancer
Abstract: 2679
Session: Signaling Pathway Inhibitors
Date and Time: 9:00 AM – 12:30 PM CST, April 12, 2022
Venue: Poster Section 25
This preclinical study was conducted to identify combination therapy regimen that could overcome the short progression free survival that is a characteristic of KRAS G12C inhibitors (linked to acquired resistance). The study evaluated the anti-tumor activity of ATG-012, a KRAS G12C inhibitor, with four other agents that are involved in the multiple pathways impacted by RASi: i) an SHP2 inhibitor (ET0038), ii) an ERK 1/2 kinase inhibitor (ATG-017), iii) an mTORC1/2 kinase inhibitor (ATG-008) or iv) the XPO-1 inhibitor, Selinexor, in preclinical solid tumor CDX models.
While ATG-012 monotherapy induced dose-dependent tumor growth inhibition at day 27, as shown in Figure, the authors also found strong in vivo synergism in 2-agent combinations. In particular, ATG-012 and clinical stage ERK inhibitor (ATG-017) demonstrate strong in vitro and in vivo synergism, suggesting potential clinical application which may overcome the rapid resistance of KRAS inhibitors. These data open the door to a range of combination partners for ATG-012 that could be fine-tuned to address drug resistance and potentially improve progression-free survival by matching tumor type/histology and combination partner for patients with the KRAS G12C mutation. Antengene is conducting preclinical studies for ATG-012.
Identification of MUC5B mutation as a positive predictive biomarker for mTORC1/2 inhibition by ATG-008 in lung cancer
Abstract: 4032
Session: Molecular Pharmacology
Date and Time: 9:00 AM – 12:30 PM CST, April 13, 2022
Venue: Poster Section 26
This study was designed to evaluate whether MUC5B could serve as a positive predictive biomarker for mTORC1/2 inhibition by ATG-008 (Onatasertib) in lung cancer. ATG-008 is a dual mTOR complex 1/2 kinase inhibitor. The mTOR complex regulates cell growth, metabolism, proliferation and survival. While the mTOR pathway is frequently deregulated in cancers, efficacy of mTOR inhibitors in lung cancer has been modest. In the study, 31 lung cancer cell lines were treated with ATG-008 to determine dose response and to correlate the gene mutation, amplification and expression with sensitivity to ATG-008.
As shown in Figure, the authors found that the presence of the MUC5B mutation correlates with more potent anti-tumor efficacy of ATG-008 in vitro and in vivo in lung cancer CDX models. The mucin MUC5B has a critical protective role in normal lung and has been identified as prognostic marker in multiple tumor types. One observation highlighted in the poster is that MUC5B is also mutated in melanoma, endometrial, colorectal, esophogastric and cervical cancers, vastly expanding the potential clinical utility of MUC5B mutation as the predictive biomarker for ATG-008. ATG-008 is being evaluated by Antengene in multiple Phase I and II clinical trials.
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 23 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010/XPOVIO® in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.
Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2020, and subsequent filings with the Hong Kong Stock Exchange.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000
View original content to download multimedia:
SOURCE Antengene Corporation Limited | https://www.kold.com/prnewswire/2022/04/11/antengene-announces-publication-five-posters-2022-american-association-cancer-research-aacr-annual-meeting/ | 2022-04-11T09:43:01 | 1 | https://www.kold.com/prnewswire/2022/04/11/antengene-announces-publication-five-posters-2022-american-association-cancer-research-aacr-annual-meeting/ |
TAIPEI, Taiwan, R.O.C., April 11, 2022 /PRNewswire/ -- ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711, "ASEH" or the "Company"), announces its unaudited consolidated net revenues for March and 1st quarter of 2022.
Consolidated net revenues (unaudited)
Pro Forma Basis**
Net revenues for ATM assembly, testing and material business are as follows:
atm net revenues (unaudited)
Pro Forma Basis**
*This press release is intended to comply with Taiwan regulatory requirements.
** Pro forma basis excludes the 4 disposed China Sites.
Safe Harbor Notice:
This press release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People's Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2021 Annual Report on Form 20-F filed on March 29, 2022.
Investor Relations Contact:
View original content:
SOURCE ASE Technology Holding Co., Ltd. | https://www.kold.com/prnewswire/2022/04/11/ase-technology-holding-co-ltd-announces-monthly-net-revenues/ | 2022-04-11T09:43:08 | 0 | https://www.kold.com/prnewswire/2022/04/11/ase-technology-holding-co-ltd-announces-monthly-net-revenues/ |
LONDON, April 11, 2022 /PRNewswire/ -- Cameroon, the Democratic Republic of the Congo (the DRC) and the Republic of the Congo have today announced their intention to adopt cryptocurrency and blockchain based solutions to drive future economic progress. Layer one proof-of-stake blockchain, The Open Network (TON) is the leading contender to become the blockchain to power this. The DRC has also confirmed that it is considering a new national stablecoin, built on the TON blockchain.
TON has been engaging with all three countries independently for some time and has taken the lead to deliver cryptocurrency and blockchain solutions for each nation. These countries will each undertake a phased transition to adopting cryptocurrency as a central pillar of their economic structures.
The future use of cryptocurrency will ensure that both banked and unbanked individuals will be better able to engage in the economy. This in turn will act as a powerful economic stimulus. In the DRC, for instance, as of 2019 12.4 million people had an account with a financial institution, whereas over 40 million have access to mobile phones or other internet enabled devices, demonstrating the significant potential for cryptocurrency.
The TON blockchain was designed to process millions of transactions within seconds. It's ultra-affordable, user-friendly and fully scalable. With TON being a decentralized platform, it will provide control and certainty for citizens, removing the possibility of interference. In addition, TON anticipates that applications will be uniquely integrated with the Telegram app to provide users with a seamless, accessible experience.
Speaking about the potential partnership, the Congolese Minister for Posts, Telecommunications and the Digital Economy, Léon Juste Ibombo, commented: "The Republic of the Congo has been on this path for a number of years, having encouraged and witnessed the widespread adoption of mobile payments across the country. This is the next step in that journey and we believe that TON is the right partner to facilitate this. This will be an invaluable, practical instrument for the growth and creation of wealth, both for the government and our people alike."
The Minister for Digital Economy for the Democratic Republic of Congo, Désiré Cashmir Eberande Kolongele, added: "We are proud to take this pioneering step, embracing new economic instruments to power our future economy. This marks the beginning of our journey to adopting cryptocurrency as a financial instrument within the DRC, and with the support of TON as a partner we aim to increase our nations exposure to modern financial tools. We are also enthusiastic to commence considering the launch of a national stablecoin on the TON blockchain, democratizing access to our financial system for millions of unbanked and underbanked citizens. The ability to integrate applications with the Telegram platform, and reach mobile users, makes TON the obvious choice as we step boldly into the world of cryptocurrency and blockchain."
Minette Libom Li Likeng, the Minister of Posts and Telecommunications for Cameroon, said: "The partnership with TON can play a fundamental role in the digital ecosystem of Cameroon for boosting the payment solutions and financial inclusion via CAMPOST, the public postal operator."
Steven Yun, Founding Member of TON Foundation, remarked: "There is an unbounded potential for these three countries to benefit from the adoption of cryptocurrency with our blockchain as the foundation. It's fantastic that TON's value is recognized, both in terms of its technology and utility. We're excited to embark on this journey to building strong and long-lasting partnerships."
This announcement follows the adoption of Bitcoin by El Salvador as legal tender, and it is anticipated that new stablecoins will be developed for Cameroon and the Republic of the Congo, in addition to the DRC, to provide confidence and assurance to citizens.
About The Open Network (TON)
The Open Network (TON) is a third-generation Proof-of-Stake blockchain originally designed in 2018 by the Durov brothers, the founders of Telegram Messenger. Later, it was handed over to the open TON Community, which has been supporting and developing it ever since.
TON was designed for lightning-fast transactions. It's ultra-cheap, user-friendly, and fully scalable. True to its predecessor, it aims to develop unique integrations with the Telegram app to provide its users with a seamless blockchain experience in a portable and familiar format.
TON is managed by community of non-commercial developers and supporters (the TON Foundation).
View original content:
SOURCE The Open Network (TON) | https://www.kold.com/prnewswire/2022/04/11/cameroon-democratic-republic-congo-republic-congo-take-major-step-towards-adoption-cryptocurrency-with-ton-leading-pack/ | 2022-04-11T09:43:15 | 1 | https://www.kold.com/prnewswire/2022/04/11/cameroon-democratic-republic-congo-republic-congo-take-major-step-towards-adoption-cryptocurrency-with-ton-leading-pack/ |
BEIJING, April 11, 2022 /PRNewswire/ -- Chinese President Xi Jinping, also general secretary of the Communist Party of China Central Committee, paid a visit to Sanya City of south China's Hainan Province on Sunday.
During the trip, Xi visited a seed laboratory to learn about seed industry innovation, and a research institute of the Ocean University of China to learn about the development of marine science and technology.
Link: https://youtu.be/ZGt18BH3TgU
View original content to download multimedia:
SOURCE CCTV+ | https://www.kold.com/prnewswire/2022/04/11/cctv-chinese-president-xi-jinping-inspects-sanya-city-south-chinas-hainan/ | 2022-04-11T09:43:21 | 1 | https://www.kold.com/prnewswire/2022/04/11/cctv-chinese-president-xi-jinping-inspects-sanya-city-south-chinas-hainan/ |
BEIJING, April 11, 2022 /PRNewswire/ -- China Online Education Group ("51Talk" or the "Company") (NYSE: COE), a leading online education platform in China, with core expertise in English education, announced that Mr. Liming Zhang has tendered his resignation as the Company's Chief Operating Officer due to personal reasons. His last day with the Company will be May 15, 2022.
The Company greatly appreciates Mr. Zhang's significant contributions to the management of the Company's operations as well as his role as the co-founder of the Company, and sincerely wishes his continued success in his future endeavors.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. 51Talk may also make written or oral forward-looking statements in its periodic reports to the Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about 51Talk's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in 51Talk's filings with the SEC. All information provided in this press release is as of the date of this press release, and 51Talk does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
About China Online Education Group
China Online Education Group (NYSE: COE) is a leading online education platform in China, with core expertise in English education. The Company's mission is to make quality education accessible and affordable. The Company's online and mobile education platforms enable students to take live interactive English lessons on demand. The Company connects its students with a large pool of highly qualified teachers that it assembled using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students.
For more information, please visit http://ir.51talk.com.
View original content:
SOURCE China Online Education Group | https://www.kold.com/prnewswire/2022/04/11/china-online-education-group-announces-management-change/ | 2022-04-11T09:43:28 | 0 | https://www.kold.com/prnewswire/2022/04/11/china-online-education-group-announces-management-change/ |
BOLIDEN, Sweden, April 11, 2022 /PRNewswire/ -- Ongoing geotechnical investigations in Aitik show the need to eventually change to a new dam construction method to ensure long-term disposal of tailings. In addition, there is a need to strengthen the current dam construction to meet the best international industry standards. The investments over the next two years are expected to lead to increased investments of a total of SEK 5 billion, of which SEK 1 billion in 2022.
- A high level of dam safety is always our top priority. The new direction naturally entails challenges in the short term, but it also creates long-term opportunities in Aitik and a clear direction for how the business can be developed going forward, says Mikael Staffas, President and CEO of Boliden.
Normally, the dam structures at Aitik's tailings pond are built and filled in line with production. In connection to ongoing geotechnical surveys for future dam heightening, areas with poorer soil conditions than previously estimated have been identified. Additional dam heightening and deposition of tailings against dams in these areas has therefore been suspended. In a first step, existing dam structures will now be strengthened and certain infrastructure will need to be moved. This is estimated to take about two years, after which dam heightenings and deposition in this area can be resumed.
Production in Aitik is not expected to be affected during this time as tailings can continue to be deposited in other parts of the tailings pond. The measures depend on environmental permits and other approvals, but work can be started prior to the permitting process.
For 2022, the total investments in the Group are now expected to increase from previously communicated just over SEK 10 billion to just over SEK 11 billion.
This information is information that Boliden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Director Group Communication, at 08:00 CET on April 11, 2022.
For further information, please contact:
Klas Nilsson, Director Group Communications, phone: +46 70-453 65 88
Mail: klas.nilsson@boliden.com
Due to this communicated press release, a telephone conference for analysts will be held today at 09.00 Stockholm time zone. From Boliden, Mikael Staffas, President and CEO and Håkan Gabrielsson, CFO, participate.
To participate, please call 5 minutes before the opening of the conference:
- from Sweden +46 856642651
- from United Kingdom +44 3333000804
- from United States +1 6319131422
PIN Code: 69409035#
The presentation will be held in English
Boliden is a metals company with a focus on sustainable development. Our roots are Nordic, our market global. Our core competence lies within the fields of exploration, mining, smelting and metal recycling. Boliden has around 6,000 employees and an annual turnover of around SEK 70 billion. The share is listed in the Large Cap segment on NASDAQ OMX Stockholm.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Boliden | https://www.kold.com/prnewswire/2022/04/11/decision-adjust-dam-construction-aitik/ | 2022-04-11T09:43:34 | 0 | https://www.kold.com/prnewswire/2022/04/11/decision-adjust-dam-construction-aitik/ |
- Valour has been admitted to The Financial Services Standards Association (in German: Verein zur Qualitätssicherung von Finanzdienstleistungen, "VQF"), a self-regulatory organization.
- The membership assures people that all DeFi Europe AG ("DeFi Europe") trade operations are compliant with Swiss anti-money laundering legislation and provides a regulatory stamp of approval strengthening the Company's trust as an issuer of digital assets
- The membership marks Valour as the first and only ETP issuer with admission to VQF association and it also enables the company to offer digital assets directly to businesses and institutions.
TORONTO, April 11, 2022 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (NEO: DEFI) (GR: RMJR) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that Valour Inc. ("Valour"), its wholly owned subsidiary and a pioneer in digital asset exchange traded products ("ETPs"), has been approved for a Swiss VQF membership through its Switzerland-based entity DeFi Europe.
The Swiss VQF membership was awarded by VQF, a self-regulatory association for the financial industry in Switzerland. The SRO is supervised by the country's official watchdog, the Swiss Financial Market Supervisory Authority ("FINMA").
DeFi Europe is a wholly owned subsidiary of Valour Inc. based in Zug, Switzerland. With the approval, DeFi Europe can now operate as a broker for digital assets, fully compliant with Swiss anti-money laundering legislation, enabling the company to offer access and liquidity in digital assets to businesses and institutions. The membership provides a regulatory stamp of approval strengthening the Company's trust as an issuer of digital assets. Valour becomes the first and only ETP issuer with admission to the VQF association.
"We see a tremendous amount of development across the broker landscape with continued adoption and demand for ETPs and digital assets," said Tommy Fransson, CEO of Valour. "In addition to ETPs, the most innovative brokers are searching for the possibility to offer crypto directly to their clients. With our state of the art infrastructure already in place, in combination with the transparency and trust that is a guiding principle for us at Valour, we see this as our next phase to leverage our existing operations that will enable us to support our counterparts."
"We continue to focus on providing transparency and utility to investors," said Russell Starr, CEO of DeFi Technologies. "Receiving admission to the VQF association further strengthens our value proposition and validates our ambition to be a leading provider of digital assets. We believe this will be an important step in our roadmap to access an even larger part of the institutional market."
Learn more about DeFi Technologies and Valour at defi.tech and valour.com.
The Financial Services Standards Association (in German: Verein zur Qualitätssicherung von Finanzdienstleistungen - VQF) is a self-regulatory organization. In Switzerland, the Swiss Financial Market Supervisory Authority (FINMA) is the Swiss government body responsible for financial regulation of financial institutes/intermediaries such as banks, insurances, broker-dealers, funds as well as SRO's.
DeFi Europe is a wholly owned subsidiary of Valour Inc. based in Zug, Switzerland. Once approved, DeFi Europe will be operating as a broker for virtual assets, fully compliant with Swiss anti-money laundering legislation and enable the company to offer access and liquidity in virtual assets.
Valour Inc. issues exchange-listed financial products that enable retail and institutional investors to access investment in disruptive innovations, such as digital assets, in a simple and secure way. Established in 2019 and based in Zug, Switzerland, Valour is a wholly owned subsidiary of DeFi Technologies Inc. (NEO:DEFI) (GR: RMJ.F) (OTC: DEFTF). For more information on Valour, visit www.valour.com.
DeFi Technologies Inc. is a technology company bridging the gap between traditional capital markets and decentralized finance. Our mission is to expand investor access to industry-leading decentralized technologies which we believe lie at the heart of the future of finance. On behalf of our shareholders and investors, we identify opportunities and areas of innovation, and build and invest in new technologies and ventures in order to provide trusted, diversified exposure across the decentralized finance ecosystem. For more information or to subscribe to receive company updates and financial information, visit https://defi.tech/.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to: the DeFi Europe's Swiss VQF membership; the business plans for DeFi Europe; the growth and adoption of decentralized finance; the pursuit by DeFi Technologies of business opportunities; the development of future ETPs and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited to, regulatory approval of DeFi Europe; the growth and development of the DeFi and cryptocurrency sector; rules and regulations with respect to DeFi; regulatory approval of ETPs and future adoption of Valour's ETPs. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
THE NEO STOCK EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
View original content to download multimedia:
SOURCE DeFi Technologies, Inc. | https://www.kold.com/prnewswire/2022/04/11/defi-technologies-subsidiary-valour-approved-swiss-vqf-membership/ | 2022-04-11T09:43:41 | 0 | https://www.kold.com/prnewswire/2022/04/11/defi-technologies-subsidiary-valour-approved-swiss-vqf-membership/ |
STOCKHOLM, April 11, 2022 /PRNewswire/ --
- Ericsson suspends affected business in Russia
- Records a SEK 0.9 b. provision in first quarter 2022
In late February, Ericsson (NASDAQ: ERIC) suspended all deliveries to customers in Russia. In the light of recent events and of European Union sanctions, the company will now suspend its affected business with customers in Russia indefinitely. Ericsson is engaging with customers and partners regarding the indefinite suspension of the affected business. The priority is to focus on the safety and well-being of Ericsson employees in Russia and they will be placed on paid leave.
As a consequence, Ericsson records a SEK 0.9 b. provision in first quarter 2022 for impairment of assets and other exceptional costs. No staff redundancy cost is included. The provision will be recorded in Other Operating Expenses in Segment Networks. Around one third of this amount will impact cashflow.
NOTES TO EDITORS:
FOLLOW US:
Subscribe to Ericsson press releases here.
Subscribe to the Ericsson Blog here.
https://www.twitter.com/ericsson
https://www.facebook.com/ericsson
https://www.linkedin.com/company/ericsson
MORE INFORMATION AT:
Ericsson Newsroom
media.relations@ericsson.com
(+46 10 719 69 92)
investor.relations@ericsson.com
(+46 10 719 00 00)
About Ericsson
Ericsson enables communications service providers to capture the full value of connectivity. The company's portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson's investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Ericsson | https://www.kold.com/prnewswire/2022/04/11/ericsson-suspends-business-russia-indefinitely-records-provision-q1-2022/ | 2022-04-11T09:43:48 | 0 | https://www.kold.com/prnewswire/2022/04/11/ericsson-suspends-business-russia-indefinitely-records-provision-q1-2022/ |
SPRING, Texas, April 11, 2022 /PRNewswire/ -- ExxonMobil introduced today its new Exceed™ S performance polyethylene (PE) resins, which deliver industry-leading combinations of stiffness and toughness while being easy to process. Utilizing the company's latest innovations in polymer science, the new PE platform provides opportunities to reduce the complexity of film formulations and designs while improving film performance, conversion efficiency, and packaging durability versus current market references.
Modern film design is a story of increasing complexity and compromise between performance and processability that is accepted to ensure durable packaging and high customer satisfaction. Multi-component resin blends in coextruded and laminated films with high layer counts are common-place. Every step of producing and converting printed film into durable packaging is prone to complexity-induced inefficiency, scrap and human mistakes. What if your resin could help simplify all of this?
"Exceed™ S performance PE resins deliver simplicity without compromise," said Tom Miller, Exceed™ S marketing manager at ExxonMobil. "With Exceed S, converters can obtain high levels of performance with easy processing, stiffness and toughness with less blending, and resin solutions that can simplify operations and improve package durability. In short, it is a platform of performance polyethylene grades designed to do so much, so simply."
Innovative converters can rethink film design with Exceed™ S performance PE by…
- Creating stiff, tough functional layers to maximize performance
- Leveraging increased performance to help facilitate solutions with sustainability benefits
- Reducing the need to add HDPE for stiffness or LDPE for processing
- Creating flatter, less extensible films to increase print and package line efficiency
- Delivering more durable flexible packaging, contributing to consumer satisfaction and helping to reduce food waste
The first three commercially available grades of Exceed™ S resins are designed to ensure low melt pressure and high output on blown film lines. The combined benefits allow the creation of a broad range of packaging and film applications:
- Large-format heavy duty sacks used in industry and agriculture along with silo bags for farming can benefit from increased puncture, impact and tear resistance. Exceed™ S resin's combination of low melt pressure and high extrusion output can also help increase converter's production capacity.
- In primary packaging, non-laminated coextruded films used in pouches and bags containing liquid, food, or other goods can benefit from improved toughness and are less likely to break when transported or dropped. For example, multi-wall bladders used in hot-filled bag-in-box packaging exhibit exceptional resistance to heat-induced blocking and flex cracking.
- PE//PE laminates with improved stiffness, toughness and bag drop survival can help facilitate larger pouch sizes and accommodate bulkier, heavier contents, helping to expand market usage of mechanically recyclable packaging.*
In these types of applications, the outstanding mechanical properties of Exceed™ S resins can be used to increase film performance, maintain comparable performance at a thinner gauge, produce more durable mono-material products, or incorporate high percentages of recycled content. Providing such solutions are part of ExxonMobil's four-pronged approach of using performance polymers to help facilitate solutions with sustainability benefits.
"ExxonMobil has been at the forefront of polyethylene innovation for nearly thirty years," said David Hergenrether, vice president for polyethylene at ExxonMobil. "The new Exceed™ S platform embodies our most advanced product and process development informed by deep, long-standing partnerships with our customers."
"The innovation opportunities that Exceed™ S performance polyethylene offers have already resulted in successful collaborations with more than 75 customers globally working on more than 100 different applications. We look forward to collaborating with our customers on new opportunities to advance their products."
Learn more about ExxonMobil's Exceed™ S solutions, visit: https://www.exxonmobilchemical.com/pe
View original content to download multimedia:
SOURCE Exxon Mobil Corporation | https://www.kold.com/prnewswire/2022/04/11/exxonmobil-introduces-new-exceed-s-performance-polyethylene-enabling-converters-rethink-film-design-simpler-solutions/ | 2022-04-11T09:43:54 | 0 | https://www.kold.com/prnewswire/2022/04/11/exxonmobil-introduces-new-exceed-s-performance-polyethylene-enabling-converters-rethink-film-design-simpler-solutions/ |
RADNOR, Pa., April 10, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Astra Space, Inc. ("Astra") (NASDAQ: ASTR) f/k/a Holicity Inc. ("Holicity") (NASDAQ: HOL). The action charges Astra with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Astra's materially misleading statements to the public, Astra investors have suffered significant losses.
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE
CLICK HERE TO SUBMIT YOUR ASTRA LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/astr-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=tal&utm_content=astra
LEAD PLAINTIFF DEADLINE: APRIL 11, 2022
CLASS PERIOD: FEBRUARY 2, 2021 AND DECEMBER 29, 2021
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com
ASTRA'S ALLEGED MISCONDUCT
Astra operates as an operational space launch company. On June 30, 2021, Astra and Holicity, a special purpose acquisition company, merged.
On February 2, 2021, Holicity filed a Form 8-K, which attached a press release dated February 2, 2021 entitled "Astra to become the first publicly traded space launch company on NASDAQ via merger with Holicity" which announced the merger with Astra. The February 2, 2021 8-K also attached an investor presentation which included slides touting Astra's ability to "[l]aunch anywhere in the world in 24 hours", its timeline, and its potential market.
The truth emerged on December 29, 2021, when market researcher Kerrisdale Capital released a report entitled "Astra Space, Inc (ASTR): Headed for Dis-Astra" (the Kerrisdale Report"), which alleged myriad issues with Astra. Specifically, the Kerrisdale Report stated that "[m]anagement habitually describes Astra as having the flexibility to launch from 'anywhere in the world,' which is simply not true" reasoning that "[in] the US, Astra can only launch from an FAA-licensed commercial spaceport approved for vertical launch. There are only 5 such sites (plus SpaceX's private Boca Chica spaceport) located in the U.S." The Kerrisdale Report also stated that Astra's "main competitors will soon be launching larger 1,000kg+ payload rockets while Astra has yet to overcome developmental hurdles necessary to successfully launch even a single satellite into any of the emerging broadband mega-constellations." Further, the Kerrisdale Report stated that "[c]onversations with an individual familiar with Astra's rocket design and manufacturing suggest investors may have to endure an uncomfortably high rate of failure as the company ramps to a targeted monthly launch cadence in 2022." Finally, the Kerrisdale Report stated that "[w]hile others in the industry like Rocket Lab are developing well-suited, best-in-class technology, enabling a variety of TAM-expanding missions, Astra is settling for suboptimal acquired technology with only niche applications."
Following this news, Astra's share price fell $1.10 per share, or approximately 14%, to close at $6.61 per share on December 29, 2021.
WHAT CAN I DO?
Astra investors may, no later than April 11, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member Kessler Topaz Meltzer & Check, LLP encourages Astra investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View original content to download multimedia:
SOURCE Kessler Topaz Meltzer & Check, LLP | https://www.kold.com/prnewswire/2022/04/11/final-deadline-kessler-topaz-meltzer-amp-check-llp-reminds-investors-lead-plaintiff-deadline-securities-fraud-class-action-lawsuit-filed-against-astra-space-inc-fka-holicity-inc-astr/ | 2022-04-11T09:44:00 | 0 | https://www.kold.com/prnewswire/2022/04/11/final-deadline-kessler-topaz-meltzer-amp-check-llp-reminds-investors-lead-plaintiff-deadline-securities-fraud-class-action-lawsuit-filed-against-astra-space-inc-fka-holicity-inc-astr/ |
ROCHESTER, N.Y., April 11, 2022 /PRNewswire/ -- Hyzon Motors Inc. (NASDAQ: HYZN) today announced it will supply its fuel cell electric trucks to Hylane GmbH, a wholly owned subsidiary of DEVK Versicherung, one of Germany's largest motor insurers. Hylane has purchased 18 Hyzon vehicles, with deliveries expected to begin in late 2022.
Under Hylane's sustainable mobility model, fleet owners can deploy Hyzon vehicles in their operations through a rental agreement with Hylane. Further, it is expected that customers will only pay for the miles actually driven; Hylane plans to cover maintenance or downtime costs. Through this pay-per-use approach, Hylane expects to minimize the risk for customers while accelerating the rate at which zero-emission vehicles replace diesel.
Hylane has already confirmed rental contracts for the first vehicles and is in talks with numerous prominent transport companies interested in transitioning their fleets to zero-emission options. Germany is expected to be one of the major global markets for zero emission commercial vehicle technologies in the coming years. The engine room of EU economic activity, Germany recently announced support for a total ban on sales of combustion engine cars from 2035, and there are already significant domestic incentives in place to transition heavy vehicles off diesel.
To support its exclusive focus on climate-friendly transport solutions, Hylane is aligning key elements within the value chain, including energy producers, refuelling infrastructure providers, and government subsidy programs. Through the coordinated management of these resources, Hylane aims to provide sustainable and flexible mobility management to its customers.
"Hyzon's singular mission is to decarbonize transport through zero-emission, hydrogen-powered vehicles," said Craig Knight, Hyzon CEO and co-founder. "Through Hylane's sustainable mobility program, customers across Germany can experience first-hand the vehicle performance, driver satisfaction, and emissions reductions of Hyzon's fuel cell electric trucks."
"Hyzon recognizes that, as with any new technology, customers need the chance to utilize our fuel cell electric vehicle in their regular operations. From past experience, we are confident that once fleet owners have experienced our vehicles, they will be motivated to hasten their transition to zero-emissions. Having a strong partner in the German market has the opportunity to fuel significant long-term growth for Hyzon."
About Hyzon Motors Inc.
Headquartered in Rochester, N.Y., with U.S. operations in the Chicago and Detroit areas, and international operations in the Netherlands, Singapore, Australia, Germany, and China, Hyzon is a leader in fuel cell electric mobility with an exclusive focus on the commercial vehicle market, and a near-term focus on back to base (captive fleet) operations. Utilizing its proven and proprietary hydrogen fuel cell technology, Hyzon aims to supply zero-emission heavy duty trucks and buses to customers in North America, Europe and around the world to mitigate emissions from diesel transportation, one of the single largest sources of carbon emissions globally. Hyzon is contributing to the escalating adoption of fuel cell electric vehicles through its demonstrated technology advantage, leading fuel cell performance and history of rapid innovation. Visit www.hyzonmotors.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements which include, but are not limited to, expected demand for and sales of Hyzon vechicles, are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Hyzon disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Hyzon cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Hyzon, including risks and uncertainties described in the "Risk Factors" section of Hyzon's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the "SEC") on March 30, 2022, our Amended Registration Statement on Form S-1 filed with the SEC on April 6, 2021, and other documents filed by Hyzon from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Hyzon gives no assurance that Hyzon will achieve its expectations.
View original content to download multimedia:
SOURCE Hyzon Motors Inc. | https://www.kold.com/prnewswire/2022/04/11/hyzon-motors-sells-18-trucks-hylane-gmbh-subsidiary-major-german-motor-insurance-provider-devk-versicherung/ | 2022-04-11T09:44:07 | 1 | https://www.kold.com/prnewswire/2022/04/11/hyzon-motors-sells-18-trucks-hylane-gmbh-subsidiary-major-german-motor-insurance-provider-devk-versicherung/ |
SAN FRANCISCO and SUZHOU, China, April 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase I study for IBI322 (anti-CD47 /PD-L1 bispecific antibody) in patients with advanced solid tumors were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Poster No. CT513).
This is a first-in-human, phase Ia/Ib dose escalation/expansion study of IBI322 monotherapy in patients with advanced solid tumors who failed standard of care treatment. 58 subjects were enrolled in the study, 16 of which (27.6%) had previously received PD-1/L1 treatment. The highlights for the study results were as follows:
- 20 patients with various advanced solid tumors at active doses of IBI310 ≥10 mg/kg group were evaluable per RECISTv1.1, 4 achieved PR, with investigator assessed ORR 20%.
- Among 9 patients with NSCLC treated at active doses of IBI310 ≥10 mg/kg group, 3 achieved PR, with investigator assessed ORR 33.3% and the DCR 88.9%.
- IBI322 was well tolerated and showed a favorable safety profile. Treatment related adverse events (TRAEs) occurred in 74.1% (43/58) patients, most frequent TRAEs including anemia, platelet count decreased, pyrexia. The majority of the TRAEs were in grade 1-2. No treatment related death occurred as the cut-off date.
Phase Ia dose expansion study with IBI322 monotherapy has kept updating with longer follow-up after the cut-off date. Preliminary response and disease control have been observed in specific indications (such as SCLC). More clinical data will be mature and presented in the future.
Furthermore, given that IBI322 has demonstrated promising efficacy signals and favorable safety and tolerability profile, phase Ib trial has been conducted to further explore the safety and efficacy of IBI322 in multiple indications.
Professor Jie Wang, principal investigator of the study, Chief of Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, stated: "Immune checkpoint inhibitors (ICI) have shown promising efficacy in various tumor types, but many clinical challenges still remain. With the increasing prescription of ICI in first-line setting, many patients developed into ICI resistance or has poor response rate in clinical practice. Therefore, it is of great clinical significance to develop next generation bi-specific immune checkpoint inhibitors. CD47 is one of the most promising targets in immunotherapy. With innovate bispecific antibody development technology, IBI322 showed favorable safety and preliminary efficacy signals in subjects who had failed previous standard treatment, which increased our confidence in the subsequent expansion cohort study."
Dr. Hui Zhou, Vice President of Innovent, stated: "IBI322 is a bispecific antibody that specifically targeting recombinant anti-differentiation cluster 47 (CD47) and anti-programmed death ligand 1 (PD-L1).IBI322 is independently developed by Innovent Biologics and the company owns global proprietary rights. We are very excited to observe preliminary efficacy and manageable safety profile in patients with advanced malignancy who failed standard of care treatment. We will continue to proceed the phase Ib expansion cohort study and further explore the safety and efficacy of IBI322 in multiple indications. By developing a comprehensive and advanced pipeline of next generation immune checkpoint inhibitors, we hope to bring clinical benefit to more patients."
About IBI322
IBI322 is a recombinant anti-human CD47/PD-L1 bispecific antibody developed by Innovent Biologics. As a bispecific antibody, IBI322 targets CD47 on the surface of tumor cells, blocks SIRPα/CD47 pathway and activates macrophages to attack the tumor cells. Furthermore, IBI322 target PD-L1 on the surface of tumor cells, blocks the PD-1/PD-L1 pathway, which counteracts the inhibition of T cells and activates the T cells to attack the tumor cells. By inhibiting two different targets, IBI322 can not only activate both innate immune pathway and adaptive immune pathway, which provides synergistic effect, but also reduce the red blood cell destruction. IBI322 has received IND approvals from both the NMPA and the U.S. FDA and has been actively developed globally.
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 32 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 7 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection), PEMAZYRE® (pemigatinib), olverembatinib (BCR ABL inhibitor) and Cyramza® (ramucirumab), 1 asset under NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials, and an additional 19 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
Disclaimer:
1. This indication is still under clinical study, which hasn't been approved in China.
2. Innovent does not recommend any off-label usage.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:
SOURCE Innovent Biologics | https://www.kold.com/prnewswire/2022/04/11/innovent-release-phase-1-results-ibi322-anti-pd-l1cd47-bispecific-antibody-patients-with-advanced-solid-tumors-aacr-annual-meeting-2022/ | 2022-04-11T09:44:14 | 1 | https://www.kold.com/prnewswire/2022/04/11/innovent-release-phase-1-results-ibi322-anti-pd-l1cd47-bispecific-antibody-patients-with-advanced-solid-tumors-aacr-annual-meeting-2022/ |
PALO ALTO, Calif., April 11, 2022 /PRNewswire/ -- Ladder, the company offering flexible life insurance in minutes, today released "Crocodile," the second installation of its "So Good" brand campaign — a series of humorous and memorable films built around the unique consumer insight that almost 1 in 2 couples with life insurance joke about taking each other out for the payout.
Created in partnership with creative/culture agency FRED & FARID Los Angeles and award-winning director and costume designer Casey Storm (of Spike Jonze and David Fincher credits), the new film stars the Ladder mom unleashing another inventive plot on her beloved husband: this time with the ruse of a romantic parental rendezvous and a little help from a crocodile. Once again, dad escapes the outlandish trap (mostly) unphased, retorting "I'm ok, guys!" with his signature happy-go-lucky demeanor.
With the continuation of this daring campaign and its innovative digital life insurance product, Ladder is cementing its position as the unavoidable disruptor in life insurance — attracting a new generation of consumers and flipping traditional life insurance rhetoric on its head to create easy and open conversations within families.
To champion these conversations, the "Crocodile" spot leads to a landing page with additional videos featuring the So Good cast: a delightful series of father-daughter interview sessions that cover the basics of life insurance. By centering these discussions, Ladder is further shifting life insurance away from a taboo topic to appreciating it as a crucial part of every family dynamic.
"We feel so lucky to have such an amazing client partner. They understand the power of creativity and are willing to take risks and to be bold and disruptive. We hope to continue to capitalize on the success of the campaign with many more films," says FRED & FARID Los Angeles creative agency.
"I love this campaign," says Casey Storm. "For me as a director, the scripts and the campaign are a home run. I've heard how effective the last campaign was and I'm sure this next devilish round will be equally successful at raising brand awareness and making people smile."
"Crocodile is about more than the next installment in our campaign," says Olivia Borsje, VP of Marketing at Ladder. "It's representative of the way Ladder is revolutionizing life insurance for customers — not only through product and distribution innovation, but also through brand. Giving digital consumers a fresh way to re-engage with the category is fundamental to achieving our mission of making life insurance as affordable, accessible, and beloved as it should be."
Ladder's "Crocodile" spot is now live across the country on digital platforms and TV networks.
About Ladder
Ladder is the next generation life insurance company. Offering flexible term coverage in minutes that can save policyholders up to 40%*, Ladder uses an all-digital architecture and real-time underwriting to make life insurance as accessible, affordable, and beloved as it should be. The company is headquartered in Palo Alto, CA and offers coverage up to $8M in all 50 states. To learn more, visit ladderlife.com.
About FRED & FARID
FRED & FARID is a creative/culture agency producing meaningful ideas, grounding brands into culture. Based in Los Angeles, New York, Paris, Shanghai, FRED & FARID's culture is a peculiar mix of the French sense of craft and taste, the Chinese sense of tactic and digital, and the American sense of vision and strategy. The agency focuses on creative consulting, brand strategy, branding, content & social activation, and has produced 1800+ creative campaigns for 250+ brands in 33+ industries, winning 1200+ awards and 30+ industry titles – including Cannes Grand Prix and D&AD 3rd Independent Network.
Media Contact
Liana Corwin, media@ladderlife.com
Jalila Levesque, jalila.levesque@fredfarid.com
Assets
"CROCODILE" FILM: https://www.youtube.com/watch?v=W7sQnmwGsbc
KEY VISUAL: https://www.dropbox.com/sh/9exdup3hhqnb4ew/AADvrGxzUh2ZNzRISIYibz3ta?dl=0
101 FILMS: https://www.ladderlife.com/so-good
KEY VISUALS: https://www.dropbox.com/sh/a6vctsyvgp8wr2a/AACBC9egEJa8u92223b1g-bQa?dl=0
Credits
Title of Ad: "CROCODILE"
Brand: Ladder
VP of Marketing: Olivia Borsje
Brand Marketing Manager: Casey Dubie
Director of Communications: Liana Corwin
Agency: FRED & FARID Los Angeles
Chief Creative Officers: Fred & Farid
Creative Director: Chelsea Steiger
Account Director: Sarah Silberstein
Copywriter: Ciana Alessi
Executive Producer: Amanda Van Caneghem
Strategy Director: Eileen Zhao
Head of Global Communications: Jalila Levesque
Business Affairs Lead: Michelle Fink
Production Company: Production Company Productions
Director: Casey Storm
Executive Producer: Rob Hatch-Miller
Executive Producer: Puloma Basu
Executive Producer: Tom Scharpling
DP: Jake Polonsky
Producer: Rob Hatch-Miller
Producer: Puloma Basu
Editorial: EXILE
Editor: Matt Murphy
Assistant Editor: Ersin Dogruer
Executive Producers: CL Kumpata, Jennifer Locke
Post Producer: Samantha Axelrod
Company 3 Color
Senior Colorist: Sean Coleman
Senior Color Producer: Matt Moran
Executive Producer Color: Connor Callaghan
Company 3 Finish
Lead Flame Artist: Brian Conlon
Flame Artists: Kelly Bumbarger, Sean Wilson, Cecile F. Tescon
Roto Artists: Pam Gonzales, Marianne Magne
Senior Finishing Producer: Paula S. Jiménez
Executive Producer Finish: Connor Callaghan
Music by Human
Head of Sync and A&R Kamela Anderson
Creative Director Craig DeLeon
Composer Jon Hubbell
Sound Design & Mix: Lime Studios
Mixer: Sam Casas
Executive Producer:Susie Boyajan
Disclosure
Ladder Insurance Services, LLC (CA license # OK22568; AR license # 3000140372) distributes term life insurance products issued by multiple insurers – for further details see ladderlife.com. All insurance products are governed by the terms set forth in the applicable insurance policy. Each insurer has financial responsibility for its own products.
*Savings in premium compared with the same customer maintaining their full coverage amount for the policy term. Savings attained by decreasing coverage every three years over the policy's full term on a $1.4M, 20 year policy. Prices valid as of June 15, 2021.
View original content to download multimedia:
SOURCE Ladder; FRED & FARID Los Angeles | https://www.kold.com/prnewswire/2022/04/11/ladder-releases-crocodile-spot-second-chapter-so-good-campaign/ | 2022-04-11T09:44:21 | 1 | https://www.kold.com/prnewswire/2022/04/11/ladder-releases-crocodile-spot-second-chapter-so-good-campaign/ |
Specialty broker expands NFP capabilities and expertise
NEW YORK, April 11, 2022 /PRNewswire/ -- NFP, a leading insurance broker and consultant providing property and casualty (P&C), corporate benefits, retirement, and individual solutions, today announced it has acquired Irish-owned ReSure Corporate Brokers, a specialist commercial insurance broker. This latest announcement marks NFP's third acquisition in Ireland within the past two years, having acquired local brokers HMP Insurance and Pension Advisors and Aiken Insurance Limited.
Established just over two years ago, Dublin-based ReSure currently employs 14 people and is among the fastest growing corporate insurance brokers in the Irish market, generating gross written premiums valued at more than €24m/$26.2m USD in 2021. To date, the business has focused on building and enhancing its specialist capabilities by supporting complex risk placements of restructuring, recycling, real estate, construction, domiciliary homecare and financial lines among others.
John Paul Allcock, UK and Ireland managing director at NFP, commented: "NFP always looks for quality over quantity and the market feedback about ReSure's business, culture and management team was exemplary. We have acquired a great business with great clients, and a group of extremely talented brokers and client managers. Most importantly, we are confident they will fit into the culture of NFP, which encourages independence, entrepreneurial spirit, ethics and a focus on doing the right thing for employees and clients."
ReSure's directors, Aidan Brady, Ross Barron and Garry Fitzroy, have built on their deep experience over two decades working in the global and local insurance broking environment. The Directors and full team at ReSure will continue in their roles and remain fully engaged in the growth of the business, working with NFP to bring added value to new and existing clients.
"Our ambition at ReSure is to continue our incredible growth journey to scale the business and support our clients as they expand into new markets and sectors. In joining the NFP family, we also see great value in integrating our insurance solutions and services with NFP's corporate benefits and wealth management clients.
I cannot let this moment pass without acknowledging the overwhelming support we have enjoyed from our loyal clients and our excitement in continuing our strong partnership for years to come," said Aidan Brady, managing director at ReSure.
He added: "In NFP, we have found a likeminded partner with shared values that will help us accelerate and achieve this plan and help to create further opportunities for our talented team to continue to thrive and prosper."
Commenting on what this latest acquisition means for NFP, Matt Pawley, NFP's managing director in Europe said: "We are delighted to welcome the ReSure team to the NFP family. They are a great fit in terms of people, expertise and attention to customer service and relationships. We are very confident they will make significant contributions that elevate our business further in Ireland and across Europe as we continue to expand and seek new opportunities for growth, both organically and through further additional acquisitions."
About NFP
NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement, and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 6,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 7th largest US-based privately owned broker, 9th best place to work in insurance and 13th largest broker of U.S. business (Business Insurance); 10th largest commercial lines agency by P&C commercial lines revenue and 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best's Review).
Visit NFP.com to discover how NFP empowers clients to meet their goals.
About ReSure
ReSure Corporate Brokers are proud to be among the fastest growing Commercial Insurance brokers operating in the Irish & UK market. Our goal is to forge partnerships with our clients and build a relationship where trust is at the core, whilst providing the necessary peace of mind through access to reliable insurance markets. We pride ourselves on our exceptional customer service and professional approach; and we believe strongly that with the experience our team has acquired in the global insurance broking environment, combined with our local business knowledge, we have a unique blend of qualities to offer clients.
ReSure placed over €24m Gross Written Premium (GWP) into the Irish and UK markets in 2021. We are projecting €30m GWP in 2022, and our success has been achieved to date by working hand in hand with our clients to attain the best possible results in the insurance market.
We are a growth-orientated business and have exceeded targets to date by focusing on particular niches in Restructuring, Recycling, Real Estate, Construction, Domiciliary Homecare and Financial Lines among others. We specifically target markets where we can add value and make a real difference to our loyal clients, forming an integral partnership with their business.
View original content to download multimedia:
SOURCE NFP Corp. | https://www.kold.com/prnewswire/2022/04/11/nfp-acquires-resure-continues-grow-business-ireland/ | 2022-04-11T09:44:28 | 0 | https://www.kold.com/prnewswire/2022/04/11/nfp-acquires-resure-continues-grow-business-ireland/ |
NEWINGTON, Conn., April 11, 2022 /PRNewswire/ -- PCX Aerosystems, LLC ("PCX"), a market-leading producer of advanced mechanical systems for the aerospace industry, today announced the April 1, 2022 acquisition of Honematic Machine Corporation ("HMC" or "Honematic") from the Cusimano family, whose stewardship of HMC began in 1992. HMC is a leading supplier of extendable refueling probes for the rotorcraft market. In addition to supplying fully tested complex assemblies, HMC excels in precision, large-format drilling, boring, milling and finishing for mission-critical defense, aerospace, and industrial applications.
"The HMC acquisition adds value both by enabling the vertical integration of certain existing production processes on flight-critical masts and shafts, and by creating the opportunity to deliver complete, fully-integrated mechanical assemblies. We are particularly excited about the potential for collaboration between HMC and the recently-acquired Aero-K business. Aero-K supplies aerial refueling boom sub-assemblies and complex mission-critical components and assemblies for fixed wing aviation and submarine applications," said Tom Holzthum, CEO of PCX. The acquisition of Aero-K, an El Monte, a California-based specialty manufacturer, was completed in January, 2022.
Greg Cusimano, President of Honematic, said "Joining the PCX family represents a great opportunity for both our customers and our team. With the resources and relationships that PCX brings to the table, we will be better able to meet growing customer demands and identify new applications for our know-how. For our employees, this will create both stability and opportunity."
About PCX
Headquartered in Connecticut, PCX Aerosystems is a leading privately-owned supplier of highly engineered, precision, flight-critical assemblies for rotorcraft and fixed wing aerospace platforms. PCX focuses on producing complex parts machined from alloys such as aluminum, magnesium, titanium, and steel - where tight tolerances and quality are imperative. The company provides direct delivery of components and large assemblies to customers such as Boeing, General Electric Aircraft Engines, Bell and Sikorsky. PCX Aerosystems is owned by Greenbriar Equity Group, L.P.
To learn more about PCX please visit www.pcxaero.com.
About Honematic
HMC is a Boylston, Massachusetts-based manufacturer of precision deep-bored, turned and honed components, with specialized assembly and testing capabilities. Since 1956, HMC has reliably delivered medium- and large-format customer solutions across Aerospace, Defense, Power Generation and other Industrial markets.
For more information:
Trevor Hartman
Vice President – Sales & Marketing
(860) 594-4388
View original content to download multimedia:
SOURCE PCX Aerosystems | https://www.kold.com/prnewswire/2022/04/11/pcx-aerosystems-llc-announces-acquisition-honematic-machine-corporation/ | 2022-04-11T09:44:35 | 0 | https://www.kold.com/prnewswire/2022/04/11/pcx-aerosystems-llc-announces-acquisition-honematic-machine-corporation/ |
The partnership will accelerate Cloud Transformation and Better Serve Its Citizens
SUNNYVALE, Calif, and JERUSALEM, April 11, 2022 /PRNewswire/ -- Today, Google Cloud and Israeli judiciary, The Rabbinical Court announced a collaboration to accelerate its Cloud transformation journey. This new collaboration will see the Rabbinical Court leverage Google Cloud's infrastructure, storage and applications to better serve its Israeli citizens.
Following Google Cloud's win in the Nimbus tender for delivering cloud services to the Israeli government, the Rabbinical Courts migrated most of its workloads to Google Cloud with minimum disruption to the business and with a cost-effective deployment. Google Cloud also needed to design a virtual desktop infrastructure (VDI) solution to enable dozens of employees to work in a virtual environment, from home, safely and securely, due to the Covid-19 pandemic. Google Cloud has created a partner interconnect with a high level of security that allows the customer to work directly with the VDI stations.
The Rabbinical Courts, the legal Jewish authority in Israel, deals with issues relating to divorce, property, child custody rights, wills, inheritances, confirmation of Jewish status, and conversion. There are 12 regional rabbinical courts throughout the country, with the Jerusalem High Court serving as an appellate court. President of the Rabbinical Court, heads the Great Court and serves as Chief Rabbi of Israel. The organisation is led by a CEO appointed by the Minister of Religious Affairs.
The two organisations will collaborate to:
- Further enhance citizens' experience: Leveraging many of Google Cloud's products and services—including infrastructure, applications and more—the Courts will drive operational efficiency and create more compelling experiences for its citizens. This Includes helping citizens access the documents they need to seamlessly navigate court proceedings such a divorce.
- Accelerate cloud transformation: The Courts are using Google Cloud-based infrastructure-as-a-service (IaaS) products—like storage, networking, and compute—to more rapidly digitise its operations into the cloud.
- Strengthen the security of citizen data: The Courts are piloting Cloud Identity to help protect organisational data with a wide variety of multi-factor authentication (MFA) verification methods, such as push notifications, Google Authenticator, and phishing-resistant Titan Security Keys—all while ensuring privacy of citizens' data.
- Maintain and manage databases: The Courts are making use of Google Cloud Structured Query Language that helps the organisation set up, maintain, manage, and administer relational databases on the Google Cloud Platform.
- WideOps partnership: WideOps has been chosen by Google Cloud to perform the RBC migration. Using Google Cloud native tools, the WideOps expert migration team has managed to migrate the entirety of RBC infrastructure to Google Cloud, while adhering to high architectural and security standards—resulting in a robust, highly available, and secure environment. Due to the seamless deployment process, RBC staff can continue their work with minimal-to-no impact on the end-user experience.
"We are delighted to work with Google Cloud on the next stage of our digital transformation journey," said Chief Information Officer Mr. Uri Aharonson. "We are looking forward to this collaboration to develop applications that will make our services faster and more accessible for our Israeli citizens."
"We are thrilled to start providing services to the Rabbinical Court and improve the lives of Israelis throughout the country,'' said Shay Mor, head of Government and Public Sector, Google Cloud, Israel.
Google Cloud accelerates every organisation's ability to digitally transform its business. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology – all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.
View original content to download multimedia:
SOURCE Google Cloud | https://www.kold.com/prnewswire/2022/04/11/rabbinical-court-collaborates-with-google-cloud-part-nimbus-project/ | 2022-04-11T09:44:41 | 0 | https://www.kold.com/prnewswire/2022/04/11/rabbinical-court-collaborates-with-google-cloud-part-nimbus-project/ |
BEIJING, April 11, 2022 /PRNewswire/ -- Recently, Realsee, a world-leading space digitalization integrated solution provider, officially entered into strategic cooperation with Realestate.com.kh, a real estate portal platform in Cambodia. The partnership will facilitate the sharing of technology and allow both parties to jointly explore new ways to advance the digitalization of real estate.
As a pioneer in digital space capture and processing, Realsee has taken the lead in the large-scale application of 3D reconstruction technology in China. Realsee has not only developed VR hardware acquisition equipment applicable to a range of industries and use cases, but also launched VR inspection, and AI-design functionality. These products have revolutionized the real estate transaction experience for homebuyers and sellers around the world. As of the end of 2021, Realsee had completed the 3D reconstruction of more than 18.44 million physical spaces generating more than 1.6 billion VR views annually.
Built on its advantages in technological leadership and low cost digital space solutions, Realsee has been adopted by more than 100 brands across 27 countries. After formalizing cooperation with Realsee, Realestate.com.kh will fully integrate a range of digital real estate solutions into its network, creating digital twins for potentially tens of thousands of new and existing properties. Realsee's VR solutions offer users the ability to experience lifelike restorations of properties, providing a high level of detail include property dimensions, orientation, surrounding environment – all seamlessly accessed through mobile or web browser.
In the era of COVID-19, VR is making property inspections safer, faster, and easier. Thomas O'Sullivan, CEO of Realestate.com.kh, pointed out that, "Customers usually prefer online housing inspection at present. VR-based housing inspection created by Realsee integrates everything into a 3D space with a more immersive panoramic effect and provides customers with an immersive house inspection experience. This cooperation with Realsee will not only provide a truly improved experience for offline property seekers, but also create significant benefits and value for real estate developers and brokers."
View original content:
SOURCE Realsee | https://www.kold.com/prnewswire/2022/04/11/realestatecomkh-partners-with-realsee-transform-real-estate-emerging-markets/ | 2022-04-11T09:44:48 | 0 | https://www.kold.com/prnewswire/2022/04/11/realestatecomkh-partners-with-realsee-transform-real-estate-emerging-markets/ |
- Underscoring its commitment to world-class technology, DAZN has recruited Sandeep Tiku to drive innovation and lead the next phase of platform development
- Sandeep is internationally recognised as a world-class technologist and innovator
LONDON, April 11, 2022 /PRNewswire/ -- DAZN Group, the global sports entertainment company, today announces that Sandeep Tiku will be joining the company as Chief Technology Officer.
Sandeep will lead DAZN's global technology and product teams to drive the next phase of development for its core sports streaming media platform as it integrates new experiences to become an interactive sports entertainment ecosystem and expands into new markets.
Having spent over 20 years designing and developing transformational technology and complex platforms for B2C digital products, Sandeep is recognised as a global technology leader and respected innovator.
Sandeep's impeccable track record in building complex technology, coupled with his entrepreneurial spirit and customer-centric approach, will be invaluable to DAZN.
His appointment follows the launch of DAZN X, the company's innovation lab, and underscores DAZN's ongoing investment in world-class technology and commitment to an exceptional fan experience as it integrates richer and more interactive content for fans to enjoy alongside live sports.
Sandeep joins from Entain, a FTSE 100 global gaming and entertainment company, where he was most recently Chief Operating Officer, and oversaw the technology and operations that supports a portfolio of brands in over 30 markets. During his eight years at Entain, Sandeep was instrumental in developing their industry-leading global platform to be robust and scalable.
CEO of DAZN Group Shay Segev said, "Having worked alongside Sandeep for many years at Entain, I know that he is an exceptional and visionary technologist and the right person to lead DAZN's technology teams. He will be invaluable as we expand our offering with even more ways to entertain and engage sports fans and forge ahead with transforming the global sports market."
Sandeep Tiku said, "To join a company like DAZN that has boundless ambitions and puts the customer at the heart of everything it does, is fantastic. With their vision and my tech experience, the potential is phenomenal. I look forward to working with Shay and the global technology teams to grow DAZN's platform as a true destination for sports fans across the world."
Photo - https://mma.prnewswire.com/media/1793931/DAZN_Sandeep_Tiku.jpg
Logo - https://mma.prnewswire.com/media/1097249/DAZN_Gr
View original content to download multimedia:
SOURCE DAZN | https://www.kold.com/prnewswire/2022/04/11/sandeep-tiku-join-dazn-group-chief-technology-officer/ | 2022-04-11T09:44:54 | 1 | https://www.kold.com/prnewswire/2022/04/11/sandeep-tiku-join-dazn-group-chief-technology-officer/ |
SÖDERTÄLJE, Sweden, April 11, 2022 /PRNewswire/ -- In a judgment rendered earlier this year, the General Court of the EU found in favour of the EU Commission that Scania had violated EU antitrust rules. Scania has now appealed against this judgment, to the European Court of Justice.
On 27 September 2017, the European Commission adopted a decision holding Scania liable to pay a fine of more than 880 MEUR for allegedly having participated in inappropriate exchanges of information and collusion with other European truck manufacturers with regard to pricing and the introduction of emissions technologies during the period of 1997-2011.
Scania appealed to the General Court later the same year. On 2 February 2022, the General Court rendered a judgment that confirmed the EU Commission's findings against Scania, dismissed Scania's appeal entirely and upheld the amount of fines as set by the EU Commission.
Scania still contests all findings of the EU Commission, as subsequently confirmed by the General Court, and maintains that the company neither entered into any pan-European agreement with other manufacturers with regard to pricing, nor colluded to delay the introduction of new engines compliant with EU legislation for exhaust emissions.
Scania therefore filed an appeal on 8 April 2022 against the General Court's judgment, to the European Court of Justice as the last court of instance in the EU.
For further information, please contact:
Erik Bratthall, Corporate Public and Media Relations Manager, Scania
Phone: +46 76 724 45 27
E-mail: erik.bratthall@scania.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Scania | https://www.kold.com/prnewswire/2022/04/11/scania-appeals-against-judgment-by-eu-general-court-case-alleged-violations-eu-antitrust-rules/ | 2022-04-11T09:45:01 | 0 | https://www.kold.com/prnewswire/2022/04/11/scania-appeals-against-judgment-by-eu-general-court-case-alleged-violations-eu-antitrust-rules/ |
Stock price doubles in value
HONG KONG, April 11, 2022 /PRNewswire/ -- Hong Kong Aerospace Technology Group Limited (HKATG; 01725. HK) announced its strategic cooperation with the Company and Shandong Institute of Industrial Technology for the construction and operation of the first high-resolution agricultural satellite constellation (''Golden Bauhinia — Qilu Satellite Constellation'') on 4 April. It is known that the first phase of the project comprising 9 satellites and the first experiment satellite is expected to be launched in July 2022, and the remaining eight operational satellites with 8-band multi-spectral observation capability will be launched in December 2022.
After the news came out, a huge amount of smart money poured into HKATG, its stock soared for 4 consecutive days between 4 April and 8 April. HKATG recorded a four-day gaining streak from its latest low of HK$12.2, in addition to crossing above 10-day and 20-day exponential moving average (EMA), the stock, a new high in three months was made during intraday trading on 8 April. HKATG surged by more than 100% in a few days, and the trading volume moved against the market which up to nearly 800,000 shares, with a capital of HKD 16.83 million involved and an amazing momentum.
According to the Flow of Funds, several foreign and local banks have been increasing their holdings in the past few days, showing confidence in HKATG's prospects. Previously, HKATG announced its collaboration with the College of Engineering of the City University of Hong Kong (''CityU''), the parties have entered into a letter of intent (the ''LOI'') concerning the strategic cooperation in the research and development of advanced satellite technology and related applications in Hong Kong, covering communication systems, antenna technology, advanced materials, data processing, and energy management. With the dominant position in the local commercial aerospace market, HKATG is well-positioned for endless business opportunities.
Annual Results Not Fully Reflected Upcoming Profits
HKATG announced the consolidated annual results for the year ended 31 December 2021, though the gross profit recorded a year-over-year decline of approximately 25.2%, smart investors seem to be aware that last year's results did not reflect several strategic agreements signed by the company since the beginning of 2022, so they bought immediately while the stock price pulled back.
If you read the company's annual report carefully, it is not difficult to analyze the reasons that influence HKATG's gross profit in 2021. The company's key construction, the Satellite Operation Control, and Application Centre at the AMC Premises put into operation last year, which has led to an increase in operating costs while representing a milestone in the production capacity expansion. It is worth mentioning that, according to the latest annual results, the company's net impairment losses on financial assets as of 31 December 2021 have narrowed significantly, from RMB 5,122,000 in 2020 to RMB 131,000 in 2021, the result is quite encouraging.
An exclusive aerospace manufacturer in HK
According to the management of HKATG, the company will gradually put into production batches of optical remote sensing satellites, these satellites will have different types of payloads such as multi-spectral and synthetic aperture radar and can comprehensively provide satellite remote sensing data and products that integrate different bands. The company also announced earlier that those 25 satellites are planned to be launched in 2022 for the "Golden Bauhinia Constellation'', and the ''Golden Bauhinia Satellite No. 1 (04)'' is also ready to launch. With the launch of small satellites in batches, HKATG is expected to realise the on-orbit verification of miniaturized aerospace systems, laying the foundation for next year's business constellation development.
''Golden Bauhinia Satellite No. 1 (04)'' is another pilot satellite of the "Golden Bauhinia Constellation", on the one hand, the satellite will conduct on-orbit testing and verification of micro-miniature remote sensing payloads, and on the other hand, the data generated during the satellite's in-orbit operation will be widely used in agricultural monitoring, disaster prevention, and mitigation, as well as comprehensive urban management and watershed control.
Taking the supporting role in the development of Hong Kong into an international innovation and technology hub, HKATG certainly has a market-dominating position with explosive growth potential in the upcoming years and beyond.
View original content:
SOURCE Hong Kong Aerospace Technology Group | https://www.kold.com/prnewswire/2022/04/11/smart-money-pours-into-hkatg/ | 2022-04-11T09:45:08 | 1 | https://www.kold.com/prnewswire/2022/04/11/smart-money-pours-into-hkatg/ |
NWEA Releases Research Analysis Illuminating Impact of Learning Interruptions on Historically Underserved Students; Underscores Benefits of High-Quality Summer Learning Opportunities
PORTLAND, Ore., April 11, 2022 /PRNewswire/ -- As we approach the end of the third straight year of learning disrupted by the COVID-19 pandemic, U.S. classrooms continue to address the immediate needs of students while prioritizing academic progress for all. For many students—particularly those that are historically underserved—the summer break from learning perpetuates inequitable achievement gaps.
This insight was among those released today by NWEA in an overview of current research studies that examined K-8 student progress during a typical school year (non pandemic) and over the summer. The research reveals important information about the degree to which being in school reduces achievement gaps and points to the importance of high-quality summer programming in supporting student success.
"Our research analysis revealed reasons for both optimism and concern. While the findings disrupt some long-held deficit-based thinking about some of these student groups, they also demonstrate the disproportionate impact that learning interruptions have on their achievement in the long-term, making high quality summer learning opportunities and other interventions critical," said Lindsay Dworkin, VP of Policy and Advocacy at NWEA. "Taken collectively, these studies can help education leaders and policymakers identify interventions needed for these student groups to help address the inequitable learning patterns in U.S. public schools."
The research used MAP Growth assessment data and revealed that while students with disabilities, English learners, and rural students make gains at rates equal to or faster than their grade-level peers during the school year, these students also experience greater learning loss in the summer, leading to persistent achievement gaps.
"We have long known the impact of the summer slide on student learning; however, this data gives us a deeper look into just how critical high-quality summer opportunities are for many of our underserved students," said Deborah Delisle, CEO of All4Ed, formerly the Alliance for Excellent Education. "This information demonstrates that our system is effective at educating our students during the school year, and it is a call to action for states and districts on how to target summer programming so that all students can excel in school and beyond. Our children deserve nothing less."
Highlights from the research include:
- Rural Students — In a study of K-8 students nationwide, rural students came into kindergarten with higher achievement levels in math and reading than their non-rural peers; but by the end of third grade non-rural students consistently outperformed those from rural communities across the grades. Rural students grow at slightly faster rates in math and reading than other students when school is in session, but lose more ground almost every summer.
- Students with Disabilities — In a study of K-4 students nationwide, students with disabilities enter kindergarten behind their peers in reading and math, but go on to make gains at similar or higher rates than their peers during some school years. However, students with disabilities lose more ground every summer, which contributes to widening disparities in achievement.
- English Learners (ELs) — A third research study looked at achievement and growth for K - 4 for ELs. It showed that ELs had lower test scores than their non-EL peers through their elementary years, but they also made academic growth similar to or at greater levels as their non-EL peers. However, the student group that was consistently identified as needing EL services tended to lose more ground over the summer than their non-EL peers or their multilingual peers who were ELs at some point but not consistently through K-4.
"This new study underscores both the urgency and need to invest in interventions that support the academic recovery of English learners. Even before the pandemic, multi-lingual learners lost more ground than their peers during the summer when they were out of school," said Eric Rodriguez, SVP of Policy and Advocacy at UnidosUS. "After the last two years of interrupted learning for all students, it is more crucial than ever to target significant resources to support retaining and accelerating academic progress and learning for English learners during the summer. Summer support should include bilingual programming that combines academic and enrichment activities staffed with specialists to provide specific language development support and appropriate materials for English learners."
Previous NWEA assessment data show that all students started this school year behind where they would be in a typical year and that historically marginalized groups were most severely impacted. Hispanic, American Indian and Alaska Native (AIAN), and Black students had much bigger declines in achievement than Asian American and White students.
NWEA researchers will also continue to conduct research into learning patterns that occur during the school year and over the summer and hope that new data will show a narrowing of gaps and more equitable learning conditions for all students. Additionally, NWEA researchers are partnering with CALDER at American Institutes of Research (AIR) and the Center of Education Policy and Research at Harvard to support a group of districts in determining how interventions are supporting COVID recovery.
"With the school year soon coming to an end, we can all look to summer as the perfect time to provide additional quality learning opportunities for students impacted by the pandemic. To ensure these opportunities are engaging and successful, states need actionable research on effective strategies that leverage afterschool, summer learning, and community partners," said Paolo DeMaria, NASBE President and CEO. "This summer learning research brief can inform state boards about what works to support students in high-quality summer programs that sustain positive gains made during the school year. High quality summer programs coupled with relevant ongoing evaluation will help unlock the tools we need to reduce summer learning loss and continue to accelerate student learning so each and every student thrives."
NWEA's Let's Talk about Summer Twitter Chat
NWEA's Policy and Advocacy Team will host a Twitter chat on April 12th at 2pm EDT to discuss barriers these student groups face, how high-quality summer programs could close these gaps, as well as how districts can use federal recovery funds to support students who have been disproportionately impacted by the pandemic. Join @NWEApolicy on Twitter using the hashtag #SummerLearningChat.
About NWEA
NWEA® (formerly known as Northwest Evaluation Association) is a mission-driven, not-for-profit organization that supports students and educators in more than 146 countries through research, assessment solutions, policy and advocacy services, professional learning and school improvement services that fight for equity, drive classroom impact and push for systemic change in our educational communities. Visit NWEA.org to learn more about how we're partnering with educators to help all kids learn.
Media Contact:
Contact: Simona Beattie,
Sr. Manager, Public Relations,
simona.beattie@nwea.org or 971.361.9526
View original content to download multimedia:
SOURCE NWEA | https://www.kold.com/prnewswire/2022/04/11/some-students-lose-more-ground-when-school-is-out/ | 2022-04-11T09:45:14 | 0 | https://www.kold.com/prnewswire/2022/04/11/some-students-lose-more-ground-when-school-is-out/ |
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Person Declaration issued by a Qualified Person ("QP") for the Group's manufacturing facility for its recombinant protein COVID-19 vaccine, ReCOV ("ReCOV") in Taizhou, the People's Republic of China (the "PRC").
Pursuant to Eudralex Vol 4 regulations (EU Good Manufacturing Practice) and the guiding principles of International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Parenteral Drug Association (PDA) and International Society for Pharmaceutical Engineering (ISPE), etc., this EU QP audit mainly focused on the bulk and preparation of antigen and the novel adjuvant BFA03, covering manufacturing management system, quality management system, production equipment and facility management system, validation and computerized systems, material management systems, product testing and release management and other aspects of a comprehensive systematic and in-depth inspection. This signifies the Group's manufacturing facility in Taizhou and its quality management system have met EU GMP standards, laying a solid foundation for the high-quality development and future international commercialisation of ReCOV.
ReCOV is a recombinant COVID-19 vaccine being developed by the Group with its technology platforms including the novel adjuvant and protein engineering platforms. Based on the relevant studies conducted by the Group, ReCOV has shown favourable neutralizing effect and immune persistence against variants including Omicron variant and Delta variant. Clinical data from the Group's phase I trial for ReCOV in New Zealand also showed that it has an overall favorable safety profile and may potentially induce similar or higher level of neutralizing antibodies than other marketed mRNA COVID-19 vaccines and vaccine candidates.
About Recbio
Recbio is an innovative vaccine company founded in 2012. With the vision of "Become the Leader of Innovative Vaccine in the Future," Recbio takes "Protect Human Health with Best-in-Class Vaccines" as its mission. It has established three major cutting-edge technology platforms including novel adjuvants platform, protein engineering platform, and immunological evaluation platform. Recbio has a high-value vaccine portfolio consisted of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates etc. The core management team has more than 20 years of experience in the development and commercialization of innovative vaccines. For more information, please visit https://www.recbio.cn/.
About Recombinant Two-Component COVID-19 Vaccine (ReCOV)
In May 2020, Recbio, together with Jiangsu Provincial Center for Disease Control and Prevention ("Jiangsu CDC") and Taizhou Medical New & High-tech Industrial Development Zone, jointly developed a recombinant two-component COVID-19 vaccine(ReCOV). Under the guidance of Professor Fengcai Zhu from the Jiangsu CDC, the R&D team thoroughly optimized the vaccine using protein engineering and new adjuvant technologies, so that ReCOV has promising safety and strong immunogenicity against SARS-CoV-2 and variants of concern such as Omicorn and Delta. A series of comprehensive advantages such as better cross-protection against emerging variants, easy scale-up of production, cost advantages, worldwide accessibility, good preparation stability, and storage and transportation at room temperature which become a very competitive second-generation new COVID-19 vaccine.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Recbio, are intended to identify certain of such forward-looking statements. Recbio does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Recbio with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Recbio's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Recbio's competitive environment and political, economic, legal and social conditions.
Jiangsu Recbio Technology Co., Ltd.
Investor Inquiry:
Email: ir@recbio.cn
Tel: +86-0523-86818860
Media Inquiry:
Email: media@recbio.cn
Tel: +86-0523-86818860
Related Links:
https://www.recbio.cn/
View original content to download multimedia:
SOURCE Jiangsu Recbio Technology Co., Ltd. | https://www.kold.com/prnewswire/2022/04/11/successful-passing-eu-qualified-person-audit-groups-manufacturing-facility-recov-taizhou/ | 2022-04-11T09:45:21 | 0 | https://www.kold.com/prnewswire/2022/04/11/successful-passing-eu-qualified-person-audit-groups-manufacturing-facility-recov-taizhou/ |
Stay up-to-date with the latest Korean dramas on Rakuten Viki and watch all-new episodes with subtitles available in more than 150 different languages. Subscribe to Viki Pass and enjoy exclusive shows in HD, completely ad-free.
SAN MATEO, Calif., April 11, 2022 /PRNewswire/ -- April is going to be an exciting month for kdrama fans. Viki presents a line-up of new and exclusive dramas that are sure to satisfy viewers of all ages. From Queendom 2 to Again My Life, viewers can watch the latest episodes online on Viki's website.
Top Korean Drama Picks to Watch This April
Starring Lee Joon Gi and Kim Ji Eun, Again My Life is a crime and mystery Korean drama that follows a hardworking prosecutor who gets killed while investigating a politician suspected of corruption. Kim Hee Woo (Lee Joon Gi) gets another shot at life and tries to discover the truth about what happened to him.
Viewers looking for a romance Korean drama to watch can look forward to Sh**ting Stars (Shooting Stars). Top star, Gong Tae Sung (Kim Young Dae), is viewed as a kind and polite young man in the public's eyes. However, he has a different personality off-screen. As the PR team head, Oh Han Byeol (Lee Sung Kyung) always employs her excellent speech and crisis management skills to maintain Tae Sung's image. Despite their endless bickering, the two gradually develops feelings for each other.
Another must-watch Korean drama is From Now, Showtime! starring Park Hae Jin and Jin Ki Joo. Park Hae Jin plays a famous magician, Cha Cha Woong, who is able to see ghosts. Go Seul Hae (Jin Ji Joo) is a passionate police officer that shares the same ability but is afraid of using it. With Hae Jin's ghostly retinue, they start to work together to catch fiendish criminals.
Check Out More Exciting Shows
Apart from these new Korean dramas, viewers can also watch Queendom 2, a Korean reality survival show that pits six all-female acts against each other in a series of musical challenges. Viewers can look forward to exciting performances as the competitors battle it out to win the crown.
Additionally, viewers can also watch Japanese dramas like Promise Cinderalla – now available on Viki. When her husband reveals that he has met another woman, Katsuragi Hayama (Nikaido Fumi) leaves the house only to be robbed of the money she has. Homeless and penniless, she meets Issei (Maeda Gordon). The bratty high school student offers her a place to stay, only if she plays a game with him.
Watch Korean Dramas Online with Subtitles Free
Viki offers a wide range of genres, including romance, action and comedy. Viewers can watch shows for free or subscribe to Viki for an ad-free experience and be entertained anytime, anywhere. Dramas and movies on Viki are also subtitled in a variety of language options. Viewers can look forward to enjoying their favorite shows in English, French, Traditional Chinese and more.
About Rakuten Viki:
Rakuten Viki is a premier destination for Asian entertainment, offering the best and most accessible selection of Asian movies and shows, including dramas, variety and award shows, and originals across many popular genres. Reaching more than 55 million fans in 190 countries, Rakuten Viki's content is translated into 150+ languages by a community of avid fans. Viki, Inc. as well as Soompi, an entertainment news community, is a part of the Rakuten Group (TSE: 4755), a global leader in e-commerce and internet services that empower individuals, communities, businesses, and society.
View original content to download multimedia:
SOURCE Rakuten Viki | https://www.kold.com/prnewswire/2022/04/11/watch-these-new-korean-dramas-online-rakuten-viki-this-april/ | 2022-04-11T09:45:28 | 0 | https://www.kold.com/prnewswire/2022/04/11/watch-these-new-korean-dramas-online-rakuten-viki-this-april/ |
The Midtown East Starbucks in Raleigh. | Photo by Brett Villena
On February 13, while washing dishes in the back room of the Raleigh Starbucks she works at, Sharon Gilman says that the three-compartment sink separated from the wall, falling toward her. She stepped backward and called for her shift supervisor. The two documented the damage, taking photos and videos, and the shift supervisor called in a work order. Then Gilman went home.
On April 9, Ed Harvey, a Starbucks manager, showed up at the 2901 Sherman Oaks store that Gilman works at, called her out from her shift, and fired her.
In a notice of termination reviewed by the INDY, Starbucks cited "intentional miuse of store equipment" by Gilman that generated a "concern for personal safety."
"Ed sat me down and asked, 'Were you upset? Did something happen that night? Maybe you were frustrated'? I was like, No. First of all, this was literally a month and a half ago," Gilman says. "It just broke off the wall."
Gilman, 20, is one of the seven employees at the 2901 Sherman Oak Place location in Raleigh to put their names on a letter declaring intent to unionize. The letter was submitted to former Starbucks CEO Kevin Johnson—who has since been replaced by Howard Schultz—on February 15.
As reported in a feature by the INDY Week in mid-March, workers at the 2901 Sherman Oaks Starbucks location are the first Starbucks workers in North Carolina to file for a union election. Ballots for the company's union election are supposed to go out this week.
Over the phone, a Starbucks spokesperson maintained to the INDY that the termination is "unrelated to current unionization efforts at the stores."
"This is an extreme example of retaliation by Starbucks," says Chris Baumann, Southern Region Director of Workers United, an affiliate of Service Employees International Union (SEIU). "Instead of firing her, the company should have been apologetic that equipment in their store was in such disrepair that a sink almost fell on an employee."
Gilman, a student at North Carolina State University, says that she was surprised to be fired and agrees that the termination feels like retaliation.
"My name was on the letter," she says. "My name was in a news article, in the press release."
Since the first Starbucks store in Buffalo, New York, went public with a union campaign in August, an unprecedented organizing fever has swept through the company, with workers at more than 175 stores in 25 states filing for union elections as of early April. There are roughly 9,000 stores nationwide.
The company—which has largely enjoyed a progressive reputation since its 1971 founding—has responded strongly to organizing efforts with a full-court anti-union press, sending senior officials to stores, holding meetings with workers, and firing several workers in prominent organizing roles.
Gilman is at least the tenth unionizing Starbucks worker to be fired from the company. Last week—the same day that Howard Schultz started his role as interim CEO of the company—Laila Dalton, an outspoken Phoenix barista and union leader, was fired from her job for recording co-workers' conversations without their permission.
At a forum that day Schultz told employees that “we can’t ignore what is happening in the country as it relates to companies throughout the country being assaulted in many ways by the threat of unionization.”
The most high-profile store firings occurred at a Memphis Starbucks in early February, when seven unionizing employees were fired for violating company safety rules; earlier this week, NLRB officials determined that the Memphis worker terminations were illegal and announced intent to issue a complaint unless there is a settlement.
Baumann says that SEIU is planning to file charges with the National Labor Relations Board (NLRB) first thing on Monday morning requesting that Gilman be reinstated at her job.
"I love the people I work with," Gilman says. "They're some of the best friendships and relationships that I've formed. I'm not from Raleigh, I'm actually from Virginia, so when I moved down here for school they took me under their wing."
In a text message, Alyssa White, another barista at the 2901 Sherman Place store, told the INDY that organizing employees plan to protest at the store on Monday.
"Starbucks is determined to try to crush this union drive that's being led by Starbucks partners across the country," says Baumann. "Now that Howard Schultz the old CEO has come back, it sounds like it's his mission to destroy this union drive. He keeps trying to make it sound like it's this effort that's coming from outside the company. It's very much the reverse."
Support independent local journalism. Join the INDY Press Club to help us keep fearless watchdog reporting and essential arts and culture coverage viable in the Triangle.
Follow Arts & Culture Editor Sarah Edwards on Twitter or send an email to sedwards@indyweek.com. | https://indyweek.com/food-and-drink/news/starbucks-fires-raleigh-worker-unionizing/ | 2022-04-11T09:57:56 | 1 | https://indyweek.com/food-and-drink/news/starbucks-fires-raleigh-worker-unionizing/ |
Congratulations to over 1,000 local businesses and people who have been nominated by the community as the "Best of the Triangle!" The final round of voting begins today through May 8. The top four vote-getters (plus ties) made it to the final multiple choice ballot. Take 10 minutes to support your favorite dives, healthcare providers, and museums from across the Triangle by clicking the banner below.
Winners will be announced in the June 15 print edition of INDY Week. The top vote-getters will receive an INDY branded "Best of" poster to proudly display, while all finalists will receive a window decal for rising to the top. *
For Businesses:
The finalist ballot receives over 500,000 votes from readers, and June 15’s "Best of the Triangle" issue is the most-read issue of the year. Reach out now to reserve your spot and thank your supporters in this memorable edition.
For promotional opportunities on the ballot, please take a moment to watch this video, and click here to download our rate card. For information on all print and digital advertising opportunities, please email sales@indyweek.com.
Click here to download additional resources to reach your customers and patrons, both in-person and online. You can download posters and images for your newsletters, social media platforms, and front doors. Share far and wide using the hashtags #bestofthetriangle #bestof2022 and #indyweek. Got questions? Please email sales@indyweek.com.
Lastly, consider joining the INDY Week Press Club. Support like yours allows us to continue to provide you with free local news coverage in both print and digital formats, as well as special issues like the “Best of the Triangle.”
*Note: Businesses that made it onto the finalist ballot will likely receive phishing attempts via whatever public-facing communication channel you use. Any offer to sell you a plaque, poster, sign or any other "Best of the Triangle"-related product should be handled as a scam. INDY Week provides window decals to all finalists, and winners receive a poster to proudly display. If you are a previous finalist or winner and have not received these for previous years, please contact sales@indyweek.com. | https://indyweek.com/guides/best-of-the-triangle/bott-2022-final-voting-begins/ | 2022-04-11T09:58:02 | 1 | https://indyweek.com/guides/best-of-the-triangle/bott-2022-final-voting-begins/ |
Caught on camera: Man rescues driver after car plunges into Houston port
HOUSTON (KTRK) - A Texas man saved a driver from drowning after the man’s car plunged off a boat ramp in Houston.
The U.S. Coast Guard honored Cody Moore with one of its highest civilian honors for his lifesaving efforts on New Year’s Eve 2021 at the Lynchburg Ferry boat ramp in the Port of Houston. Surveillance video of the rescue was recently released.
Cody Moore and his family had just arrived at the nearby Monument Inn for dinner when the car came whizzing by and launched into the water. The father of five rushed to the car. He initially tried to talk to the driver, but a few moments later, he jumped in.
“When he said, ‘Call 911′ and I was running to the car to get something, I knew he was going in the water. I knew that he wouldn’t just stand by,” said Cody’s wife, Karen Moore.
Somehow, Cody Moore was able to convince the driver, in his 60s, to try and open the window.
As the car quickly sank, the man got out through the window. Cody Moore scooped him up and swam him to the shore.
Neighbors having dinner with the family captured the dramatic scene. They also used their shirts as a rope to get the two men onto the ramp.
Miraculously, nobody was seriously hurt.
“Whenever it happened, it seemed so surreal. I didn’t understand the gravity of it because he got out, he was soaking wet and we went and had dinner,” Karen Moore said.
While New Year’s Eve came and went, Cody Moore’s heroic efforts weren’t forgotten. The U.S. Coast Guard honored him Friday with a certificate of merit as his whole family watched with pride.
“It is really dangerous, and because he did it for someone else, I was really proud of him,” said Cody’s daughter, Ellen Moore.
Copyright 2022 KTRK via CNN Newsource. All rights reserved. | https://www.wflx.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ | 2022-04-11T09:58:08 | 1 | https://www.wflx.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ |
Average US gas price drops 10 cents over past 2 weeks
The average U.S. price of a gallon of regular-grade gasoline dropped 10 cents over the past two weeks to $4.27 per gallon as oil prices continue to “yo-yo," industry analyst Trilby Lundberg said Sunday.
The price at the pump was $1.32 above what it was one year ago, according to the Lundberg Survey taken Friday.
Nationwide, the highest average price for regular-grade gas was in Los Angeles, at $5.85 per gallon. The lowest average was in Tulsa, Oklahoma, at $3.52 per gallon.
According to the survey, the average price of diesel was $5.13 per gallon, down 2 cents over two weeks.
Lundberg said prices dropped dramatically in the past two weeks, in part because higher prices reduced demand during the second half of March.
However, the drop isn't predictive of further declines because among other things, the global oil supply is tight due to a dip in output last month by OPEC, Lundberg said.
The war in Ukraine also has sparked global uncertainty. The U.S. has banned all Russian energy supplies but Lundberg said sanctioned Russian oil is still finding “big buyers like India and China happy to pay discount prices.”
In a bid to reduce spiking energy prices, President Joe Biden last month ordered the release of 1 million barrels of oil per day from the nation’s strategic petroleum reserve for six months.
On Thursday, the International Energy Agency said that its member countries are releasing 60 million barrels of oil from their emergency reserves on top of previous United States pledges.
The Paris-based organization says the new commitments made by its 31 member nations, which include the U.S. and much of Europe, amount to a total of 120 million barrels over six months, the largest release in the group’s history. | https://www.koat.com/article/average-us-gas-price-drops-10-cents/39684048 | 2022-04-11T10:02:17 | 0 | https://www.koat.com/article/average-us-gas-price-drops-10-cents/39684048 |
Can cancer blood tests live up to promise of saving lives?
Joyce Ares had just turned 74 and was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer.
After a repeat blood test, a PET scan and a needle biopsy, she was diagnosed with Hodgkin lymphoma.
"I cried," the retired real estate broker said. "Just a couple of tears and thought, 'OK, now what do we do?'"
The Canby, Oregon, resident had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells.
Such blood tests, called liquid biopsies, are already used in patients with cancer to tailor their treatment and check to see if tumors come back.
Now, one company is promoting its blood test to people with no signs of cancer as a way to detect tumors in the pancreas, ovaries and other sites that have no recommended screening method.
It's an open question whether such cancer blood tests — if added to routine care — could improve Americans' health or help meet the White House's goal of cutting the cancer death rate in half over the next 25 years.
With advances in DNA sequencing and data science making the blood tests possible, California-based Grail and other companies are racing to commercialize them.
And U.S. government researchers are planning a large experiment — possibly lasting seven years and with 200,000 participants — to see if the blood tests can live up to the promise of catching more cancers earlier and saving lives.
"They sound wonderful, but we don't have enough information," said Dr. Lori Minasian of the National Cancer Institute, who is involved in planning the research. "We don't have definitive data that shows that they will reduce the risk of dying from cancer."
Grail is far ahead of other companies with 2,000 doctors willing to prescribe the $949 test. Most insurance plans don't cover the cost. The tests are being marketed without endorsements from medical groups or a recommendation from U.S. health authorities. Review by the Food and Drug Administration isn't required for this type of test.
"For a drug, the FDA demands that there is a substantial high likelihood that the benefits not only are proven, but they outweigh the harms. That's not the case for devices like blood tests," said Dr. Barry Kramer of the Lisa Schwartz Foundation for Truth in Medicine.
Grail plans to seek approval from the FDA, but is marketing its test as it submits data to the agency.
The history of cancer screening has taught caution. In 2004, Japan halted mass screening of infants for childhood cancer after studies found it didn't save lives. Last year, a 16-year study of 200,000 women in the United Kingdom found regular screening for ovarian cancer didn't make any difference in deaths.
Cases like these have uncovered some surprises: Screening finds some cancers that don't need to be cured. The flip side? Many dangerous cancers grow so fast they elude screening and prove deadly anyway.
And screening can do more harm than good. Anxiety from false positives. Unnecessary costs. And serious side effects from cancer care: PSA tests for men can lead to treatment complications such as incontinence or impotence, even when some slow-growing prostate cancers would never have caused trouble.
The evidence is strongest for screening tests for cancers of the breast, cervix and colon. For some smokers, lung cancer screening is recommended.
The recommended tests — mammography, PAP tests, colonoscopy — look for one cancer at a time. The new blood tests look for many cancers at once. That's an advantage, according to Grail executive Dr. Joshua Ofman.
"We screen for four or five cancers in this country, but (many) cancer deaths are coming from cancers that we're not looking for at all," Ofman said.
Dr. Tomasz Beer of Oregon Health & Science University in Portland led the company-sponsored study that Joyce Ares joined in 2020. After a miserable winter of chemotherapy and radiation, doctors told her the treatment was a success.
Her case isn't an outlier, "but it is the sort of hoped-for ideal outcome, and not everyone is going to have that," Beer said.
While there were other early cancers detected among study participants, some had less clear-cut experiences. For some, blood tests led to scans that never located a cancer, which could mean the result was a false positive, or it could mean there's a mystery cancer that will show up later. For others, blood tests detected cancer that turned out to be advanced and aggressive, Beer said. One older participant with a bad case declined treatment.
Grail continues to update its test as it learns from these studies, and is sponsoring a trial with Britain's National Health Service in 140,000 people to see if the blood test can reduce the number of cancers caught in late stages.
Although Ares feels lucky, it's impossible to know whether her test added healthy years to her life or made no real difference, said Kramer, former director of the National Cancer Institute's Division of Cancer Prevention.
"I sincerely hope that Joyce benefited from having this test," Kramer said when told of her experience. "But unfortunately, we can't know, at the individual Joyce level, whether that's the case."
Cancer treatments can have long-term side effects, he said, "and we don't know how fast the tumor would have grown." Treatment for Hodgkin lymphoma is so effective that delaying therapy until she felt symptoms might have achieved the same happy outcome.
For now, health experts stress the Grail blood test is not a cancer diagnosis; a positive result triggers further scans and biopsies.
"This is a path in diagnostic testing that has never been tried before," Kramer said. "Our ultimate destination is a test that has a clear net benefit. If we don't do it carefully, we'll go way off the path." | https://www.koat.com/article/can-cancer-blood-tests-lsaving-lives/39685712 | 2022-04-11T10:02:27 | 1 | https://www.koat.com/article/can-cancer-blood-tests-lsaving-lives/39685712 |
- Two sets of inflation data are due out this week, with the March consumer price index scheduled for release on Tuesday.
- The March producer price index is set to follow on Wednesday.
- There are no major economic data releases due out on Monday.
The 10-year U.S. Treasury yield topped 2.76% on Monday morning, while the 5-year and 30-year rates remained inverted.
The yield on the benchmark 10-year Treasury note climbed 4 basis points to 2.7629% at 4 a.m. ET on Monday, having hit 2.7741% on Sunday evening. The yield on the 30-year Treasury bond moved 1 basis point higher to 2.7560%, while the 5-year rate jumped 5 basis points to 2.8154%. Yields move inversely to prices and 1 basis point is equal to 0.01%.
Treasury yields have been on the rise recently, with concerns that rising inflation and the Federal Reserve's plans to aggressively tighten monetary policy could slow economic growth.
These fears have caused Treasury yields to invert, with investors selling out of shorter-dated government bonds in favor of long-dated debt, which has historically occurred prior to recessions. However, investors have been careful to point out that the yield curve inversion is not guarantee of a recession and that this signal can flash red as many as two years before an economic downturn takes hold.
Paul Jackson, global head of asset allocation research at Invesco, told CNBC's "Squawk Box Europe" on Monday that while the effects of rising costs are starting to be felt in the economy, he doesn't think a recession is in the cards this year.
He expects the global economy to see around 3% growth, rather than the 4% he had previously forecast, but added that he believes recessionary fears are something that "will come back from time to time this year and that we will worry about."
Money Report
Cleveland Fed President Loretta Meester told CBS' "Face the Nation" on Sunday that she still believes the Fed can get inflation under control without causing major damage to the economy.
Two sets of inflation data are due out this week, with the March consumer price index scheduled for release on Tuesday and last month's producer price index slated to follow on Wednesday.
There are no major economic data releases due out on Monday.
Fed Governor Michelle Bowman is due to give the welcoming remarks at a FedListens session in Nashville, Tennessee, at 9:30 a.m. ET on Monday.
Investors will also be keeping an eye on developments in Ukraine. Russia's invasion of the country has caused volatility in oil and other commodities markets, which has, in turn, disturbed stocks.
Auctions are scheduled to be held on Monday for $57 billion of 13-week bills, $48 billion of 26-week bills and $46 billion of 3-year notes.
— CNBC's Jesse Pound contributed to this market report. | https://www.nbcnewyork.com/news/business/money-report/10-year-treasury-yield-tops-2-76-to-start-the-week/3639651/ | 2022-04-11T10:05:17 | 1 | https://www.nbcnewyork.com/news/business/money-report/10-year-treasury-yield-tops-2-76-to-start-the-week/3639651/ |
On Dec. 1, 2020, federal agents knocked on an apartment door looking for an Atlanta-area rapper — a key suspect in a monthslong investigation into a ring trafficking guns from Georgia to Philadelphia.
Fredrick Norman — aka “Slowkey Fred” — wasn’t there that December day, but the woman who answered the door, Brianna Walker, texted Norman, warning him the agents were there, according to a search warrant affidavit.
For months, agents with the Bureau of Alcohol, Tobacco, Firearms and Explosives had been building a case against Norman, Walker and two other suspects. The agents ultimately traced nearly 300 firearms purchased in Georgia from dozens of gun retailers to the suspects after some were found at crime scenes and in the possession of convicted felons in Philadelphia, according to records and interviews with federal law enforcement.
“I think it’s an astronomical amount of firearms,” said Priya De Souza, an assistant U.S. attorney in the Eastern District of Pennsylvania, who is prosecuting the case and plans to hold a news conference about it on Monday.
The federal investigation expanded to include 11 suspects in Georgia and Pennsylvania, all of whom face a conspiracy charge. Kenneth Burgos, 23, and Edwin Burgos, 29 — brothers accused of brokering sales in Pennsylvania — are also charged with dealing firearms without a license, officials said.
As of Friday, there was no attorney listed for nine defendants named in the indictment, most of whom court records listed as in federal custody pending arraignment and who could not be reached for comment. A lawyer for Edwin Burgos declined to comment. A lawyer for another defendant, Roselmy Rodriguez, did not respond to requests for comment. Both Burgos and Rodriguez have pleaded not guilty to all charges. | https://www.nbcnewyork.com/news/national-international/trafficking-ring-moved-nearly-300-guns-from-georgia-to-pennsylvania-prosecutors-say/3639707/ | 2022-04-11T10:13:59 | 0 | https://www.nbcnewyork.com/news/national-international/trafficking-ring-moved-nearly-300-guns-from-georgia-to-pennsylvania-prosecutors-say/3639707/ |
FORT WAYNE, Ind. (WANE)– The amount of injuries are unknown after a truck crashed into the Brooks Construction building early Monday morning.
It happened just before 5 a. m. in the 6500 block of Ardmore Avenue.
A WANE 15 crew is on the scene and saw an ambulance leave with one person inside.
The Fort Wayne Police Department would not confirm that person’s condition, but they did say they’re holding the scene in case the injuries are critical.
This story is still developing and updates can be found on wane.com. | https://www.wane.com/news/truck-crashes-into-brooks-construction-building/ | 2022-04-11T10:15:15 | 0 | https://www.wane.com/news/truck-crashes-into-brooks-construction-building/ |
Caught on camera: Man rescues driver after car plunges into Houston port
HOUSTON (KTRK) - A Texas man saved a driver from drowning after the man’s car plunged off a boat ramp in Houston.
The U.S. Coast Guard honored Cody Moore with one of its highest civilian honors for his lifesaving efforts on New Year’s Eve 2021 at the Lynchburg Ferry boat ramp in the Port of Houston. Surveillance video of the rescue was recently released.
Cody Moore and his family had just arrived at the nearby Monument Inn for dinner when the car came whizzing by and launched into the water. The father of five rushed to the car. He initially tried to talk to the driver, but a few moments later, he jumped in.
“When he said, ‘Call 911′ and I was running to the car to get something, I knew he was going in the water. I knew that he wouldn’t just stand by,” said Cody’s wife, Karen Moore.
Somehow, Cody Moore was able to convince the driver, in his 60s, to try and open the window.
As the car quickly sank, the man got out through the window. Cody Moore scooped him up and swam him to the shore.
Neighbors having dinner with the family captured the dramatic scene. They also used their shirts as a rope to get the two men onto the ramp.
Miraculously, nobody was seriously hurt.
“Whenever it happened, it seemed so surreal. I didn’t understand the gravity of it because he got out, he was soaking wet and we went and had dinner,” Karen Moore said.
While New Year’s Eve came and went, Cody Moore’s heroic efforts weren’t forgotten. The U.S. Coast Guard honored him Friday with a certificate of merit as his whole family watched with pride.
“It is really dangerous, and because he did it for someone else, I was really proud of him,” said Cody’s daughter, Ellen Moore.
Copyright 2022 KTRK via CNN Newsource. All rights reserved. | https://www.wnem.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ | 2022-04-11T10:23:49 | 1 | https://www.wnem.com/2022/04/11/caught-camera-man-rescues-driver-after-car-plunges-into-houston-port/ |
Ukraine digs in to fight Russia’s looming eastern offensive
KYIV, Ukraine (AP) - A showdown looms in Ukraine after Russia appointed a new military commander and looked to concentrate its attacks in the east, while Ukraine’s president said his troops will hold their ground, urging Western leaders, in particular President Joe Biden, to do more.
Ukrainian President Volodymyr Zelenskyy warned Sunday in a nightly address that this week will be as crucial as any during the war, saying “Russian troops will move to even larger operations in the east of our state.”
Ukraine’s fate as the war shifts south and east depends on whether the United States will help match a surge in Russian weaponry, he said, echoing comments he made in an interview with The Associated Press on Saturday.
“To be honest, whether we will be able to (survive) depends on this,” Zelenskyy said in a “60 Minutes” interview. “Unfortunately, I don’t have the confidence that we will be receiving everything we need.”
Zelenskyy said he was grateful to Biden for U.S. military aid to date but added that he “long ago” forwarded a list of specific items Ukraine desperately needed.
“He has the list,” Zelenskyy said. “President Biden can enter history as the person who stood shoulder to shoulder with the Ukrainian people who won and chose the right to have their own country. (This) also depends on him.”
WARNING: Videos may contain graphic content.
Austrian Chancellor Karl Nehammer was due to meet Monday in Moscow with Putin, after meeting with Zelenskyy in Kyiv. Austria, a member of the European Union, is militarily neutral and not a member of NATO.
Also Monday, New Zealand’s Prime Minister Jacinda Ardern said it was sending a military transport plane and a support team of 50 to Europe to carry much-needed equipment and supplies to key distribution centers.
More than six weeks of war in Ukraine has flattened cities, killed untold thousands and isolated Moscow economically and politically, and experts say the next phase of the battle may begin with a full-scale offensive that could determine the course of the conflict.
Questions remain about the ability of depleted and demoralized Russian forces to conquer much ground after their advance on the capital, Kyiv, was repelled by determined Ukrainian defenders. Britain’s Defense Ministry says Russia is trying to compensate for mounting casualties by recalling veterans discharged in the past decade.
In his Sunday night address, Zelenskyy also accused Russia of trying to evade responsibility for war crimes in Ukraine.
“When people lack the courage to admit their mistakes, apologize, adapt to reality and learn, they turn into monsters. And when the world ignores it, the monsters decide that it is the world that has to adapt to them,” Zelenskyy said.
“The day will come when they will have to admit everything. Accept the truth,” he added.
Ukrainian authorities accuse Russian forces of committing war crimes against civilians, including airstrikes on hospitals, a missile attack that killed at least 57 people at a train station and other violence.
In another report of atrocities, the village of Buzova outside the capital, Kyiv, charred vehicles and buildings marked an area where local official Taras Didych told Ukrainian media Sunday that bodies showing “evidence of execution” were found after Russian forces withdrew from the region. It was unclear how many bodies were discovered.
Buzova is near Bucha, another of the towns near Kyiv, where hundreds of bodies, many with their hands bound and signs of torture, were found after the Russian retreat. Russia has falsely claimed the scenes in Bucha were staged.
In Washington, a senior U.S. official said Russia has appointed Gen. Alexander Dvornikov, one of its most seasoned military chiefs, to oversee the invasion. The official was not authorized to be identified and spoke on condition of anonymity.
Until now, Russia has had no central war commander on the ground.
Dvornikov, 60, takes over as Russian military prepares to focus on expanding control in Ukraine’s east, where Russia-backed separatists have fought Ukrainian forces in the Donbas region since 2014, declaring some areas independent.
He gained a record for brutality as head of Russian forces deployed to Syria in 2015 to back President Bashar Assad’s government during the country’s devastating civil war.
Russian authorities do not generally confirm such appointments and have said nothing about a new role for Dvornikov, who received the esteemed Hero of Russia medal from President Vladimir Putin in 2016.
U.S. national security adviser Jake Sullivan, speaking Sunday on CNN’s “State of the Union,” played down the appointment’s significance.
“What we have learned in the first several weeks of this war is that Ukraine will never be subjected to Russia,” Sullivan said. “It doesn’t matter which general President Putin tries to appoint.”
Western military analysts say Russia’s assault increasingly is focusing on a sickle-shaped arc of eastern Ukraine — from Kharkiv, Ukraine’s second-largest city, in the north to Kherson in the south.
That could counter Russia’s earlier problem of spreading its offensive too widely over too broad a geographic area.
Newly released Maxar Technologies satellite imagery showed an 8-mile (13-kilometer) convoy of military vehicles headed south through Ukraine to Donbas, recalling images of the convoy that stalled outside Kyiv before Russia gave up trying to take the capital.
On Sunday, Russian forces shelled government-controlled Kharkiv and sent reinforcements toward Izyum to the southeast to try to break Ukraine’s defenses, the Ukrainian military command said. The Russians also kept up their siege of Mariupol, a key southern port that has been under attack and surrounded for nearly 1 ½ months.
A Russian Defense Ministry spokesman, Maj. Gen. Igor Konashenkov, said Russia’s military used air-launched missiles to hit Ukraine’s S-300 air-defense missile systems in the southern Mykolaiv region and at an air base in Chuhuiv, a city not far from Kharkiv.
Sea-launched Russian cruise missiles destroyed the headquarters of a Ukrainian military unit stationed farther west in the Dnipro region, Konashenkov said. Neither the Ukrainian nor the Russian military claims could be independently verified.
Missiles twice struck the airport in Dnipro, Ukraine’s fourth-largest city, on Sunday, the regional governor said.
In Mariupol, Russia deployed Chechen fighters, reputed to be particularly fierce. Capturing the city on the Sea of Azov would give Russia a land bridge to the Crimean Peninsula, which Russia seized from Ukraine eight years ago.
The city’s residents have lacked food, water and electricity since Russian forces surrounded the city and frustrated evacuation missions. Ukrainian authorities think an airstrike on a theater that was being used as a bomb shelter killed hundreds of civilians, and Zelenskyy has said he expects more evidence of atrocities to be found once Mariupol no longer is blockaded.
On Sunday night, Zelenskyy again appealed for more assistance. Speaking with German Chancellor Olaf Scholz, he said he discussed “how to strengthen sanctions against Russia and . . . force Russia to seek peace.”
“I am glad to note that the German position has recently changed in favor of Ukraine. I consider it absolutely logical,” Zelenskyy said.
The Institute for the Study of War, an American think tank, predicted that Russian forces will “renew offensive operations in the coming days” from Izyum, a town southeast of Kharkiv, in the campaign to conquer the Donbas, which comprises Ukraine’s industrial heartland.
But in the view of the think tank’s analysts, “The outcome of forthcoming Russian operations in eastern Ukraine remains very much in question.”
___
This story has been updated to correct that the war began just over six weeks ago, not 10 weeks.
___
Anna reported from Bucha, Ukraine. Yesica Fisch in Borodyanko, Ukraine, Robert Burns and Calvin Woodward in Washington, and Associated Press journalists around the world contributed to this report.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.wnem.com/2022/04/11/ukraine-digs-fight-russias-looming-eastern-offensive/ | 2022-04-11T10:23:56 | 1 | https://www.wnem.com/2022/04/11/ukraine-digs-fight-russias-looming-eastern-offensive/ |